Aspects of The Preoperative Pathway in Pancreatic Head Malignancy by Amr, Bassem Ismail Metwaly Ismail
	
	 1	
Copyright	Statement		
	
	
	
	
	
This	copy	of	the	thesis	has	been	supplied	on	condition	that	anyone	who	consults	it	is	
understood	to	recognise	that	its	copyright	rests	with	its	author	and	that	no	
quotation	from	the	thesis	and	no	information	derived	from	it	may	be	published	
without	the	author's	prior	consent
	
	 2	
	 	
	
ASPECTS	OF	THE	PREOPERATIVE	PATHWAY	IN	PANCREATIC	HEAD	
MALIGNANCY	
By 
	
BASSEM	ISMAIL	METWALY	ISMAIL	AMR	
	
A	thesis	submitted	to	Plymouth	University	in	partial	fulfillment	for	the	degree	of	
	
DOCTOR	OF	MEDICINE	
	
Peninsula	College	of	Medicine	and	Dentistry	
	
 
July 2018
	
	 3	
Acknowledgement	
Dr.	Gemma	Miles	
Consultant	Radiology,	Plymouth	Hospitals	NHS	Trust	
Role:		Re-reporting	scan	images	
Dr.	Simon	Jackson	
Consultant	Radiology,	Plymouth	Hospitals	NHS	Trust	
Role:		Third	opinion	reporting	areas	of	scan	discrepancy		
Dr.	Helen	Neilens	
Research	Advisor/Innovation	Lead,	Plymouth	Hospitals	NHS	Trust	
Role:	Expert	advice	for	research	ethics	
Dr.	Christopher	Rollinson	
Research	Governance	Manager,	Plymouth	Hospitals	NHS	Trust	
Role:	Research	governance	training	and	online	study	registration			
Dr.	Golnaz	Shahtahmassebi	
Lecturer	in	statistics,	School	of	Science	and	Technology,	Nottingham	Trent	University	
Role:	Research	supervisor,	statistical	advice	and	performance	of	inferential	statistical	tests	
Professor	Carl	Roboottom	
Professor	of	Radiology,	PU	PSMD	
Role:	Research	supervisor,	Re-reporting	scan	images	
Mr.	David	Stell	
Consultant	Hepato-pancreatico-	biliary	Surgeon,	Plymouth	Hospitals	NHS	Trust	
Role:	Director	of	Studies
	
	 4	
Author	declaration	
At	no	time	during	the	registration	for	the	degree	of	Doctor	of	Medicine	has	the	author	been	
registered	for	any	other	University	award	without	prior	agreement	of	 the	Graduate	Sub-
Committee.		
Work	submitted	for	this	research	degree	at	the	Plymouth	University	has	not	formed	part	
of	any	other	degree	either	at	Plymouth	University	or	at	another	establishment.		This	is	an	
original	research	project.	 I	undertook	data	collection	and	descriptive	statistical	analyses.	
This	project	was	self-funded.	This	research	has	been	conducted	under	a	formal	agreement	
with	Plymouth	Hospitals	NHS	Trust.	
Ø Regional	presentations	
• Delay	to	surgery	influences	survival	in	patients	with	ampullary	carcinoma	
Oral	 and	 Poster	 presentation	 at	 the	 annual	 post-graduate	 PUPSMD	 research	 event,	
22ndOct.	2014	Cornwall,	UK	
• The	 pre-operative	 pathway	 in	 pancreatic	 head	 malignancy-Assessment	 of	
interval	to	surgery	on	oncological	outcome	and	survival	
Oral	 presentation	 at	 Postgraduate	 Society	 Conference,	 19th	 March	 2014.	 Plymouth	
University,	UK	(Best	Oral	presentation	Prize)	
Ø National	presentations	
• Impact	of	 interval	 to	surgery	on	resectability	and	histological	outcome	of	peri-
ampullary	carcinoma	
Poster	presentation	at	 the	2nd	 Scientific	Meeting	of	GBIHPBA,	12th	 -13th	March	2014,	
Warwickshire,	UK	(P05)	
	
	 5	
Ø International	presentations	
• Effect	 of	 patient	 travel	 distance	 on	 resection	 rate	 and	 outcome	 in	 pancreatic	
head	malignancy	
Poster	 presentation	 at	 the	 First	World	 Pancreatic	 Forum	 18th-19th	 June	 2015,	 Bern,	
Switzerland	(Best	Poster	Travel	Grant	Prize)	
• Longer	 interval	 to	 surgery	 improves	 outcome	 in	 surgery	 for	 ampullary	 cancer	
Poster	 presentation	 at	 the	 First	World	 Pancreatic	 Forum	 18th-19th	 June	 2015,	 Bern,	
Switzerland	
• Correlation	of	CT	with	histopathological	 outcome	 in	 the	 assessment	of	 tumour	
origin	in	pancreatic	head	malignancy	
Poster	presentation	at	European	Society	of	Gastrointestinal	and	Abdominal	Radiology	
Conference	(ESGAR	)	2015,	9th-12th	June	2015,	Paris,	France	
Ø Publications	
• Amr	B	et	al,	Systematic	evaluation	of	radiological	findings	in	the	assessment	of	
resectability	of	peri-ampullary	cancer	by	CT	using	different	contrast	phase	protocols.	
Clin	Radiol.	2017	Mar	11.	pii:	S0009-9260(17)30077-6.	
doi:10.1016/j.crad.2017.02.012.	[Epub	ahead	of	print].	
• Amr	B	et	al,	Variation	in	survival	after	surgery	for	peri-ampullary	cancer	in	a	regional	
cancer	network.	BMC	surgery.	2017;17	(1):23.	
• Amr	 B	 et	 al,	 Assessment	 of	 the	 effect	 of	 interval	 from	 presentation	 to	 surgery	 on	
outcome	in	patients	with	peri-ampullary	malignancy.	HPB,	Vol.	18,	(4),	354	–	359.	
Word	count	of	main	body	of	thesis:	30,670	
Signed	 	 	 	
	 Date:	
	
	 6	
Abstract		
ASPECTS	OF	THE	PREOPERATIVE	PATHWAY	IN	PANCREATIC	HEAD	MALIGNANCY	
BASSEM	ISMAIL	METWALY	ISMAIL	AMR	
	
Malignancy	 within	 the	 pancreatic	 head	 can	 arise	 from	 pancreatic	 duct,	 distal	 bile	 duct,	
ampulla	or	duodenum.	Since	September	2000,	surgery	for	all	pancreatic	head	malignancy	
(PHM)	 has	 been	 centralised	 into	 regional	 pancreatic	 centres	 where	 assessment	 of	
preoperative	 imaging	 and	 subsequent	 surgery	 is	 undertaken.	 	 As	 part	 of	 this	 guidance,	
surgery	must	be	performed	within	62-days	of	referral.		
This	project	will	assess	four	aspects	of	the	pre-operative	pathway	in	PHM:	
1) Potential	 variation	 in	 outcome	 of	 patients	 referred	 from	 different	 sites	 within	 a	
Cancer	Network	
2) Potential	variation	in	outcome	associated	with	different	intervals	to	surgery	within	
the	62	day	guideline	
3) The	 ability	 of	 interpretation	 of	 heterogeneous	 pre-operative	 CT	 scans	 from	
different	hospitals	to	determine	the	resectability	of	PHM	
4) The	ability	of	CT	scan	to	distinguish	the	different	tumour	types	of	PHM	
Images	 of	 a	 consecutive	 series	 of	 patients	 were	 re-reported	 and	 compared	 with	 final	
pathology	reports.	Good	agreement	was	noted	 in	determining	 the	 tumour	origin	of	PHM	
(observed	agreement	=	0.758,	Kappa=	0.6	(0.51-0.68)).			
In	the	assessment	surgical	outcomes,	geographical	isolation	from	the	regional	centre	was	
not	associated	with	delay	to	surgery.	Variation	 in	outcome	between	referral	centres	was	
however	noted	but	this	was	not	associated	with	travel	distance.		Although	little	association	
was	noted	between	delay	to	surgery	and	outcome	overall,	a	paradoxical	 improvement	 in	
survival	was	noted	however	for	the	small	group	of	patients	with	ampullary	tumours	who	
waited	longer	than	the	median	interval	to	surgery.	
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1 Introduction		
Pancreatic	 head	 malignancy	 (PHM)	 includes	 a	 group	 of	 malignant	 tumours	 arising	
from	 the	 Ampulla	 of	 Vater	 or	 from	 the	 nearby	 organs.	 The	 terms	 pancreatic	 head	
malignancy	and	periampullary	cancer	(PC)	are	used	interchangeably	in	this	thesis.	These	
include	 carcinoma	of	 the	head	of	 pancreas,	 ampullary	 carcinoma,	 distal	 bile	 duct	 cancer	
and	duodenal	 cancer.	 	 Cancers	 arising	 from	 these	 origins	 often	 cause	 obstruction	 of	 the	
distal	common	bile	duct	within	the	pancreatic	head	leading	to	a	similar	presentation	with	
obstructive	jaundice.	Identification	of	the	exact	site	of	the	tumour	origin	could	be	difficult	
due	to	the	close	anatomical	proximity	of	these	sites.		
Pancreatic	 ductal	 adenocarcinoma	 (PDA)	 is	 a	 cancer	 arising	 from	 the	 exocrine	
glandular	 cells	 of	 the	 pancreas,	 and	 carries	 a	 poor	 prognosis.	 	 It	 is	 one	 of	 the	 most	
aggressive	fatal	malignant	neoplasms	being	the	fifth	most	common	cause	of	cancer	related	
deaths	in	the	USA	and	Europe.	In	USA,	PDA	accounts	for	about	3%	of	all	cancers	and	about	
7%	of	all	cancer	related	mortality	with	an	estimated	increased	mortality	figures	to	rank	4th	
among	 cancer	 related	 deaths	 (1).	 In	 Europe,	 it	 is	 expected	 that	 deaths	 from	 pancreatic	
cancer	 to	 overtake	 breast	 cancer	 related	 deaths	 (2).	 Less	 than	 20%	 of	 patients	 have	 a	
resectable	 tumour	at	 the	 time	of	diagnosis	with	5-year	survival	 rate	of	3-5%	that	would	
increase	to	about	6.5%-20%	in	patients	with	successful	surgical	resection	(3-10).		
While	 there	 is	 an	 approximate	 delay	 of	 18	 and	 12	 months	 for	 the	 data	 collection	
regarding	 the	 incidence	 and	mortality	 rates	 respectively,	 it	 is	 estimated	 that	 pancreatic	
cancer	is	the	eleventh	most	common	diagnosed	cancer	in	the	UK	in	2015	(11,	12)	with	a	
peak	age	between	65	and	80	years	old	at	the	time	of	diagnosis	with	slight	female	gender	
predominance	 (13,	 14).	 Most	 recent	 published	 data	 in	 2016	 showed	 that	 there	 was	 an	
overall	increase	in	the	incidence	with	4,364	males	and	4,091	females	registered	in	the	UK	
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(15),	 with	 total	 deaths	 of	 4,7520	 and	 4,538	males	 and	 females	 patients	 respectively	 in	
2016	with	pancreatic	 cancer	 remained	 the	 fifth	most	 common	cause	of	 cancer	mortality		
(Figure	1-1&	Figure	1-2)(16).		
	
Figure	1-1	Female	cancer	mortality	(%	all	malignant	mortality)	in	the	United	Kingdom,	2016		
	
	
	Figure	1-2	Male	cancer	mortality	(%	all	malignant	mortality)	in	the	United	Kingdom,	2016	
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Ampullary	cancer	arises	 from	the	epithelium	of	 the	Ampulla	of	Vater,	 into	which	 the	
common	 bile	 duct	 drains.	 Ampullary	 tumours	 are	 usually	 diagnosed	 at	 an	 earlier	 stage	
than	PDA	and	generally	have	a	less	aggressive	clinical	course.	
Bile	 duct	 cancer	 or	 cholangiocarcinoma	 arises	 from	 the	 bile	 duct	 epithelium.	 These	
tumours	may	occur	within	the	intra-pancreatic	portion	of	the	distal	common	bile	duct	and	
mimic	PDA.	These	tumours	are	characterised	by	an	infiltrative	growth	pattern,	often	along	
adjacent	nerves.	
Surgery	is	indicated	for	the	treatment	of	this	group	of	malignant	tumours	and	evidence	
shows	 that	 the	 five-year	survival	 following	surgical	 resection	 for	PDA	varies	 from	6.5%-
20%	(3-9),	for	bile	duct	cancer	19.2%-30%	(3,	5,	7,	8,	17,	18)	and	33%-45%	for	ampullary	
cancer	(3,	5,	7,	8).		
Distinguishing	 between	 the	 main	 causes	 of	 periampullary	 cancers	 by	 histological	
examination	 can	 be	 difficult	 and	 is	 reflected	 in	 the	wide	 range	 at	which	 the	 lesions	 are	
reported	in	published	series	of	pancreatic	head	resections.	Histological	examination	of	the	
resected	malignant	pancreaticoduodenectomy	specimens	revealed	pancreatic	head	ductal	
adenocarcinoma	 (PDA)	 in	 33-89%,	 being	 the	 most	 common	 histological	 type	 of	 these	
malignant	tumours,	ampullary	carcinoma	in	5-42%,	distal	bile	duct	cancer	in	15-38%	and	
duodenal	carcinoma	in	about	10%	(19-22).	
Recent	attempts	have	been	made	to	standardise	and	improve	the	histology	reporting	
of	 pancreatic	 and	 periampullary	 cancer	 specimens	 according	 to	 Royal	 College	 of	
Pathologists	 guidelines	 (23).	 This	 has	 generally	 led	 to	 a	 higher	 rate	 of	 diagnosis	 of	
ampullary	 and	 bile	 duct	 cancer	 compared	 to	 pancreatic	 cancer	 (24).	 These	 techniques	
have	 been	 adopted	 by	 the	 Pathology	 Department	 at	 Derriford	 Hospital	 including	 axial	
slicing	of	resection	specimens	(in	transverse	section	rather	than	longitudinal	along	ducts)	
with	careful	macroscopic	examination	of	the	tumour	centre	in	relation	to	peri-ampullary	
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structures,	 rather	 than	 a	 reliance	 on	 histological	 staining	 which	 has	 low	 specificity	 in	
determining	 precise	 tumour	 phenotype	 (25).	 In	 addition	 identification	 of	 associated	
epithelial	dysplasia	can	be	helpful,	particularly	for	ampullary	lesions	(26).	
Precise	 identification	 of	 the	 tumour	 origin	 is	 of	 clinical	 significance	 as	 the	 adjuvant	
treatment	 is	 different	 for	 this	 group	 of	 malignant	 tumours.	 	 The	 prognosis	 also	 varies	
widely	 after	 surgical	 resection	 of	 these	 lesions	 from	 the	 high	 chance	 of	 cure	 following	
resection	of	localised	ampullary	cancer	to	the	dismal	prognosis	following	resection	of	PDA	
with	 evidence	 of	 local	 and	 nodal	 spread.	 	 This	 has	 major	 implications	 for	 patients’	
counseling.	 	 Also	 historical	 confusion	 of	 these	 diagnoses	 has	 reduced	 the	 reliability	 of	
earlier	studies	of	adjuvant	chemotherapy,	where	inclusion	of	ampullary	cancers	may	have	
increased	 the	 overall	 survival	 of	 patients	 groups	 and	 potentially	 reduced	 the	 treatment	
effect	of	drugs	targeting	pancreatic	cancer.	
Because	 of	 the	 historical	 tendency	 to	 over-diagnose	 pancreatic	 cancer	 histologically,	
radiologists	 have	 not	 made	 rigorous	 efforts	 to	 distinguish	 the	 lesions	 on	 pre-operative	
imaging.		Previously,	this	has	not	been	clinically	important	as	the	surgical	treatment	of	the	
lesions	is	identical	and	decisions	regarding	adjuvant	chemotherapy	can	be	made	after	the	
final	histology	report	is	available.		This	situation	is	changing	with	the	recent	advent	of	neo-
adjuvant	 treatment	 that	 may	 be	 recommended	 without	 a	 precise	 diagnosis	 in	 patients	
with	 borderline	 resectable	 or	 locally	 advanced	 periampullary	 cancer	 based	 on	 pre-
operative	imaging.	 	The	rationale	for	this	approach	is	that	in	a	proportion	of	patients	the	
disease	will	 be	 downsized	 by	 this	 treatment,	which	may	 facilitate	 future	 resection	 (27).	
Some	 patients	 however	will	 suffer	 tumour	 progression	 during	 the	 treatment	 phase	 and	
the	relative	benefits	of	the	technique	are	unknown.	Therefore,	it	is	likely	to	be	important	
in	 the	 future	 that	 the	 organ	 of	 origin	 of	 periampullary	 cancers	 to	 be	 identified	 prior	 to	
commencing	therapy	and	hence	correct	tumour	characterization	becomes	very	important.	
	
	 21	
A	further	aspect	of	preoperative	staging	periampullary	cancers	is	the	ability	of	imaging	
to	 predict	 resectability	 that	 has	 been	 generally	 classified	 as	 ‘resectable’,	 ‘border-line	
resectable’	or	‘unresectable’.	The	radiological	criteria	determining	the	surgical	resectability	
are	subjective	and	relate	to	assessment	of	the	involvement	of	pancreatic	vascular	structures	
and	have	not	been	validated	 in	a	UK	series	 and	 there	 is	 a	 risk	 that	patients	may	be	over-
staged	in	terms	of	their	resectability	and	be	denied	effective	treatment.	This	issue	has	also	
become	more	important	recently	due	to	the	era	of	neoadjuvant	treatment.			
The	policy	of	the	Peninsula	HPB	unit	has	been	to	offer	surgical	exploration	to	patients	
with	 borderline	 resectable	 periampullary	 cancers	 if	 they	 are	medically	 fit,	 as	 this	 is	 the	
most	effective	treatment.	
The	 publication	 of	 the	 “Improving	 Outcomes	 Document”	 in	 2000	 has	 led	 to	
restructuring	the	pancreatic	cancer	services	into	regionalized	centres	with	introduction	of	
new	 referral	 pathways.	 This	 aimed	 at	 developing	 high	 standard	 National	 Healthcare	
Services	 by	 achieving	 higher	 resection	 rates	 and	 improving	 the	 overall	 survival	 rates.
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1.1 Study	objectives	
This	project	will	address	four	aspects	of	the	current	practice	within	the	Southwest	of	
England	 HPB	 Cancer	 Network	 regarding	 the	 pre-operative	 pathway	 in	 patients	 with	
potentially	resectable	pancreatic	head	malignancy.		
1.1.1 Study	one		
Research	hypothesis:	Regionalisation	of	pancreatic	cancer	services	into	major	regional	
cancer	centres	does	not	disadvantage	patients	who	live	at	a	distance	from	the	cancer	
centre.		
The	aim	is	to	study	the	effect	of	patient	travel	distance	to	the	regional	Peninsula	HPB	
Cancer	Centre	in	an	era	of	centralisation	of	pancreatic	cancer	services	on	patients’	
outcomes	including	tumour	resectability	and	long-term	survival.	
1.1.2 Study	two	
Research	hypothesis:	Delay	to	surgery	does	not	adversely	affect	 the	resectability,	
tumour	 histological	 stage	 and	 long-term	 survival	 in	 patients	 with	 pancreatic	 head	
malignancy	treated	at	the	regional	cancer	centre.		
The	aim	of	 this	study	 is	 to	examine	the	effect	of	 the	 interval	 to	surgery	 from	the	 time	of	
symptomatic	presentation	at	the	referring	hospitals	to	the	time	of	surgery	at	the	regional	
HPB	 cancer	 centre	 on	 the	 tumour	 resectability,	 histopathological	 outcomes	 and	 overall	
survival	 of	 patients	 undergoing	 Kausch-Whipple	 procedure	 for	 presumed	 PHM	 at	 the	
Peninsula	HPB	cancer	centre.	
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1.1.3 Study	three		
Research	hypothesis:	Arterial	phase	preoperative	staging	 in	addition	 to	 standard	
abdominal	 CT	 scan	 is	 unnecessary	 in	 the	 assessment	 of	 tumour	 resectability	 in	 patients	
with	pancreatic	head	malignancy.	
The	aim	of	this	study	is	to	assess	the	relative	ability	of	preoperative	dual	and	triple-phase	
CT	scan	to	determine	the	presence	of	radiological	indicators	of	resectability	in	suspected	
pancreatic	head	malignancy.	
1.1.4 Study	four	
Hypothesis:	 Preoperative	 abdominal	 CT	 scan	 is	 unable	 to	 differentiate	 tumour	
organ	of	origin	in	patients	with	presumed	pancreatic	head	malignancy.	
The	aim	of	this	study	is	to	assess	the	ability	of	the	pre-operative	CT	scan	to	distinguish	the	
exact	 site	 of	 tumour	 origin	 in	 patients	 with	 pancreatic	 head	 malignancy	 by	 comparing	
consensus	radiological	opinion	against	final	histological	diagnosis.	 	
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2 Centralization	of	pancreatic	cancer	services	
2.1 Introduction	 of	 centralisation	 and	 the	 structure	 of	 the	 Hepato-	
Pancreaticobiliary	(HPB)	cancer	services	
In	 1995	 the	 Calman-Hine	 report	 (28)	 outlined	 the	 requirements	 for	 revolutionary	
changes	within	the	British	health	system	through	centralisation	of	the	NHS	cancer	services.	
These	 recommendations	 were	 aiming	 to	 improve	 cancer	 services	 outcome	 by	
concentrating	the	workload	within	regional	areas	with	MDT	expertise.	However	it	was	the	
publication	 of	 the	 “Improving	 Outcomes	 Document”	 in	 September	 2000	 (29),	 that	 has	
reinforced	 these	 significant	 changes	 in	 the	 provision	 of	 the	 cancer	 services.	 As	 part	 of	
these	 changes,	 the	 provision	 of	 HPB	 and	 Upper	 gastrointestinal	 cancer	 services	 has	
undergone	regionalisation	with	 increasing	emphasis	on	delivery	of	high	quality	services.	
Currently	there	are	34	tertiary	HPB	centres	(including	liver	transplant)	in	the	UK	working	
within	 designated	 cancer	 networks,	 each	 serving	 a	 population	 of	 approximately	 two	 to	
four	million	(30).		
This	shift	towards	centralisation	was	driven	by	the	volume-outcome	relationship	(31-
33).	 There	 is	 a	 current	 strong	 evidence	 of	 positive	 relationship	 between	 the	 hospital	
volumes	and	improved	outcomes	in	cancer	care	 indicated	by	higher	pancreatic	resection	
rates	 (34,	 35),	 lower	operative	mortality	 (36,	 37)	 and	 improved	 long-term	survival	 (38-
40)	in	units	with	higher	treatment	volumes.	
Several	 factors	 have	 contributed	 to	 this	 positive	 volume-outcome	 relationship.	
Firstly,	pancreatic	surgery	involves	complex	procedures	and	it	has	been	proven	that	the	
surgeon’s	 technical	 skills	 will	 improve	 with	 years	 of	 practice	 and	 experience	 (41).		
Secondly,	 the	role	of	medical	oncologists	using	multimodality	 treatment	protocols	with	
concentrated	numbers	of	patients	with	pancreatic	cancer	treated	at	high	volume	centres	
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has	 beneficial	 impact	 on	 survival	 (42).	 Thirdly,	 immediate	 postoperative	 care	 is	 an	
essential	part	of	 the	patients’	 journey.	Medical,	nursing	and	other	healthcare	personnel	
acquire	 great	 experience	 by	 dealing	 with	 postoperative	 patients.	 This	 will	 enable	
prevention	 and	 early	 detection	 of	 immediate	 postoperative	 complications,	 therefore	
reducing	 postoperative	 mortality	 (43).	 Furthermore,	 the	 availability	 of	 on	 site	
interventional	 radiology	 expertise	 dealing	with	 postoperative	 complications	 has	 led	 to	
reduction	in	re	surgery	rates	and	mortality	(44).	Their	influential	role	is	essential	part	of	
the	 regional	 cancer	 centre	 structure.	 Other	 health	 care	 systems	 in	 the	 USA	 and	
Netherlands	 have	 shown	 a	 similar	 reduction	 in	 postoperative	 mortality	 and	 better	
survival	rates	by	concentrating	the	service	into	large	volume	centres	(33,	34,	45,	46).	
2.2 Structure	of	HPB	cancer	services	
The	NHS	executive	evidence	in	2001	“	Improving	outcomes	in	upper	gastrointestinal	
cancers”	 (47)	 has	 highlighted	 the	 key	 recommendations	 necessary	 for	 creating	 a	 new	
service	model	for	the	cancer	services	(Figure	2-1).	Establishment	of	 inter-linked	cancer	
units	 and	 cancer	 centres	 within	 appropriate	 cancer	 networks	 is	 part	 of	 the	
reconfiguration	 process	 of	 cancer	 services	 in	 the	 NHS	 in	 order	 to	 provide	 effective	
treatment	and	to	reduce	treatment	associated	morbidity	and	mortality.	
2.2.1 Cancer	Units	
The	following	are	the	minimum	requirements	to	set	up	a	pancreatic	cancer	unit	are:	
I. Multidisciplinary	 team	 (MDT)	 formed	 of	 medical	 and	 surgical	
gastroenterology,	 radiology,	 pathology,	 cancer	 nurse	 specialist	 and	
oncology.	
II. Radiological	 facilities	 include	ultrasound	 scan,	MDCT,	MRI,	 endoscopic	 or	
laparoscopic	guided	biopsy	especially	for	patients	deemed	non	resectable.	
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These	 facilities	 should	 establish	 a	 diagnosis	 and	 assess	 the	 tumour	
resectability.	
III. Therapeutic	 facilities	 including	 resources	 for	 radiological	 or	 endoscopic	
biliary	stent	application	and	at	least	surgical	palliation.	It	is	anticipated	that	
the	cancer	unit	is	able	to	provide	effective	palliation	for	70-80%	of	patients.	
IV. Ancillary	 services	 include	 intensive	 care	 unit,	 high	 dependency	 unit,	 pain	
team	able	to	provide	acute	and	chronic	pain	service,	and	dedicated	nutrition	
team.	
2.2.2 Cancer	centre	
The	designated	HPB	cancer	centres	are	usually	based	in	either	university	teaching	
hospitals	 or	 large	 regional	 hospitals	 where	 full	 radiology,	 endoscopy	 and	 oncology	
services	are	available.	In	addition	to	the	basic	requirements	to	provide	the	service	at	the	
pancreatic	 cancer	 units	 level,	 the	 HPB	 cancer	 centres	 must	 have	 at	 least	 weekly	 MDT	
meetings	 where	 patients	 are	 jointly	 assessed	 by	 relevant	 MDT	 members	 including:	
physicians,	surgeons,	oncologists,	cancer	nurse	specialists,	radiologists,	histopathologists,	
palliative	care	specialists,	nutritionists	and	research	personnel.	The	referring	units	should	
have	access	 to	 these	MDT	meetings	and	 to	 the	 final	decision	made	by	 the	specialist	HPB	
team	 in	 order	 to	 start	 treatment	 for	 referred	 patients.	 This	 link	 between	 the	 referring	
hospital	 and	 the	 regional	 centre	 could	 be	 established	 by	 means	 of	 electronic	 image	
transfer	system	and	through	virtual	video-link	meeting.	
2.2.3 Numbers	of	surgeons	and	surgeon	volume	
It	is	recommended	that	the	specialised	HPB	units	should	have	at	least	5	surgeons,	
with	 each	 surgeon	 required	 for	 approximately	 0.5	 million	 of	 population	 in	 order	 to	
provide	continuous	elective	and	emergency	services.	All	 surgeons	should	be	able	 to	deal	
with	acute	HPB	referrals	regardless	of	the	subspecialisation	interest.		
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The	number	of	resections	is	expected	to	be	about	60-70	pancreatic	resections	per	year	
for	 every	 2	 million	 population	 served.	 As	 the	 workload	 is	 currently	 shared	 between	
consultants	within	the	unit,	there	is	no	current	recommendations	regarding	the	individual	
surgeon’s	volume;	however	 it	 is	 expected	 to	be	equally	 shared	between	 the	members	of	
the	surgical	team.	The	practice	of	two-consultant	operation	should	be	encouraged	within	
the	unit	especially	for	high-risk	complex	cases.	
2.2.4 Specialist	radiologist		
The	HPB	cancer	centre	is	expected	to	have	consultant	radiologists	with	special	interest	
and	 expertise	 in	HPB	 radiology	 including	Ultrasound	 scans,	 CT	 scan,	MRI,	 PET	 scan	 and	
EUS.	 It	 is	 recommended	 that	 the	 unit	 should	 have	 24-	 hour	 interventional	 radiology	
service	 to	 support	 the	 emergency	HPB	 services.	 It	 is	 also	 recommended	 that	 the	 cancer	
centre	has	expert	 interventional	oncology	 for	purpose	of	 chemo	and	radio-embolization,	
however	when	 this	 service	 is	not	 available	on	 site,	 there	 should	be	a	 link	with	a	nearby	
centre	to	provide	the	service	when	required.	
2.2.5 Specialist	endoscopy	
Endoscopy	 service	 is	 essential	 part	 of	 the	 regional	 HPB	 centre	 providing	 daily	
routine	 and	 emergency	 services.	 The	 service	 includes	 OGD,	 ERCP	 and	 EUS	 provided	 by	
expert	surgeons,	radiologists,	gastroenterologists	and	hepatologists.	
2.2.6 Specialist	pathology	
Consultant	 pathologist	 with	 a	 special	 interest	 in	 HPB	 malignancy	 is	 a	 crucial	
member	of	the	regional	MDT	meeting.	This	service	should	be	available	onsite	with	regular	
involvement	in	the	weekly	MDT	meeting.		
2.2.7 Cancer	nurse	specialist	
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The	role	of	the	cancer	nurse	specialist	is	to	support	patients	and	their	family	from	
the	time	of	the	diagnosis	and	during	their	treatment	journey	and	postoperative	care.			
2.2.8 Anaesthetist	and	critical	care	specialists		
It	 is	 expected	 that	 HPB	 regional	 centre	would	 have	 a	 team	 of	 anaesthetists	 and	
intensivists	with	special	interest	in	HPB	disease.	Their	role	is	to	ensure	optimal	pre-,	peri-	
and	post-operative	management	of	patients	undergoing	major	HPB	surgery.	This	 include	
access	to	both	level	2	and	level	3	beds.	
2.2.9 Non-surgical	oncology	specialist	
It	 is	 required	 that	 the	 regional	 HPB	 centre	 would	 have	 medical	 and	 clinical	
oncology	 expertise	 to	 cover	 the	 range	 of	HPB	 cancers	 including	 primary	 and	metastatic	
cases.	They	are	encouraged	to	take	part	of	clinical	trials	when	available.	
2.2.10 Audit	and	monitoring			
Each	 HPB	 centre	 should	 adopt	 regular	 monitoring	 with	 regular	 peer	 review	
assessment	 to	 be	 able	 to	 validate	 their	 data	 and	 to	 maintain	 their	 status	 as	 a	 tertiary	
regional	centre.	The	process	of	data	collection	has	become	an	integral	part	of	the	surgeon’s	
portfolio	as	well	as	the	appraisal	and	revalidation	requirements.	Furthermore	there	is	an	
increasing	 public	 demand	 for	 information	 about	 the	 quality	 of	 the	 services	 indicated	 by	
volume	 of	 work	 and	 outcomes.	 Currently,	 the Association	 of	 Upper	 Gastrointestinal	
Surgeons	(AUGIS)	and	the	Great	Britain	and	Ireland	Hepato-Pancreaticobiliary	Association	
(GBIHPBA)	 are	 developing	 the	 Surgical	 Workload	 Outcomes	 Audit	 Database	 (SWORD)	
(48),	 a	national	database	 to	 facilitate	 individual	 surgeons	and	 cancer	units	 to	 view	 their	
own	data	 as	well	 as	 their	peers	outcomes.	Auditing	process	 also	 includes	 examining	 the	
referral	pathway,	management	protocols,	outcomes	 including	the	resection	rate,	hospital	
mortality	and	the	morbidity,	and	survival	rate.	
	
	 29	
2.2.11 Education,	training	and	research	
The	current	training	recommendation	for	surgeons	to	specialise	in	HPB	surgery	is	
to	achieve	successful	completion	of	their	training	in	General	Surgery	as	well	as	spending	a	
minimum	of	one	and	preferably	two	years	at	senior	training	years	(ST7	and	ST8)	in	a	HPB	
unit.	A	Post-CCT	senior	 fellowship	 is	also	recommended	for	one	to	two	years	 in	order	to	
consolidate	advanced	surgical	skills	especially	for	complex	procedures.		
Clinical	 research	and	 involvement	 in	randomised	 trials	 is	an	essential	part	of	 the	
continuous	professional	development	 for	doctors.	 It	 is	 therefore	recommended	that	HPB	
surgeons	should	actively	participate	in	research	activities	and	clinical	trials.	Nominating	a	
research	 lead	 that	 could	 co-ordinate	 and	 plan	 research	 projects	 locally	 or	 through	 a	
collaborative	 work	 could	 facilitate	 engagement	 in	 clinical	 research	 activities	 as	 well	 as	
recruiting	patients	into	NIHR	funded	randomised	trials.	This	could	be	a	good	opportunity	
for	trainees	who	wish	to	pursue	HPB	research.		
2.2.12 Early	diagnosis	and	screening	
In	the	UK,	there	are	no	current	guidelines	for	pancreatic	cancer	screening.	This	is	
probably	due	to	the	fact	that	 low	disease	incidence	as	well	as	there	is	no	ideal	screening	
tools.	 It	 is	 recommended	 however	 that	 high-risk	 patients	 such	 as	 patients	with	 Familial	
Adenomatous	Polyposis	 	(FAP)	should	undergo	3-yearly	duodenoscopy	starting	from	age	
of	18	years	old.	
2.2.13 Outcome	standards	
The	quality	pancreatic	 cancer	 service	 is	measured	by	 certain	 criteria	 including	 a	
yearly	pancreatic	resection	rate	of	60-70	with	postoperative	mortality	rates	less	than	5%,	
10%	 and	 20%	 for	 in–hospital,	 90-day	 and	 1-year	 mortality	 respectively.	 Whipple’s	
procedure	 as	 well	 as	 Pylorus	 Preserving	 Pancreatico-Duodenectomy	 (PPPD)	 are	 the	
recommended	surgical	approaches	with	the	aim	to	achieve	a	median	number	of	at	last	15	
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lymph	 nodes	 harvested.	 Postoperatively,	 all	 patients	 should	 follow	 Enhanced	 Recovery	
After	Surgery	(ERAS)	protocols	with	expected	length	of	stay	to	be	less	than	14	days.	The	
long-term	survival	is	determined	by	several	factors;	nevertheless	the	cancer	unit	survival	
rates	should	be	consistent	with	published	figures.	
	
Figure	2-1	Service	model	for	pancreatic	and	oesophagogastric	cancer	services	“	Improving	
outcomes	in	upper	gastrointestinal	cancers”	(47).	
 
 
 
 
 
 
  
Frail patients 
 
 
 
 
 
Symptoms	meeting	
urgent	referral	criteria	
Histologically	confirmed	
Upper	GI	Cancer	
GP/Primary	Care	 Routine	Referral	
Community	Palliative	
Care	
Local	Upper	GI	cancer	
Team	
Palliative care team 
Tests	suggesting	
Pancreatic	cancer	
Discuss with specialist 
OG team 
Specialist OG cancer 
team 
Specialist pancreatic 
cancer team 
Discuss with specialist 
pancreatic team 
Fat Track 
	
	 31	
2.3 Referral	pathway	into	the	tertiary	HPB	centre	
In	 the	 UK,	 the	 current	 practice	 shows	 that	 gastroenterologists	 often	 investigate	
patients	presented	with	jaundice	who	might	be	developing	a	pancreatic	head	malignancy.	
There	 are	 several	 steps	 in	 the	 referral	 pathway	before	 surgery	 is	 undertaken	which	 are	
summarised	 in	 (Figure	 2-2).	 This	 current	 pathway	 commonly	 takes	 about	 2-3	 months	
before	surgery	is	undertaken	and	is	longer	for	patients	referred	from	outside	the	regional	
centres.	 Although	 many	 of	 these	 patients	 do	 not	 suffer	 pain,	 they	 can	 suffer	 other	
symptoms	 due	 to	 biliary	 obstruction	 including	 pruritus,	 indigestion,	 loss	 of	 weight	 and	
diarrhoea.	 For	 this	 reason	 most	 patients	 undergo	 an	 ERCP	 and	 insertion	 of	 a	 stent	 to	
relieve	 biliary	 obstruction	 at	 the	 referring	 unit,	 although	 there	 is	 a	 strong	 evidence	 to	
support	 proceeding	 to	 pancreatic	 resection	 without	 preoperative	 biliary	 drainage	 on	
patients	with	 bilirubin	 level	 less	 than	 250umol	 (49,	 50).	 Therefore,	 patients	 presenting	
with	 jaundice	 need	 to	 be	 discussed	 with	 the	 tertiary	 HPB	 centre	 with	 regard	 to	 the	
appropriate	management	protocol.	
The	current	operational	pressures	 relating	 to	 theatre	capacity	and	 ITU	availability	
within	the	NHS	might	cause	a	further	delay.	Patient	anxiety	regarding	delays	to	surgery	is	
commonly	experienced	during	consultations	and	the	possible	influence	of	these	delays	on	
the	outcome	is	often	raised.	
	
	 32	
	
Figure	2-2	Patient	pathways	before	surgery	for	periampullary	cancer	
	
It	 is	 recommended	 that	 patients	 with	 symptoms	 that	 might	 raise	 the	 suspicion	 of	
pancreatic	cancer	should	be	referred	for	investigations	such	as	ultrasound	scan,	CT	scan	or	
MRI,	 which	 could	 be	 arranged	 at	 the	 DGH	 on	 an	 outpatient	 basis.	 Further	 specialised	
investigations	such	as	EUS	or	ERCP	should	be	carried	out	at	the	specialised	HPB	centre.	
	The	following	criteria	should	be	referred	to	the	cancer	unit	for	further	investigations:	
I. Obstructive	jaundice		
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II. Unexplained	weight	loss	
III. Unexplained	gastrointestinal	bleeding	or	iron	deficiency	anaemia	(in	absence	of	an	
upper	gastrointestinal	or	colorectal	cause)	
IV. Unexplained	upper	abdominal	or	back	pain	
V. Unexplained	steatorrhoea.	
VI. ‘‘Idiopathic’’	 acute	 pancreatitis	 (no	 gall	 stones,	 no	 alcohol)	 in	 patients	 over	 50	
years	of	age.	
VII. Unexplained	diabetes	 in	patients	over	50	years	of	age	(no	family	history,	obesity,	
or	steroids).	
	
Patients’	referral	should	follow	an	agreed	documented	referral	policy	between	the	general	
practitioner	(GP)	and	the	cancer	unit	and	also	between	the	local	district	general	hospital	
(DGH)	and	the	specialized	HPB	centre	which	expected	to	provide	a	24-hour	on	call	service	
by	the	regional	HPB	surgeon.	This	allows	regional	cover	for	HPB	emergencies	that	might	
require	 immediate	patient	transfer	to	the	centre	or	urgent	transfer	within	24	hours.	The	
two-week	waiting	policy	should	be	adopted	by	the	cancer	units	receiving	GP	referrals	and	
by	the	regional	HPB	centres	responding	to	the	cancer	unit	referrals.	
	
2.4 Structure	and	current	practice	of	the	Peninsula	HPB	cancer	centre	
The	Peninsula	HPB	unit,	established	in	2006,	is	the	regional	centre	for	liver,	pancreatic	
and	biliary	cancer	services	as	well	as	benign	diseases	within	the	South	West	of	England.		It	
is	based	in	Derriford	Hospital,	Plymouth,	UK.		The	current	team	consists	of	four	consultant	
surgeons,	six	consultant	hepatologists,	four	consultant	radiologists	with	special	interest	in	
gastro-intestinal	 diseases,	 two	 consultant	 oncologists,	 two	 cancer	 nurse	 specialists	 and	
one	consultant	histopathologist.	The	unit	acts	as	both	local	and	tertiary	referral	centre	that	
receives	 referrals	 from	 other	 hospitals	 across	 the	 South	 West	 Peninsula.	 The	 unit	 is	
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currently	 benefiting	 from	 having	 on	 site	 facilities	 such	 as	 CT	 scan,	MRI,	 PET	 scan,	 EUS,	
Endoscopy,	 ERCP	 as	 well	 as	 interventional	 radiology	 to	 ensure	 continuous	 24-	 hour	
service	 provision	with	 on	 call	 consultant	 surgeon	 dealing	with	 acute	 referrals	 and	 HPB	
emergencies.	 All	 patients	 referred	 to	 the	 unit	 are	 discussed	 at	 the	 regional	 HPB	 MDT	
before	being	offered	surgery.	Video-audio	link	with	the	referring	hospitals	have	been	used	
to	ensure	access	to	these	meetings.	The	current	practice	is	to	offer	surgery	to	all	referred	
patients	with	resectable	or	borderline	resectable	disease.	Surgical	resection	is	performed	
by	 classic	Whipple’s	 procedure	 with	 pancreatico-gastrostomy	 reconstruction.	 In-patient	
care	follows	a	standard	Enhanced	Recovery	After	Surgery	(ERAS)	protocol.	
The	unit	 is	 actively	 engaged	 in	 audit,	 research	 and	publications	within	 areas	of	HPB	
diseases.	The	unit	offers	opportunities	for	surgical	trainees	and	clinical	research	fellows	to	
enhance	their	knowledge	in	HPB	related	research	projects.	The	unit	offers	higher	training	
opportunities	 in	HPB	 surgery	 via	 an	 established	 fellowship	 program	 for	 senior	 trainees	
with	special	interest	in	liver,	pancreatic	and	biliary	surgery.	 
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3 Anatomy	and	physiology		
3.1 Anatomic	history	
Eristoratos	(310-250	BC)	was	 the	 first	 to	mention	“Pancreas”	 in	his	writings	(51).	 In	
1543,Vesalius	mentioned	 the	word	 ‘Pancreas’	 as	derived	 from	 its	Greek	name	 ‘pan’	 (all)	
and	 ‘kreas’	 (flesh)(52,	 53).	 In	 1642,	Wirsung	 described	 the	main	 pancreatic	 duct	 (main	
pancreatic	 duct	 of	 Wirsung)(54).	 Santorini	 noticed	 the	 presence	 of	 the	 accessory	
pancreatic	duct	later	in	1724	(55).	He	also	described	the	main	and	the	accessory	duodenal	
papillae.	 In	1685,	Gottfreid	Bidloo	was	 the	 first	 to	 illustrate	 the	presence	of	 the	ampulla	
(the	common	duct	dilatation)	and	the	papilla	(the	projection	into	the	postero-medial	wall	
of	the	second	part	of	the	duodenum)(56).	However	it	was	named	after	Abraham	Vater	in	
1720	who	subsequently	confirmed	Bidloo’s	findings	(57).	
3.2 Morphological	description,	anatomical	location	and	relationship	
3.2.1 Pancreas	
For	 morphological	 description,	 the	 pancreas	 is	 divided	 into	 the	 head	 representing	
about	30%	of	the	gland	while	the	neck,	body	and	tail	represents	nearly	70%	(51,	58).	
It	weighs	about	80	g	and	lies	transversely	fixed	in	the	retroperitoneal	space	between	
the	 duodenum	 on	 the	 right	 side	 and	 the	 spleen	 on	 the	 left	 side	 with	 the	 transverse	
mesocolon	 lying	 anteriorly.	 The	 omental	 bursa	 lies	 superiorly	 and	 the	 greater	 sac	 lies	
inferiorly	(59,	60).	The	pancreatic	head	lies	within	the	duodenal	concavity	opposite	to	the	
level	of	the	second	lumbar	vertebra.	Osler	has	described	the	relationship	of	the	pancreatic	
head	 and	 the	duodenal	 loop	 as	 “The	 abdominal	 area	 of	 romance,	where	 the	head	of	 the	
pancreas	lies	folded	in	the	arms	of	the	duodenum”(61).			
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Coming	off	the	head	is	the	uncinate	process,	which	lies	in	front	of	the	aorta	and	the	inferior	
vena	cava	(IVC)	and	relates	anteriorly	to	the	superior	mesenteric	vessels.	
The	 pancreatic	 neck	 represents	 the	 junction	 between	 the	 head	 and	 the	 body	 and	 is	
related	 posteriorly	 to	 the	 superior	mesenteric	 vessels	 and	 the	 junction	 between	 splenic	
vein	and	the	superior	mesenteric	vein	(SMV)	forming	the	portal	vein	(PV).	
The	 body	 is	 separated	 anteriorly	 from	 the	 posterior	 surface	 of	 the	 stomach	 by	 the	
lesser	sac.	The	transverse	mesocolon	lies	anteriorly.	 It	 is	related	posteriorly	to	the	aorta,	
the	 origin	 of	 the	 superior	 mesenteric	 artery	 (SMA),	 left	 crus	 of	 the	 diaphragm,	 splenic	
vessels,	left	kidney	along	with	the	left	renal	vessels	and	the	left	suprarenal	gland.	
The	 tail	 extends	 to	 the	 left	 between	 the	 two	 layers	 of	 the	 lienorenal	 ligament.	 It	 is	
relatively	mobile,	compared	to	other	parts,	and	reaches	the	splenic	hilum	in	about	50%	of	
individuals	(51,	61).	
3.2.2 Pancreatic	ducts	and	Common	bile	duct	
The	pancreatic	duct	system	classically	consists	of	the	main	pancreatic	duct	of	Wirsung	
and	the	accessory	duct	of	Santorini.	
The	 main	 pancreatic	 duct	 of	 Wirsung	 starts	 at	 the	 pancreatic	 tail	 by	 junction	 of	
multiple	lobular	ducts	and	runs	through	the	tail	and	the	body,	midway	between	the	upper	
and	lower	pancreatic	margins	closer	to	the	posterior	surface,	towards	the	head.	As	it	runs	
within	the	body	it	increases	in	diameter	as	it	receives	further	lobular	ducts	that	open	into	
the	main	duct	at	right	angles	in	alternate	fashion	(Herringbone	pattern)(51,	60).	
At	 the	head	 it	 joins	 the	common	bile	duct	 (CBD),	 formed	by	 junction	of	 the	common	
hepatic	duct	and	the	cystic	duct	in	the	lateral	portion	of	hepato-duodenal	ligament,	into	a	
common	 pancreaticobiliary	 duct,	 which	 then	 opens	 into	 the	 papilla	 of	 Vater	 (major	
duodenal	papilla)	on	the	posteromedial	wall	of	the	second	part	of	the	duodenum	(62,	63).	
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The	 accessory	 duct	 of	 Santorini	 starts	 at	 the	 pancreatic	 head	 closer	 to	 its	 anterior	
surface	 (opposed	 to	 the	 main	 duct)	 by	 junction	 of	 several	 lobular	 ducts.	 It	 drains	 the	
antero-superior	 part	 of	 the	 head	 and	 the	 uncinate	 process.	 It	 opens	 into	 the	 minor	
duodenal	 papilla,	 which	 lies	 cephalad	 to	 the	 major	 duodenal	 papilla,	 or	 into	 the	 main	
pancreatic	duct	in	some	cases	(60,	62).	
3.2.3 Ampulla	of	Vater	
Ampulla	 is	defined	as	 a	dilatation	of	 the	 common	pancreatico-biliary	 channel	on	 the	
postero-medial	wall	of	 the	second	part	of	 the	duodenum	adjacent	 to	 the	major	duodenal	
papilla.	 It	 lies	approximately	7-10	cm	 from	the	pylorus	 (61)	and	has	been	classified	 into	
three	 types	by	Michels	 (64)	based	on	 the	 site	of	opening	of	 the	pancreatic	 and	 common	
bile	ducts	and	colleagues	have	classified	the	ampulla	into	three	types:	
3.3 Arterial	supply	and	venous	drainage	
The	pancreatic	vascular	system	(Figure	3.1)	is	a	complex	system	with	frequent	normal	
variations.	The	arterial	vascular	network	is	derived	from	the	coeliac	axis	and	the	superior	
mesenteric	 artery	 (SMA).	 The	 head	 of	 pancreas	 receives	 its	 arterial	 blood	 supply	 via	
branches	 derived	 from	 anterior	 and	 posterior	 arterial	 arcades.	 Arteries	 forming	 this	
complex	 arterial	 circulation	 arise	 from	 the	 gastro-duodenal	 artery	 (GDA),	 forming	 the	
superior	 component	 of	 the	 arcade,	 and	 the	 SMA	 forming	 the	 inferior	 component.	 This	
arterial	arcade	is	almost	always	present	and	it	supplies	the	head	of	the	pancreas	and	the	
duodenal	wall	along	its	concave	surface.	The	anterior	arterial	arcade	is	formed	by	junction	
of	anterior	superior	pancreatico-duodenal	artery	from	the	GDA,	branch	of	the	celiac	trunk,	
and	the	anterior	inferior	pancreatico-duodenal	artery	from	the	SMA.	Junction	of	posterior	
superior	 pancreatico-duodenal	 artery,	 from	 the	 GDA,	 and	 the	 posterior	 inferior	
pancreatico-duodenal	artery	of	the	SMA	forms	the	posterior	arterial	arcade.	
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The	 body	 and	 tail	 are	 supplied	 via	 numerous	 named	 and	 unnamed	 branches	 of	 the	
splenic	 and	 the	 left	 gastro-epiploic	 arteries	 (51,	 58,	 60,	 65,	 66).	 The	 ampulla	 of	 Vater	
receives	 arterial	 blood	 supply	 via	 the	 posterior	 superior	 pancreatico-duodenal	 artery,	
branches	 of	 the	 gastro-duodenal	 artery,	 which	 anastomose	 with	 the	 posterior	 inferior	
pancreatico-duodenal	artery,	 and	branches	of	 the	 superior	mesenteric	artery.	The	 retro-
duodenal	 artery,	 branch	 of	 the	 GDA,	 gives	 origin	 to	 the	 ascending	 branches	 that	
anastomose	with	 the	descending	branches	of	 the	 cystic	 and	 right	hepatic	 arteries	 at	 the	
lower	part	of	the	CBD	(61).	
The	venous	drainage	of	the	pancreas	(Figure	3.1)	is	through	veins	that	run	parallel	and	
superficial	 to	 their	 arterial	 counterparts.	 The	 main	 venous	 drainage	 is	 into	 the	 portal,	
splenic,	superior	and	inferior	mesenteric	veins	while	the	pancreatic	neck	represents	a	site	
of	confluence	of	the	entire	portal	circulation	where	the	splenic	vein	joins	the	SMV	forming	
the	 portal	 vein	 posterior	 to	 the	 neck,	 which	 in	 turn	 receives	 the	 posterior	 superior	
pancreatico-duodenal	vein	(51,	58,	60).	
	
Figure	3-1	The	arterial	blood	supply	and	the	venous	drainage	of	the	pancreas	(Cesmebasi	A,	
et	al.(67)	With	permission	granted	for	thesis	purpose).
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3.4 Lymphatic	drainage	
The	lymphatic	drainage	of	the	pancreas	is	formed	of	extensive	tributaries	followed	by	
lymphatic	channels,	which	accompany	the	blood	vessels	in	the	interlobular	spaces	and	on	
the	 surface	 of	 the	 pancreas.	 They	 drain	 into	 five	 main	 collecting	 lymphatic	 trunks	 and	
lymph	node	groups	namely	superior,	inferior,	anterior,	posterior	and	splenic	as	classified	
in	 1978	 by	 Cubilla	 (68)	 based	 on	 their	 anatomical	 location	 around	 the	 pancreas.	 The	
mapping	 system	 published	 by	 the	 Japanese	 Pancreas	 Society	 has	 assigned	 a	 station	
numerical	 code	 corresponding	 to	 the	 node	 anatomical	 location	 (Figure	 3.2)(69).	 The	
following	 nodes	 should	 be	 included	 in	 standard	Whipple’s	 procedure:	 supra	 and	 infra-
pyloric	(station	5&6),	along	CHA	(station	8a),	along	bile	duct	(station	12b),	around	cystic	
duct	 (station	 12c),	 posterior	 aspect	 of	 the	 superior	 and	 inferior	 portions	 of	 pancreatic	
head	(station	13a),	right	lateral	side	of	SMA	(station	14a&14b),	on	anterior	surface	of	the	
superior	and	inferior	portion	of	pancreatic	head	(station	17a&17b)	(70).	
	
	Figure	3-2	Japan	Pancreas	Society	nomenclature	of	peri-	pancreatic	lymph	nodes		
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3.5 Nerve	supply	
The	sympathetic	nerve	supply	is	derived	from	the	6th	to	10th	thoracic	spine	segments.		
The	parasympathetic	 fibers	are	 through	the	coeliac	division	of	 the	posterior	vagal	 trunk.	
Sensory	 fibers	 and	 fibers	 carrying	 pain	 sensation	 from	 the	 pancreas,	 run	 through	
sympathetic	and	parasympathetic	systems	(60,	71).	
3.6 Physiology		
The	pancreas	functions	as	a	mixed	gland	with	endocrine	and	exocrine	properties	with	
the	 endocrine	 cells	 embedded	 into	 exocrine	 part.	 The	 main	 function	 of	 the	 endocrine	
pancreas	 is	 to	 regulate	 blood	 glucose	 level	 through	 production	 of	 several	 hormones	
involved	 in	 glucose	 metabolism	 including	 Glucagon,	 Insulin,	 Somatostatin,	 Gastrin	 and	
Pancreatic	Polypeptide	hormones	 secreted	by	Alpha,	Beta,	Delta	 and	Gamma	 (F)	 cells	of	
the	 islets	 of	 Langerhans	 respectively	 (72).	 The	 control	 of	 the	 endocrine	 pancreas	 is	
exclusively	under	the	parasympathetic	nervous	system	(73).	Acetylcholine	stimulates	the	
secretion	of	insulin	and	glucagon	while	noradrenaline	suppress	insulin	release	in	response	
to	high	glucose	levels.	It	also	inhibits	the	release	of	somatostatin	and	PP	hormones	(71,	72,	
74,	75).	
The	main	 function	of	 the	exocrine	pancreas	 is	 secretion	of	 clear	watery	alkaline	 (pH	
8.0-8.3)	juice	that	is	rich	in	digestive	enzymes.	These	include	proteolytic	enzymes	(trypsin,	
chymotrypsin,	 elastase,	 ribonuclease	 and	 deoxyribonuclease),	 lipolytic	 enzymes	 (lipase,	
colipase	 and	 phospholipase	 A2)	 and	 amylolytic	 enzymes	 (amylase).	 It	 is	 regulated	 by	 a	
complex	neuro-hormonal	mechanism.	In	addition	to	the	vagal	cholinergic	fibers,	the	ductal	
and	centro-acinar	cells	(bicarbonate	ions	and	water	transport)	are	under	the	control	of	the	
hormone	 Secretin	 (produced	 by	 duodenum	 and	 jejenum)	 while	 the	 exocrine	 acini	
(pancreatic	digestive	enzymes	release)	are	under	control	of	the	duodenal	cholecystokinin	
hormone	(71,	72).	
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3.7 Periampullary	cancers	
Periampullary	cancers	 include	malignant	 tumours	arising	 from	Ampulla	of	Vater	and	
other	 organs	within	 1	 cm	 as	 these	 tumours	 tend	 to	 have	 a	 similar	 clinical	 presentation.	
These	tumours	include	carcinoma	of	the	head	of	pancreas,	ampullary	carcinoma,	distal	bile	
duct	cancer	and	duodenal	cancer	(76).	Identification	of	the	exact	site	of	the	tumour	origin	
could	be	difficult	due	to	the	close	anatomical	proximity	of	these	sites	histological	similarity.	
The	 clinical	 distinction	 between	 non-pancreatic	 periampullary	 cancers	 from	 pancreatic	
cancer	found	in	the	region	of	pancreatic	head	is	challenging	however,	For	staging	purposes,	
this	distinction	between	 these	 sites	 is	purely	based	on	anatomical	origin	of	 the	 tumours	
(TNM7)	
3.8 Presentation	
Patients	 with	 pancreatic	 head	 or	 periampullary	 cancer	 can	 often	 present	 with	
similar	 symptoms	 due	 to	 the	 close	 anatomical	 proximity	 of	 the	 organs	 involved.	 The	
presenting	 symptoms	 include	 manifestations	 of	 biliary	 obstruction	 in	 form	 of	 jaundice,	
dark	 urine,	 pruritus	 and	 acholic	 stool.	 Patients	 might	 experience	 intermittent	 vague	
abdominal	pain,	which	become	constant	and	severe	that	radiates	to	the	back	in	advanced	
cases.	Some	patients	might	present	with	nausea	and	vomiting,	which	might	indicate	locally	
advanced	 disease	 with	 gastric	 outlet	 obstruction	 or	 duodenal	 involvement.	 General	
manifestations	 include	 anorexia,	 unexplained	 iron	 deficiency	 anaemia,	 fatigue,	
unexplained	weight	loss	and	malaise.		
Pancreatic	 cancer	 should	be	excluded	 in	patients	with	new	adult	onset	diabetes	with	no	
family	history	or	predisposing	 factors	and	 in	patients	with	unexplained	episode	of	acute	
pancreatitis	 (76).	 Patients	with	 duodenal	 cancer	 usually	 present	with	 vague	 symptoms,	
which	include	intermittent	abdominal	discomfort,	vague	abdominal	pain,	GIT	bleeding,		
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3.9 Blood	tests	and	tumour	markers			
Full	 blood	 count	 may	 reveal	 anaemia	 or	 reactive	 thrombocytosis.	 Patients	 with	
biliary	 obstruction	 may	 show	 evidence	 of	 abnormal	 liver	 function	 tests	 with	 raised	
bilirubin,	 alkaline	 phosphatase,	 Gamma	 Glutamyltransferase	 (GGT),	 Alanine	
aminotransferase	(ALT)	and	Aspartate	aminotransferase	(AST).	
Cancer	Antigen	19-9	(CA19-9)	is	the	most	widely	used	tumour	marker	in	association	
with	pancreatic	cancer	diagnosis	and	surveillance	and	it	is	elevated	in	nearly	75%	of	cases.	
However	 it	 is	 a	 non-specific	 marker	 as	 it	 may	 be	 elevated	 in	 benign	 hepatobiliary	
conditions	like	acute	and	chronic	pancreatitis	or	in	some	cases	of	obstructive	jaundice.	
Other	tumour	markers	not	widely	used	in	clinical	settings	include	carcinoembryonic	
antigen-related	 cell	 adhesion	 molecule-1	 (CEACAM-1)	 (77),	 SPan-1	 (78),	 PAM4	 (79),	
macrophage	inhibitory	cytokine-1	(MIC-1)	(80),	faecal	KRAS	mutation	(81),	DUPAN-2	(82),	
alpha1,4-N-Acetylglucosaminyltransferase	 (alpha4GnT)	 (83)	 and	 DNA	 methylation	 in	
pancreatic	juice	(84).	
3.10 Histopathological	diagnosis	
Histopathological	 examination	 of	 the	 resected	 malignant	 pancreaticoduodenectomy	
specimens	 have	 shown	 that	 pancreatic	 head	 ductal	 adenocarcinoma	 (PDA)	 is	 the	 most	
common	histological	 type	 in	 this	group	of	malignant	 tumours	being	 found	 in	33-76%	(5,	
24,	85-87)	of	the	specimens,	followed	by	ampullary	carcinoma	in11.5%-36%	(7,	88),	distal	
bile	duct	cancer	in	nearly	5-28%	(5,	24,	85-87),	and	duodenal	carcinoma	in	about	5-14%	
(5,	24,	85-87).	
The	Royal	College	of	Pathologists	guidelines	highlights	the	standardised	reporting	of	
pancreatic	 and	 periampullary	 cancer	 specimens	 including	 axial	 slicing	 of	 resection	
specimens	 i.e.	 slicing	 perpendicular	 to	 the	 long	 axis	 of	 the	 duodenum	 (Figure	 3.3)(23).	
	
	 43	
This	has	 led	to	a	higher	rate	of	diagnosis	of	ampullary	and	bile	duct	cancer	compared	to	
pancreatic	cancer	(24).	
	
Figure	3-3	Head	of	the	pancreas	and	the	axial	dissection	
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3.11 Pancreatic	cancer	
The	term	pancreatic	cancer	usually	refers	to	PDA,	which	represents	about	85-90%	of	
primary	 exocrine	 pancreatic	 neoplasms	 with	 about	 two-third	 of	 cases	 are	 found	 in	 the	
pancreatic	head	(89).	
3.11.1 Incidence,	epidemiology	and	mortality	of	PDA	
PDA	is	one	of	 the	most	aggressive	 fatal	malignant	neoplasms	that	accounts	 for	about	
3%	of	all	cancers	and	about	7%	of	all	cancer	related	mortality	with	an	estimated	increased	
mortality	 figures	to	rank	4th	among	cancer	related	deaths	 in	the	USA	(1).	 	 In	the	UK,	 it	 is	
the	eleventh	most	common	diagnosed	cancer	in	the	UK	(12).	
Less	 than	20%	of	patients	have	a	 resectable	 tumour	at	 the	 time	of	diagnosis	with	5-
year	 survival	 rate	 of	 3-5%	 that	 would	 increase	 to	 about	 6.5%-20%	 in	 patients	 with	
successful	surgical	resection	(3-10).		
Pancreatic	 ductal	 adenocarcinoma,	 which	 accounts	 for	 more	 than	 90%	 of	 all	
pancreatic	 tumours,	 is	 a	 devastating	 malignancy	 with	 an	 extremely	 poor	 prognosis,	 as	
shown	by	 a	 1-year	 survival	 rate	 of	 around	 18%	 for	 all	 stages	 of	 the	 disease	 and	 5	 year	
survival	 of	 less	 than	 7%	 (90).	 Survival	 rates	 for	 patients	with	 PDA	 are	 extremely	 poor,	
primarily	due	to	the	majority	of	tumours	being	at	an	advanced	stage	at	diagnosis	(91,	92).	
3.11.2 Aetiology	and	risk	factors	for	pancreatic	cancer	
Several	risk	factors	have	been	identified	as	predisposing	factors	in	the	pathogenesis	of	
pancreatic	adenocarcinoma.	
3.11.2.1 Smoking	
Smoking	 has	 been	 universally	 identified	 as	 a	well-established,	major	modifiable	 risk	
factor	accounting	for	25-30%	of	the	causes	(93).	Current	smokers	carry	a	significant	75%	
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increased	risk	of	developing	pancreatic	cancer	compared	to	non-smokers	with	a	positive	
dose	response	effect,	depending	on	the	number	of	cigarettes	smoked	and	the	duration	of	
smoking,	which	might	 persist	 for	 a	minimum	of	 ten	 years	 after	 smoking	 cessation	 (93).	
Several	epidemiological	studies	have	confirmed	the	role	of	smoking	in	the	pathogenesis	of	
pancreatic	 cancer	 (94-119).	 Moreover	 smoking	 has	 been	 identified	 as	 a	 risk	 factor	 for	
familial	pancreatic	cancer	(120).	Tobacco	carcinogens	can	reach	the	pancreatic	gland	via	
blood	stream	or	directly	through	passage	of	the	ingested	tobacco	from	duodenum	into	the	
pancreatic	 duct.	 Smokeless	 tobacco	 such	 as	 chewing	 tobacco,	 snuffs	 and	 pipes	 has	 been	
identified	 as	 a	 risk	 factor	 (121-123).	 Pancreatic	 cancer	 mortality	 is	 increased	 among	
current	smokers	with	risk	increased	as	high	as	60%	(124-126).		
Smoking	 cessation	has	been	 associated	with	potential	 risk	 reduction,	 however	 the	 exact	
duration	 of	 smoking	 cessation	 required	 to	 reduce	 the	 risk	 to	 non-smoker	 levels	 is	
debatable	and	ranges	from	5	to	20	years	(94,	97,	98,	125).	On	the	other	hand,	a	hospital	
based	case-control	study	in	Italy	by	Talmini	(99)	and	a	population	based	Canadian	study	
by	Anderson	(127),	concluded	that	no	association	existed	between	quitting	smoking	and	
pancreatic	cancer	risk	reduction.	
Implementing	 smoking	 cessation	 programs	 have	 shown	 risk	 reduction	 in	 pancreatic	
cancer	mortality	(128).		
3.11.2.2 Alcohol	
The	 role	 of	 alcohol	 consumption	 in	 the	 development	 of	 pancreatic	 cancer	 is	
controversial	 with	 inconsistent	 results.	 Several	 epidemiological	 studies	 revealed	 an	
association	 between	 alcohol	 intake	 and	 the	 risk	 of	 pancreatic	 cancer	 especially	 among	
heavy	 drinkers	 with	 increased	 years	 of	 drinking	 (96,	 99,	 129-133).	 On	 the	 other	 hand,	
some	 studies	 concluded	 no	 link	 between	 alcohol	 consumption	 and	 development	 of	
pancreatic	cancer	(95,	134).	
	
	 46	
3.11.2.3 Body	weight	and	physical	activity	
Increased	 body	 weight,	 high	 body	 mass	 index	 (BMI	 ≥30)	 and	 the	 lack	 of	 physical	
activity	 have	 been	 identified	 as	 potential	 risk	 factors	 for	 pancreatic	 cancer.	 Several	
epidemiological	studies	demonstrated	the	association	between	increased	BMI	and	the	risk	
of	developing	pancreatic	cancer	(96,	124,	127,	135-138).	On	the	contrary	reduced	risk	was	
linked	to	regular	physical	activity	but	with	inconsistent	results	(139-141).	
3.11.2.4 Pancreatitis	
The	 relation	 between	 pancreatitis	 and	 development	 of	 pancreatic	 cancer	 is	 well	
established	with	increased	relative	and	absolute	risk	especially	with	age.	The	latent	period	
between	 the	 attack	 of	 pancreatitis	 and	 the	 development	 of	 the	 pancreatic	 cancer	 is	
variable	with	each	type	of	pancreatitis	including	chronic,	acute	and	hereditary	pancreatitis	
(100,	127,	142-149).		
3.11.2.5 Diabetes	
Diabetes	is	linked	to	increased	risk	of	pancreatic	cancer	development	(127,	132,	150,	
151).	 Insulin	 dependent	 diabetic	 patients	 are	 at	 a	 higher	 risk	 when	 compared	 to	 other	
diabetic	patients	(100,	149).	
Clinical	presentation	of	recent	onset	(less	than	two	years)	adult	diabetes	should	raise	
the	suspicious	of	pancreatic	cancer,	which	should	be	excluded	especially	 if	no	associated	
family	history	of	diabetes	or	predisposing	factors	like	obesity	or	steroid	therapy	(76)	are	
present.	
3.11.2.6 Diet	
The	 association	 between	 pancreatic	 cancer	 risk	 and	 certain	 food	 ingredients	 is	
controversial	while	 food	 could	play	 a	 two-way	 risk	 associated	 factor.	 The	 risk	 increases	
with	certain	food	products	with	high	glycemic	index	(GI)	or	with	high	sugar	contents	such	
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as	sweets,	refined	carbohydrates	and	candy	(152-154).	Consumers	of	food	containing	high	
saturated	 fatty	 acids,	 lamb	 and	 beef	 products,	 high	 energy	 fat,	 saturated	 and	
polyunsaturated	fat	are	at	 increased	risk	of	pancreatic	cancer	(155-157);	while	food	rich	
in	 vegetables,	 fruits,	 fibers,	 high	 content	 of	 omega-3	 fatty	 acids,	 vitamins	 C	 and	 E	 are	
associated	with	risk	reduction	(127,	155-157).	
3.11.2.7 Genetics	
Acquired	 genetic	 alteration	 has	 been	 identified	 as	 an	 associated	 risk	 factor	 for	
pancreatic	 cancer.	 Several	 genetic	 syndromes	 with	 an	 autosomal	 dominant	 inheritance	
have	been	associated	with	increased	risk	of	pancreatic	cancer	including	hereditary	breast	
cancer	syndrome	(BRCA2),	familial	atypical	multiple	mole	melanoma	syndrome	(FAMMM),	
Peutz-Jeghers	 syndrome,	 Von	 Hippel-Lindau	 disease,	 and	 hereditary	 nonpolyposis	
colorectal	cancer	(HNPCC)(158-164).	
Individuals	 with	 family	 history	 of	 pancreatic	 cancer	 carry	 a	 risk	 of	 increased	
pancreatic	cancer	incidence	(127,	165,	166).	
3.11.2.8 Other	risk	factors	
Other	 factors	 have	 been	 identified	 as	 associated	 with	 increased	 risk	 but	 with	
inconsistent	results.		
Allergic	 conditions	 such	 as	 asthma	 and	 hay	 fever	 found	 to	 have	 an	 associated	 risk	
reduction	effect	(100,	167).	ABO-	blood	group	found	to	be	linked	to	pancreatic	cancer	risk	
where	 individuals	 with	 non-O	 blood	 type	 carry	 a	 high	 risk	 (168-171).	 The	 relationship	
between	 coffee	 consumption	 and	 increased	 risk	 of	 pancreatic	 cancer	 is	 debated	 with	
variable	results	(127,	172-174).	
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3.11.3 Histopathological	features	of	Pancreatic	Ductal	Adenocarcinoma		
PDA	 is	 a	 gland-forming	 tumour	where	 the	 glands	 tend	 to	 be	 rounded	 in	 shape	 or	
slightly	angulated	giving	the	tumour	its	indolent	appearance.	The	extent	and	the	quality	of	
the	glands	decide	the	degree	of	tumour	differentiation,	which	correlates	with	the	patient’s	
outcome	(175).	
The	characteristic	anisonucleosis	(more	than	four-one	nuclear	size	variation	within	
a	 single	 gland)	 helps	 in	 the	 histological	 confirmation	 of	 the	 diagnosis	 (176,	 177).	 The	
tumour	 characteristically	 elicits	 a	 hard	 desmoplastic	 stromal	 reaction,	 which	 is	 almost	
always	 present.	 The	 shield-like	 property	 of	 the	 stroma	 prevents	 the	 penetration	 of	 the	
chemotherapy	agents	into	the	cancer	tissues	(178).	
Rare	 cystic	 changes	 secondary	 to	 tumour	 necrosis	 may	 develop	 indicating	
aggressiveness	of	 the	 tumour	which	can	 infiltrate	 into	 the	mesenteric	vessels,	 lymphatic	
vessels	and	nodes,	nerves	(peri-neural	invasion),	distal	CBD,	duodenum,	ampulla	of	Vater	
and	extra	pancreatic	soft	tissue	(179).		
3.11.4 Morphological	and	genetic	precursors	to	the	PDA	
Several	morphological	and	genetic	mechanisms	are	involved	in	the	development	of	
PDA	which	has	been	summarised	into	the	pancreatic	cancer	progression	model	(Figure	3-
4)	 (180).	 The	 precursors	 of	 the	 PDA	 believed	 to	 be	 the	 intraepithelial	 lesions	 include	
pancreatic	 intraepithelial	 neoplasia	 (PanIN	 1A,	 1B,	 2	 and	 3),	 intraductal	 papillary	
mucinous	neoplasm	(IPMN),	mucinous	cystic	neoplasm	(MCN),	and	solid	pseudopapillary	
tumours	(181).	
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Figure	3-4	Pancreatic	Cancer	Progression	Model		(with	permission	for	thesis	purpose	from	
Hruban	et	al.(180)	
	
3.12 Ampullary	cancer		
It	 represents	 about	 11.5-36%	 (7,	 88)	 of	 all	 resected	 periampullary	 cancers	 and	
about	75%	of	 the	ampullary	 tumours	(182).	 It	carries	a	 favorable	outcome	that	 is	better	
than	PDA	and	 the	bile	duct	cancer.	 In	 the	UK,	 it	 is	a	rare	disease	with	a	stable	 incidence	
rate	 between	 1998	 and	 2007	 with	 3,258	 (52.7%	 males)	 newly	 diagnosed	 cases.	 The	
incidence	 is	 associated	 age.	 It	 was	 noticed	 that	 incidence	 is	 slightly	 higher	 in	 more	
deprived	areas	(183,	184).	The	five-year	survival	following	surgical	resection	varies	from	
33%-45%	(3,	5,	7,	8).	Smoking	has	been	identified	as	a	strong	contributing	risk	factor	for	
cancer	 ampulla	 of	 Vater	 (185).	 Ampullary	 cancer	 is	 also	 associated	 with	 familial	
adenomatous	 polyposis	 (FAP)	 (162,	 186).	 The	 adenoma-carcinoma	 sequence	 has	 been	
reported	as	a	risk	factor	(187,	188).		
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3.12.1 Histopathological	features	of	ampullary	cancer	
Ampullary	carcinoma	could	be	histologically	classified	into	two	categories	based	on	
the	epithelial	origin:	
I. The	 intestinal	 type:	 as	 the	 name	 suggests,	 it	 originates	 from	 the	 intestinal	
epithelium	overlying	the	ampulla.		
II. The	pancreaticobiliary	type:	arises	from	the	endothelium	lining	of	the	distal	CBD,	
the	distal	pancreatic	duct	or	the	common	pancreaticobiliary	channel.		
Patients	 with	 the	 pancreaticobiliary	 type	 carry	 poor	 prognosis,	 as	 this	 type	 is	 an	
aggressive	 tumour	 that	 behaves	 like	 PDA,	 while	 patients	 with	 the	 intestinal	 type	 carry	
better	prognosis	as	the	tumour	behaves	like	duodenal	cancer	(182,	187,	189-193).	
3.13 Bile	duct	cancer	
Bile	duct	cancer	is	the	commonest	biliary	malignant	neoplasm.	It	accounts	for	3%	of	
all	gastrointestinal	tract	(G.I.T)	cancers	(194)	with	five-year	survival	of	about	10%	(195)	
that	 improves	 with	 surgical	 resection	 to	 19.2%-30%	 (3,	 5,	 7,	 8,	 17,	 18).	 The	 overall	
incidence	 is	 rising	 in	 the	UK	with	 a	 slightly	higher	 incidence	 among	males	with	male	 to	
female	ration	 is	1.2:	1	 (183,	196).	The	 incidence	 is	 rare	before	 the	4th	decade	of	 life	and	
there	is	an	associated	risk	with	increased	age	where	65%	of	cases	are	diagnosed	above	the	
age	of	65	years	(195).	Most	case	are	sporadic,	however	primary	sclerosing	cholangitis	 is	
the	commonest	identified	risk	factor	with	absolute	lifetime	risk	of	5-35%	(197).	Other	risk	
factors	 include	 chronic	 intraductal	 gallstones,	 bile	 duct	 adenoma	 and	 biliary	
papillomatosis	 (198,	199).	Congenital	anomalies	 including	choledochal	cysts	and	Caroli’s	
disease	 are	 associated	 with	 increased	 risk	 (194,	 195).	 Increased	 risk	 is	 also	 associated	
with	 chronic	 viral	 hepatitis	 including	 hepatitis	B	 virus	 (HBV)	 or	 hepatitis	 C	 virus	 (HCV)	
and	 other	 causes	 of	 liver	 cirrhosis	 (195,	 198,	 200,	 201).	 In	 South-east	 Asia,	 liver	 flukes	
(Opisthorcis	 viverrini	 and	 Clonorchis	 sinensis)	 are	 responsible	 for	 increased	 risk	 (195,	
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199).	Thorotrast,	 a	previously	used	contrast	agent,	was	 found	 to	be	associated	with	300	
fold	increased	risk	(202).	
3.13.1 Histopathological	features	of	bile	duct	cancer	
Adenocarcinoma	 of	 the	 bile	 duct	 is	 the	 commonest	 histological	 type	 of	 bile	 duct	
cancers	 representing	 about	 90%	 of	 biliary	 cancers	 (203).	 It	 arises	 from	 the	 intraductal	
epithelium	of	the	biliary	tree	either	within	the	liver	(Intra-hepatic	Cholangiocarcinoma)	or	
more	 commonly	 outside	 the	 liver	 (Extra-hepatic	 Cholangiocarcinoma)	 which	 is	 further	
subdivided	into	types	I	to	IV	(Bismuth	classification)	(204)	according	to	the	tumour	 	site	
and	hepatic	duct	system	involvement.	Among	histological	types,	sclerosing	differentiation	
is	the	most	common	and	it	is	characterised	by	annular	bile	duct	thickening	(199,	205).	
3.14 Duodenal	cancer		
Duodenal	cancer	is	rare	representing	0.3%	of	all	gastrointestinal	cancers.	Duodenal	
adenocarcinoma	represents	over	50%	of	all	malignant	tumours	affecting	the	duodenum.	It	
can	arise	 from	any	part	of	 the	duodenum,	however	the	second	part	 is	 the	most	common	
site	(206,	207).	The	global	peak	incidence	is	the	7th	decade	of	life,	with	men	being	affected	
more	 than	women	 (71,	208,	209).	 In	 the	UK,	2684	patients	with	median	age	of	72	were	
diagnosed	 between	 1998-2007.	 The	male	 to	 female	 ratio	 is	 about	 1.4:1	 (183,	 184).	 The	
five-year	survival	is	16.1%	following	diagnosis	(183).	
Polyps	 found	 in	 patients	 with	 familial	 adenomatous	 polyposis	 (FAP),	 Gardner’s	
syndrome	 and	 Celiac	 disease	 carry	 a	 malignant	 transformation	 risk.	 Patients	 with	 FAP	
carry	lifetime	risk	of	nearly	100%	for	developing	precancerous	adenomatous	polyps	that	
might	progress	to	adenocarcinoma	or	might	arise	in	the	adenoma	(186,	210-213),	with	a	
median	 interval	 of	 22	 years	 between	 a	 colectomy	 for	 FAP	 and	 the	 development	 of	
duodenal	cancer	(212).	
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3.14.1 Histopathological	features	of	duodenal	cancer	
Adenocarcinoma	of	 the	duodenum	 is	 the	 commonest	 type	 among	other	malignant	
neoplasms	 affecting	 the	 duodenum.	 Three	 histological	 types	 have	 been	 identified	
including	polypoid,	schirrous,	and	sessile	differentiation	(214).	
3.15 Surveillance	of	high	risk	populations	
Due	to	the	unavailability	of	a	simple	screening	test	as	well	as	low	disease	incidence	
in	 the	 general	 population	 and	 there	 is	 no	 current	 pancreatic	 cancer	 screening	
program(215).		
The	Pancreatic	 section	of	 the	British	Society	of	Gastroenterology	has	defined	 the	
at-risk	patients	 group	 to	 include	patients	with	 chronic	pancreatitis,	 adult	onset	diabetes	
with	 no	 family	 history	 or	 predisposing	 factors,	 patients	 with	 hereditary	 pancreatitis,	
familial	pancreatic	cancer	syndrome,	familial	ovarian	or	breast	cancer	syndrome,	familial	
multiple	mole	melanoma	syndrome	and	familial	adenomatous	polyposis	(76).			
The	National	Institute	for	Health	and	Care	Excellence	(NICE)(216)	has	recommended	
surveillance	for	people	with	any	of	the	following	criteria:	
• Hereditary	pancreatitis	and	a	PRSS1	mutation	
• BRCA1,	 BRCA2,	 PALB2,	 or	 CDKN2A	 (p16)	 mutations,	 with	 one	 or	 more	 first-degree	
relatives	diagnosed	with	pancreatic	cancer	
• Peutz-Jeghers	syndrome	
• Two	 or	 more	 first-degree	 relatives	 with	 pancreatic	 cancer,	 across	two	 or	 more	
generations	
• Lynch	syndrome	and	any	first-degree	relatives	with	pancreatic	cancer.	
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NICE	has	recommended	MRI/MRCP	for	pancreatic	cancer	surveillance	for	people	without	
hereditary	 pancreatitis	 while	 CT	 scan	 (pancreatic	 protocol)	 for	 people	 with	 hereditary	
pancreatitis	without	offering	EUS	
Patients	with	long	standing	FAP	should	be	offered	an	examination	with	endoscopic	
biopsy	of	the	periampullary	region;	the	frequency	of	which	is	determined	by	the	severity	
of	 the	duodenal	polyposis,	however	 in	stage-4	duodenal	polyposis,	 surgically	 fit	patients	
should	 be	 offered	 a	 pylorus	 preserving	 pancreaticoduodenectomy	 (Grade	 III	 evidence)	
(217).		
The	 Consensus	 guidelines	 published	 by	 the	 International	 Association	 of	
Pancreatology	 (218)	 recommended	 that	 all	 patients	 at	 increased	 inherited	 risk	 of	
pancreatic	cancer	should	be	referred	to	a	dedicated	multidisciplinary	specialist	centres	for	
a	 specialist	 opinion	 with	 expert	 clinical	 assessment,	 genetic	 counseling	 and	 advice	 on	
secondary	screening	investigational	program.	
3.16 Treatment	options	
3.17 Surgical	resection	
Surgical	 resection	 is	 the	 only	 curative	 treatment	 for	 patients	 with	 pancreatic	 and	
periampullary	 cancer.	 Nevertheless,	 the	 resection	 rate	 for	 pancreatic	 head	
adenocarcinoma	is	less	than	20%	at	the	time	of	diagnosis	(6,	219),	and	about	one-third	of	
patients	with	 distal	 cholangiocarcinoma	 deemed	 resectable	 at	 the	 time	 of	 the	 diagnosis	
(205,	220,	221).	Inconsistent	results	were	noted	regarding	the	resection	rate	for	patients	
with	ampullary	cancer	(222-224).		
These	 figures	 vary	 significantly	 between	 high	 volume	 centres	 and	 low	 volume	
centres	 including	higher	resection	rates	 (34,	35),	 lower	operative	mortality	 (36,	37)	and	
improved	long-term	survival	(38)	in	units	with	higher	treatment	volumes.		
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The	contraindications	to	surgical	intervention	include		
§ Metastatic	deposits	involving	lung,	liver,	lymph	nodes	and	peritoneal	metastasis	
§ Vascular	encasement	of	portal	vein,	superior	mesenteric	vein,	superior	mesenteric	
artery,	coeliac	trunk	and	hepatic	artery	
§ Liver	cirrhosis	and	portal	hypertension	
§ Surgically	unfit	patients	
The	 prognostic	 markers	 for	 survival	 following	 surgical	 resection	 include	 tumour	 size,	
tumour	 grade,	 resection	margin	 status,	 degree	 of	 vascular	 invasion	 and	 the	 lymph	node	
status.		
3.17.1 Historical	background	
In	 1898,	 Alessandro	 Codivilla	 (1861-1912)	 performed	 the	 first	 pancreatic	 head	
resection	 (225).	 The	 patient	 died	 at	 18	 days	 postoperatively	 from	 cachexia	 and	
steatorrhoea.		
In	1898,	Halsted	performed	the	first	successful	resection	of	a	ampullary	cancer	(226).	
In	 1912,	 Walther	 Kausch	 (1867-1928)	 reported	 the	 first	 successful	 two	 stage	
pancreaticoduodenectomy	 for	 carcinoma	 of	 the	 papilla	 (227).	 The	 operation	 took	 four	
hours.	
In	 1914,	 Hirschel	 performed	 the	 first	 successful	 one	 stage	 pancreaticoduodenectomy	
(228).	Patient	died	one	year	after	surgery.	
In	 1918,	 Lester	 Reynold	 Dragstedt	 (1893-1975)	 demonstrated	 the	 feasibility	 of	 total	
duodenectomy	in	dogs	and	pigs	and	its	compatibility	with	survival(229).	
In	1922,	Tenani	(230)	performed	a	successful	two-stage	partial	pancreaticoduodenectomy.	
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In	 1935,	 Whipple	 and	 colleagues	 (231)	 reported	 successful	 en-block	 resection	 of	
pancreatic	head	and	the	duodenum	in	two	stage	procedure	in	three	patients.	First	patient	
died	30	hours	postoperative	while	second	and	third	patients	died	9	and	24	months	post	
resection.	
In	 1940,	 Whipple	 published	 the	 first	 one	 stage	 complete	 excision	 of	 the	 head	 of	 the	
pancreas	and	the	entire	duodenum	(229).	
3.17.2 Types	of	surgical	resections		
For	 pancreatic	 head	 malignancy	 and	 periampullary	 cancers,	 Kausch-Whipple	
pancreaticoduodenectomy	 or	 pylorus	 preserving	 pancreaticoduodenectomy	 is	 the	
standard	surgical	management.	It	involves	three	main	classic	operative	steps:	
I. Assessment	 of	 resectability:	 this	 involves	 careful	 examination	 of	 the	 liver,	
peritoneum	and	periampullary	area	to	rule	out	occult	metastatic	deposits.	
II. Resection:	 this	 involves	 resection	 of	 the	 head	 of	 the	 pancreas,	 duodenum,	 distal	
common	 bile	 duct	 and	 gallbladder.	 In	 a	 standard	 pancreaticoduodenectomy	 the	
stomach	 is	 divided	 proximal	 to	 the	 antrum,	 while	 in	 a	 pylorus	 preserving	
pancreaticoduodenectomy	 the	 first	 part	 of	 the	 duodenum	 is	 transected	 distal	 to	
the	pylorus.	In	case	of	SMV,	PV	invasion,	the	vein	could	be	transected	en-block	with	
the	tumour	specimen	and	reconstructed	afterwards.	
III. Reconstruction:	this	involves	reestablishing	the	biliary,	pancreatic	and	the	enteric	
continuity	 by	 means	 of	 triple	 anastomoses	 namely	 hepaticojejunostomy,	
pancreaticojujenostomy	 and	 gastrojejunostomy	 (for	 classic	 Kausch-Whipple	
pancreaticoduodenectomy)	 or	 duodenojejunostomy	 (for	 pylorus	 preserving	
pancreaticoduodenectomy).	
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The	 pylorus	 preserving	 pancreaticoduodenectomy	 has	 the	 advantage	 of	 reducing	
post	 gastrectomy	 complications	 including	 enterogastric	 reflux	when	 compared	with	 the	
standard	 Kausch-Whipple	 operation.	 It	 is	 also	 associated	 with	 improved	 postoperative	
nutritional	 status	and	weight	gain	 (232-235),	and	 it	does	not	compromise	 the	 long	 term	
survival	(236).	Nevertheless,	its	drawbacks	include	incomplete	lymph	node	clearance	and	
failure	 to	 achieve	 a	 clear	 resection	 margin	 especially	 when	 the	 tumour	 is	 close	 to	 the	
pylorus	or	if	there	is	a	proximal	duodenal	involvement	(237,	238).	
The	 radical	 extended	 resections	 proposed	 first	 in	 1977	 (239)	 involving	 en-bloc	
pancreatic,	 portal	 vein	 and	 lymph	node	 resection	 failed	 to	 achieve	 any	 survival	 benefits	
when	compared	with	the	classic	Kausch-Whipple	operation	(240).	
3.18 Adjuvant	therapy	
Precise	identification	of	the	tumour	origin	is	of	clinical	significance	as	the	adjuvant	
treatment	 and	 prognosis	 is	 different	 for	 this	 group	 of	 malignant	 neoplasms.	 Adjuvant	
chemotherapy	has	a	clearly	defined	role	starting	1-2	months	following	potentially	curative	
surgical	resection	for	pancreatic	cancer.	Gemcitabine	is	now	prescribed	as	the	standard	of	
care	(241)	with	better	long-term	disease	free	survival	compared	to	observation	group	as	
been	 studied	 in	 the	 CONKO-001	 (242,	 243).	 The	 ESPAC-3	 trial	 has	 shown	 significant	
improvement	in	survival	following	surgical	resection	in	patients	receiving	6	months	of	5-
Fluorouracil	 and	 leucovorin	 as	 adjuvant	 therapy	 (244).	 The	more	 recent	 ESPAC-4	 study	
has	 shown	 long-term	 survival	 benefits	 of	 the	 addition	 of	 Capecitabine	 to	 Gemcitabine	
(245).		
The	role	of	adjuvant	chemotherapy	has	been	less	well	assessed	in	cases	of	ampullary	
cancer,	 although	 the	 large	 ESPAC-3	 study	 had	 a	 limb	 for	 these	 patients	 also	 using	
Gemcitabine	(246).		
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For	patients	with	distal	cholangiocarcinoma,	there	is	no	current	evidence	to	support	
the	 use	 of	 adjuvant	 chemotherapy	 or	 radiotherapy.	 Appropriate	 trials	 are	 needed	 to	
address	 this	 issue.	 The	 largest	 trial	 currently	 happening	 is	 the	 BILCAP	 trial	 looking	 at	
capecitabine	following	surgical	intervention	(247).	
The	role	of	chemoradiotherapy	has	been	also	explored	as	an	adjuvant	treatment	in	
several	 trials	 namely	 the	 Gastrointestinal	 Tumor	 Study	 Group	 (GITSG)	 trial	 (248),	 the	
European	Organization	for	Research	and	Treatment	of	Cancer	(EORTC)	trial	(249),	and	the	
European	Study	Group	for	Pancreatic	Cancer	(ESPAC-1)	trial	(250),	which	did	not	reveal	
enough	 supporting	 evidence	 for	 the	 routine	 use	 of	 chemoradiotherapy	 as	 a	 standard	
adjuvant	 therapy.	 The	 combined	 non-randomised	 results	 however	 reported	 from	 Johns	
Hopkins	University	 and	 the	Mayo	Clinic	 revealed	 significant	 improvement	 in	 survival	 in	
chemoradiotherapy	group	compared	to	surgery	only	group	with	median	survival	of	21.1	
months	vs.	15.5	months	(P	<	0.001)	(251,	252).	
3.19 Neoadjuvant	therapy	
Because	 of	 the	 historical	 tendency	 of	 pathologists	 to	 over-diagnose	 pancreatic	
adenocarcinoma	 radiologists	 have	 not	made	 rigorous	 efforts	 to	 distinguish	 the	 organ	 of	
origin	on	pre-operative	 imaging.	This	has	not	previously	been	clinically	 important	as	the	
surgical	 treatment	 of	 the	 lesions	 is	 identical	 and	 decisions	 regarding	 adjuvant	
chemotherapy	 can	be	made	 after	 the	 final	 histology	 report	 is	 available.	 This	 situation	 is	
changing	with	the	recent	advent	of	neo-adjuvant	treatment,	which	may	be	recommended	
without	 a	 precise	 diagnosis	 in	 patients	 with	 borderline	 resectable	 or	 locally	 advanced	
pancreatic	 head	 malignancy	 based	 on	 pre-operative	 imaging.	 The	 advantage	 of	
neoadjuvant	therapy	is	that	it	allows	tumour	down	staging	and	locoregional	control	thus	
allowing	 curative	 surgical	 resection	 in	 patients	 with	 borderline	 resectable	 tumours,	
however	 without	 significant	 survival	 improvement	 (253-255).	 This	 issue	 has	 been	
addressed	 in	 a	 Phase	 II	 study	 (SCALOP)(256)	 and	 	 Phase	 II/III	 study	 (ESPAC-5)(257).	
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Other	 studies	 have	 shown	 survival	 improvement	 by	 intention	 to	 treat	 following	
neoadjuvant	 treatment	 for	 patients	 with	 resectable	 or	 borderline	 resectable	 pancreatic	
cancer	(258).	
Although	these	studies	have	confirmed	that	neoadjuvant	therapy	has	been	shown	to	
be	 effective	 in	 treating	 pancreatic	 cancer	 there	 is	 a	 possibility	 that	 these	 series	 have	
included	 patients	 with	 other	 diagnoses.	 Although	 there	 is	 a	 general	 agreement	 that	
neoadjuvant	 treatment	 should	 be	 offered	 to	 patients	with	 locally	 advanced	 disease	 and	
those	 with	 a	 high	 risk	 of	 R1-resection	 in	 order	 to	 increase	 the	 chance	 of	 a	 complete	
resection,	 patients	 with	 primarily	 resectable	 cancer	 potentially	 benefit	 the	 most	 from	
neoadjuvant	 therapy.	 On	 the	 other	 hand,	 some	 patients	 however	 might	 suffer	 tumour	
progression	 into	 a	 metastatic	 state	 during	 treatment,	 therefore	 becoming	 unresectable	
and	hence	avoiding	unnecessary	exposure	to	a	stressful	major	operation	(259).		
The	 role	 of	 added	 radiotherapy	 as	 neoadjuvant	 treatment	 is	 debatable.	 Currently,	
many	studies	are	being	performed	in	order	to	test	new	treatment	concepts	and	to	evaluate	
the	 true	 role	 of	 neoadjuvant	 therapy	 e.g.	 ESPAC-5F	 (260)	NEOPA(261),	 PREOPANC	 trial	
(262)and	 NEOPAC	 (263).	 The	 oncological	 benefits	 of	 neoadjuvant	 chemo-radiotherapy	
with	Gemcitabine	versus	upfront	surgery	in	patients	with	borderline	resectable	pancreatic	
cancer	 have	 been	 studied	 in	 a	 multicenter,	 phase	 2/3,	 prospective	 randomized	 trial.	
Results	 have	 shown	 that	 neoadjuvant	 chemo-radiation	 provides	 significant	 oncological	
benefits	 in	 terms	 of	 2-year	 survival	 rates	 and	 R0	 resection	 rates	 compared	 to	 upfront	
surgery	(264).	Other	trials	proved	improved	outcome	in	terms	of	survival	benefits	and	R0	
resectability	with	 chemoradiotherapy	 such	 as	 GTS-GX/RT:	 GTX	 (gemcitabine,	 docetaxel,	
and	 capecitabine)	 plus	 GX	 (gemcitabine	 and	 capecitabine)	 combined	 with	 radiation	
therapy	(RT)	(265).	
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There	 is	 no	 standardized	 neoadjuvant	 regimen;	 however	 there	 have	 been	 several	
trials	using	different	regimens	including	FOLFIRINOX	(5-flurouracil,	leucovorin,	irinotecan,	
and	oxaliplatin)	(266)	and	GTX	(gemcitabine,	docetaxel,	and	capecitabine)	(267).	
The	 current	 practice	 at	 the	 Peninsula	 HPB	 cancer	 unit	 is	 to	 offer	 neoadjuvant	
chemo-radiotherapy	 for	 patients	 with	 non-metastatic	 borderline	 resectability	 following	
regional	MDT	discussion	and	clinical	outpatient	assessment	including	biochemical	testing	
of	CA19-9.	
3.20 Biliary	decompression	and	stent	
3.20.1 Preoperative	stent	
The	role	of	biliary	stents	reducing	jaundice	related	morbidity	and	mortality	prior	
to	surgical	resection	is	controversial	(268-272).		
Stent	could	be	inserted	by	endoscopic	route	or	via	percutaneous	transhepatic	method.	
The	 use	 of	 biliary	 stents	 is	 associated	with	 complications	 include	 perforation,	 bleeding,	
fungal	colonization,	sepsis,	obstruction,	migration	and	disease	progression	(273,	274).	
3.20.2 Palliative	stent	
Compared	 to	 the	 preoperative	 biliary	 stent	 insertion,	 palliative	 biliary	 stenting	
represents	 the	 procedure	 of	 choice	 for	 patients	 with	 unresectable	 disease,	 severe	
comorbidity	and	metastatic	disease	(275-277).		
Biliary	 stents	are	available	 in	plastic,	metal,	 covered	and	uncovered	varieties.	The	metal	
stents	 are	 superior	 to	 plastic	 stents	 in	 terms	 of	 greater	 patency	 rate	 (12	 months	 vs.	 3	
months),	 fewer	complications,	shorter	hospital	stay	and	possibly	cost	effectiveness	(199,	
278,	279).	
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The	use	of	plastic	stents	is	associated	with	stent	replacement	at	least	once	and	it	could	be	
reasonable	to	be	used	in	patients	with	less	than	six	months	life	expectancy.	
The	use	of	covered	metal	stents	has	been	introduced	to	reduce	the	tumour	ingrowth	(280).	
The	preference	of	covered	stent	over	the	uncovered	stents	has	been	explored	and	results	
are	 debatable	 including	 stent	 patency,	 cost	 effective,	 stent	 dysfunction	 and	 survival	
benefits	(280,	281).	
3.21 Palliative	treatment	
3.21.1 Bypass	surgery	
Bypass	 surgery	 is	 indicated	 in	 surgically	 fit	 patients	with	 advanced	unresectable	
disease.	The	aim	is	to	relieve	the	biliary	and	the	gastric	outflow	obstruction.		
The	use	of	the	bile	duct	for	the	biliary	bypass	surgery	(i.e.	choledochoenterostomy)	
is	 more	 reliable	 relieving	 the	 jaundice	 than	 the	 use	 of	 the	 gall	 bladder	 (i.e.	
cholecystoenterostomy)	(282).	
To	relief	gastric	outflow	obstruction,	a	gastroenterostomy	is	performed	either	as	a	
single	 procedure	 or	 combined	 with	 the	 biliary	 bypass	 surgery	 (i.e.	 Roux-en-Y).	 A	
prophylactic	 retrocolic	 gastrojejunostomy,	 performed	 at	 the	 time	 of	 initial	 surgical	
intervention,	significantly	decreases	the	incidence	of	a	late	onset	gastric	outlet	obstruction	
without	increasing	the	postoperative	hospital	stay	or	postoperative	complications	(283).		
In	patients	with	distal	cholangiocarcinoma,	placement	of	a	plastic	duodenal	stent	
could	be	an	alternative	option	to	gastroenterostomy,	which	has	a	minimal	role	in	relieving	
the	gastric	outflow	obstruction.	
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3.21.2 Chemotherapy	
The	 potential	 role	 of	 chemotherapy	 as	 a	 palliative	 therapy	 in	 patients	 with	
metastatic	disease	should	be	weighted	against	 its	toxic	side	effects.	 	The	use	of	5-FU	and	
Mitomycine	 was	 used	 as	 first	 line	 therapy	 for	 advanced	 metastatic	 disease,	 however	 a	
randomized	trial	concluded	that	gemcitabine	is	more	effective	than	5-FU	in	alleviation	of	
some	 disease-related	 symptoms	 (pain,	 performance	 status	 and	weight)	 in	 patients	with	
advanced,	symptomatic	pancreas	cancer.	Treatment	with	gemcitabine	was	associated	with	
a	 survival	 advantage	 at	 1	 year	 (18%)	 compared	 with	 fluorouracil	 (2%)	 and	 median	
survival	of	5.6	vs.	4.4	months	(284).	
3.21.3 Relief	of	pain	
Abdominal	pain	experienced	in	patients	with	pancreatic	and	periampullary	cancer	
could	 be	 intolerable	 and	 represents	 a	 challenge	 facing	 the	 treating	 physician.		
Pathophysiology	of	pancreatic	pain	 includes	 increasing	parenchymal	pressure	secondary	
to	ductal	destruction,	 perineural	 infiltration,	 perineural	neuropathy	 secondary	 to	 chemo	
or	radiotherapy,	pancreatic	inflammation	and	biliary	stenosis	(285,	286).	
Management	 of	 pancreatic	 pain	 follows	 the	 analgesic	 ladder	 for	 pain	 treatment	
including	 non-opioid	 analgesia	 for	 mild	 pain,	 opioids	 for	 mild	 to	 moderate	 pain	 and	
opioids	for	moderate	to	severe	pain.	Other	methods	include	decompression	of	pancreatic	
duct	either	endoscopically	or	surgically	(287).	Coeliac	ganglion	ablation	via	percutaneous,	
laparoscopic	or	open	surgical	technique	using	phenol	5%	or	ethanol	50%	or	cryoablation	
have	shown	good	results	(287-293).	Thoracoscopic	division	of	splanchnic	nerves	has	been	
also	implemented	in	the	alleviation	of	pancreatic	pain	(294).	External	beam	radiotherapy	
and	radio-chemotherapy	have	been	also	prescribed	(295).	
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4 Pre-operative	radiological	assessment	of	pancreatic	head	
malignancy		
4.1 Introduction		
Patients	 with	 pancreatic	 and	 periampullary	 cancer	 often	 present	 with	 features	 of	
biliary	obstruction,	however	they	might	have	non-specific	symptoms	that	largely	depends	
on	 the	anatomical	 location	of	 the	 tumour	and	 its	biological	behaviour.	 In	 the	absence	of	
other	specific	diagnostic	parameters	e.g.	blood	tests,	imaging	modalities	play	an	important	
role	 in	 detection	 of	 the	 tumour	 mass,	 tumour	 extension	 and	 its	 resultant	 effects.	
Furthermore,	 it	 helps	 identifying	 the	 relationship	 between	 the	 tumour	 mass	 and	 the	
vascular	structures	in	nearby	organs.	Imaging	enables	identification	of	the	tumour’s	local	
invasion	 and	 distant	 metastases,	 which	 affect	 the	 choice	 of	 treatment.	 There	 has	 been	
significant	development	in	imaging	technology	and	computer	software	over	the	past	two	
decades	resulting	 in	 improvement	 in	 imaging	acquisition	and	reconstruction	 techniques,	
which	has	reshaped	the	management	of	patients	with	pancreatic	head	malignancy.	Precise	
pre-operative	 identification	 of	 the	 tumour	 mass	 followed	 by	 accurate	 assessment	 and	
staging	 is	 a	 crucial	 tool	 in	 the	 management	 of	 patients	 with	 periampullary	 cancers	 to	
identify	the	group	of	patients	who	would	benefit	 from	surgical	 intervention	and	to	avoid	
unnecessary	surgical	exploration.		
Transabdominal	 ultrasound	 scan	 is	 usually	 the	 first	 imaging	 modality	 for	 the	
majority	 of	 patients	 presenting	 with	 symptoms	 of	 jaundice,	 weight	 loss	 or	 vague	
abdominal	 pain.	 Further	 imaging	 adjuncts	 include	 multi-detector	 row	 computed	
tomography	 (MDCT),	 magnetic	 resonance	 imaging	 (MRI),	 magnetic	 resonance	
cholangiopancreatography	 (MRCP),	 positron	 emission	 tomography	 (PET),	 endoscopic	
ultrasound	 (EUS),	 endoscopic	 retrograde	 cholangiopancreatography	 (ERCP),	 and	
laparoscopic	 staging.	 The	 choice	 of	 the	 imaging	 modality	 depends	 on	 availability,	
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experience	and	individual	patient	circumstances.	Other	new	modalities	in	early	detection	
include	 including	 cyst	 fluid	 biomarkers,	 genomic	 profiling,	 nano-particle	 imaging,	
spectroscopy,	and	circulating	pancreatic	cells	(296).		
4.2 Ultrasound	scan	
It	is	the	most	widely	used	primary	investigation	tool	in	the	diagnosis	of	pancreatic	
and	periampullary	cancers.	It	is	non-invasive,	inexpensive,	readily	available	with	reported	
sensitivity	as	high	as	88.6-95%	(297)	and	specificity	of	98.8%	(297).	The	use	of	ultrasound	
in	 the	 preoperative	 staging	 is	 limited	 by	 the	 retroperitoneal	 position	 of	 the	 pancreas,	
which	 sometimes	might	 be	 obscured	 by	 the	 bowel	 gas.	 Additionally,	 the	 examination	 is	
operator	 dependent	 with	 inter-observer	 variation	 (297-299).	 Advances	 in	 ultrasound	
technology	 and	 the	 introduction	 of	 Doppler	 ultrasound	 could	 lead	 to	 improvement	 in	
assessing	tumour-vessel	relationship	(300,	301).	
4.3 Magnetic	resonance	imaging	(MRI)	
The	 use	 of	 MRI	 could	 be	 a	 comparable	 alternative	 to	 the	 use	 of	 MDCT	 in	 the	
preoperative	 diagnosis	 and	 staging	 of	 pancreatic	 and	 periampullary	 cancers.	 MRI	 has	
superior	soft	tissue	contrast	when	compared	with	MDCT	but	with	less	spatial	resolution.	
The	non-contrast	MRI	 is	 a	 good	alternative	diagnostic	modality	 to	 the	MDCT	 in	patients	
with	renal	insufficiency	or	patients	with	known	contrast	allergy	(302).	
With	 advances	 in	 MRI	 imaging	 techniques,	 the	 use	 of	 magnetic	 resonance	
cholangiopancreatography	 (MRCP)	 has	 improved	 the	 visualization	 of	 the	
pancreaticobiliary	 area	 resulting	 in	 better	 evaluation	 of	 the	 relationship	 of	 pancreatic	
lesions	to	the	pancreaticobiliary	structures.	Moreover,	the	use	of	the	magnetic	resonance	
angiography	(MRA)	has	advantages	in	evaluating	the	relationship	of	pancreatic	lesions	to	
the	peri-pancreatic	vasculatures	(303).	
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4.4 Endoscopic	ultrasound	(EUS)		
EUS	is	an	important	tool	in	the	pre-operative	assessment	and	staging	of	pancreatic	
and	periampullary	neoplasms	especially	when	no	masses	 identified	or	with	 inconclusive	
MDCT	 or	MRI	 findings	 (304,	 305).	 It	 uses	 high	 frequency	 ultrasonic	 waves	 (5-10	MHz)	
with	 special	 radial	 or	 linear	 echo-endoscope,	 which	 bypasses	 the	 bowel	 gas	 interface	
(compared	 to	 limited	 view	of	 the	 trans-abdominal	US)	 by	placing	 the	 transducer	within	
the	 gastrointestinal	 tract	 (306,	 307).	 When	 compared	 to	 MDCT,	 EUS	 has	 a	 higher	
sensitivity	for	tumour	detection	(308,	309)	especially	for	detecting	small	solid	lesions	less	
than	 20	 mm	 in	 comparison	 with	 MDCT	 or	 MRI	 (309,	 310).	 When	 combined	 with	 fine	
needle	 aspiration	 cytology	 (FNAC),	 the	 use	 of	 the	 EUS	 became	 a	 powerful	 diagnostic	
modality	 by	 adding	 cytological	 or	 histological	 confirmation	 of	 the	 suspected	 lesions.	 A	
metanalysis	by	Hewitt	(311)	confirmed	pooled	sensitivity	 for	malignant	cytology	of	85%	
(95%	CI,	84-86),	and	pooled	specificity	of	98%	(95%	CI,	0.97-0.99).	This	tissue	diagnostic	
advantage	supports	the	choice	of	adjuvant	therapy	especially	for	non-resectable	tumours.	
Furthermore,	 it	 is	 extremely	 useful	 tool	 confirming	 the	 presence	 of	metastatic	 deposits	
(e.g.	metastatic	 lymph	 node)	 (312,	 313)	 and	 differentiating	 pancreatic	malignancy	 from	
other	non-neoplastic	lesions	including	pancreatitis	or	pancreatic	cystic	lesions	(314).		
In	 the	 assessment	 of	 vascular	 invasion,	 the	 following	 criteria	 can	 be	 identified	
(315):	
1.	 Peri-pancreatic	 venous	 collaterals	 in	 an	 area	 of	 a	 mass	 that	 obliterates	 the	
normal	anatomic	location	of	a	major	portal	confluence	vessel.	
2.	Tumour	within	the	vessel	lumen.	
3.	Abnormal	vessel	contour	with	loss	of	the	vessel-parenchymal	plane.	
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The	EUS	diagnostic	accuracy	for	vascular	invasion	has	been	assessed	in	several	studies.	In	
a	metanalysis	by	Puli	et	al.	(316),	the	pooled	sensibility	was	73%	and	the	specificity	90%.		
The	diagnostic	accuracy	of	EUS	for	venous	invasion	(80-91%)	is	generally	reported	better	
than	that	for	arterial	invasion	(17-67%)	(317).	EUS	has	reported	increased	sensitivity	for	
portal	 vein	 assessment	 and	 100%	 for	 the	 splenic	 artery	 and	 vein	 with	 decreased	
sensitivity	for	celiac	axis	and	SMA	and	SMV	(318).	
Although	it	is	considered	a	safe	procedure,	nevertheless	EUS	has	a	low	incidence	of	
complications	including	bleeding	(1%-4%),	pancreatitis	(1%-2%)	and	(0.3%)	perforation	
rate	(319).	
EUS	is	the	most	sensitive	test	in	early	detection	of	pancreatic	cancer	and	it	is	used	
as	a	screening	tool	in	high-risk	individuals.	
4.5 Positron	emission	tomography	(PET)	
The	 role	 of	 unenhanced	 PET/CT	 in	 the	 diagnosis	 and	 staging	 of	 pancreatic	 and	
periampullary	 neoplasms	 is	 limited	 due	 to	 the	 poor	 delineation	 of	 the	 tumour	 and	 its	
relationship	 to	 surrounding	 structures.	 On	 the	 other	 hand,	 it	 has	 a	 valuable	 role	 in	
detection	of	distant	metastatic	deposits	(320).	
The	accuracy	of	staging	and	assessing	the	resectability	may	increase	with	the	use	contrast	
enhanced	PET/CT	scan	(321).	
4.6 Multi-detector	computed	tomography	(MDCT)	
With	 the	 rapid	 advances	 in	 scanning	 technology	 and	 imaging	 acquisition,	 the	
introduction	of	the	MDCT	has	made	a	significant	improvement	in	diagnosis	of	pancreatic	
and	 peri-ampullary	 cancers	 compared	 to	 single	 slice	 CT.	 According	 to	 the	 National	
Comprehensive	 Cancer	 Network	 guidelines	 (NCCN)	 (322),	 MDCT	 (also	 known	 as	
multidetector	CT,	multisection	CT,	and	multislice	CT)	could	be	defined	as	multiphase	high	
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quality	dedicated	 imaging	technique	that	 is	performed	by	acquiring	thin,	preferably	sub-
millimetre,	 axial	 sections	 using	 a	 dual-phase	 pancreatic	 protocol	 (pancreatic	 and	 liver	
portal	 venous).	 Multiplanar	 reconstruction	 is	 recommended	 as	 it	 allows	 precise	
visualization	 of	 the	 tumour-vessel	 relationship	 as	 well	 as	 detection	 of	 sub-centimetre	
metastatic	deposits.	Compared	to	the	conventional	and	the	helical	CT	scanners,	MDCT	has	
a	 two-dimensional	 array	 of	 detector	 elements	 that	 replace	 the	 linear	 array	 of	 detector	
elements	 used	 in	 the	 other	 types.	 This	 feature	 allows	 the	 MDCT	 scanners	 to	 acquire	
multiple	slices	simultaneously	and	to	increase	the	speed	of	image	acquisition	significantly.	
MDCT	has	 the	 advantage	 of	 providing	 high	 spatial	 resolution	 in	 all	 imaging	 planes	with	
large	volume	coverage	in	a	short	scanning	time	typically	7-9	seconds	for	64-slice	MDCT	of	
the	 abdomen	 and	 pelvis	 (323).	 The	 use	 of	 a	 dedicated	 pancreatic	 protocol	 as	 a	 routine	
investigating	tool	of	patients	presenting	with	suspicious	diagnosis	of	pancreatic	cancer	has	
improved	 the	 preoperative	 assessment	 of	 pancreatic	 and	 periampullary	 tumours.	
Furthermore,	 it	 improves	 visualization	 of	 the	 periampullary	 duodenum,	 to	 assist	 in	
distinguishing	 ampullary	 neoplasms,	 with	 good	 prognosis,	 from	 other	 periampullary	
neoplasms.	
.	 With	 a	 relatively	 uniform	 consensus,	 the	 overall	 accuracy	 of	 MDCT	 in	 detecting	
pancreatic	 tumour	 and	 predicting	 resectability	 ranges	 from	 86	 to	 99%	 (324-328).	 The	
MDCT	has	a	reported	sensitivity	in	pancreatic	cancer	detection	is	as	high	as	86%-97%	for	
tumours	 larger	 than	 2	 cm	 and	 68-	 77%	 for	 tumours	 less	 than	 2	 cm	 (306,	 329-333).	
Legmann	et	al.	(334)	reported	100%	sensitivity	for	detecting	tumours	greater	in	size	than	
15	 mm.	 The	 reported	 specificity	 ranges	 between	 88%	 and	 100%	 in	 identification	 of	
pancreatic	tumours	(335,	336).	
4.6.1 	Indications	
The	 use	 of	 a	 dedicated	 pancreatic	 CT	 scan	 protocol	 is	 indicated	 in	 patients	 with	
clinically	 suspected	 pancreatic	 or	 periampullary	 cancers,	 unexplained	 episode	 of	 acute	
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pancreatitis,	chronic	pancreatitis,	adult	onset	diabetes	in	absence	of	family	history	or	risk	
factors,	evaluation	of	jaundice	and	in	patients	with	unexplained	wight	loss	(76).	
4.6.2 	Timing	
It	 is	 extremely	 important	 to	 consider	 the	 timing	of	 scanning	during	 the	 suspected	
cancer	 pathway.	 Trans-abdominal	 ultrasound	 scan	 is	 the	 first	 imaging	modality	 for	 the	
majority	of	patients	presenting	with	 jaundice.	 If	biliary	dilatation	 is	detected,	 then	ERCP	
will	 be	 considered	 possibly	with	 biliary	 stent	 insertion.	 	 At	 this	 stage,	 pancreatic	MDCT	
should	be	undertaken	preceding	 the	endoscopic	biliary	 intervention	as	 the	use	of	ERCP,	
stent,	brush	cytology	or	endoscopic	biopsy	could	result	in	local	inflammatory	changes	that	
mimic	 the	 tumour.	 This	 could	 limit	 the	 ability	 to	 visualise	 the	 tumour	 on	 subsequent	
scanning	 which	 might	 lead	 to	 a	 delay	 in	 the	 accurate	 radiological	 staging	 and	 the	
assessment	of	the	tumour-vessel	relationship	(331,	337).	
4.6.3 	Contraindications	and	precautions	
The	use	of	CT	scan	is	contraindicated	in	patients	with	known	allergy	to	the	contrast	
medium	 (iodine-based),	 renal	 impairment	 and	 during	 pregnancy.	 Certain	 precautions	
should	be	taken	when	scanning	diabetic	patients	on	Metformin	or	related	medications	as	
it	 might	 result	 in	 metabolic	 acidosis.	 Patients	 with	 hyperthyroidism	 might	 develop	
thyrotoxic	 crisis.	 There	 is	 a	 theoretical	 risk	 of	 hypertensive	 crisis	 in	 patients	 with	
phaeochromocytoma.		In	patients	with	myasthenia	gravis,	there	is	slight	risk	of	worsening	
the	 condition	 upon	 use	 of	 the	 contrast	 medium.	 There	 is	 an	 increased	 risk	 of	
bronchospasm	in	patients	suffering	from	bronchial	asthma	(338).	
Certain	 conditions	 might	 interfere	 with	 the	 accuracy	 of	 the	 imaging	 and	 hence	 the	
reporting.	 These	 include	 patients	 with	 metallic	 intra-abdominal	 objects	 from	 previous	
surgery	 or	 the	 presence	 of	 contrast	 in	 the	 gut	 especially	 barium	 following	 a	 previous	
contrast	study.	
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4.6.4 Technique	of	MDCT	Pancreatic	protocol	
A	dedicated	MDCT	pancreatic	protocol	has	four	essential	components	(332):	
I. Neutral	oral	contrast.		
II. Rapid	bolus	of	intravenous	contrast.		
III. Thin	section	biphasic	scanning.	
IV. Reconstruction	 with	 two-dimensional	 (2D)	 and	 3D	 volumetric	 images	
combination.	
Patient	 preparation	 requires	 fasting	 for	 at	 least	 4	 hours.	 On	 the	 day	 of	 the	
examination,	an	intravenous	catheter	(size	18-20	gauge)	will	be	inserted	under	antiseptic	
precautions	 in	 the	 antecubital	 vein	 (preferred	 site	 allowing	 the	 power	 injection	 of	 the	
intravenous	contrast	agent	at	a	rate	of	4-5	ml/second).		Patient	is	asked	to	drink	750	ml	to	
1	 L	 of	 a	 neutral	 oral	 contrast	 (near	 water	 attenuation,	 in	 contrast	 to	 the	 positive	 and	
negative	 contrast	 medium	 with	 higher/lower	 attenuation	 than	 the	 surrounding	
structures).	Several	agents	have	been	used	such	as	water	(339),	barium	suspension	with	
low	Hounsfield	unit	such	as	Volumen®	(340),	and	whole	milk	(341).	
The	use	of	a	neutral	oral	contrast	just	before	the	scheduled	scanning	time	causes	gastro-
duodenal	distension	allowing	delineation	of	the	bowel	loops	adjacent	to	the	pancreas.	This	
facilitates	 identification	 of	 any	 invasion	 of	 these	 structures.	 When	 3-D	 processing	 is	
incorporated,	the	discrimination	between	periampullary	duodenal	and	ampullary	tumours	
from	the	periampullary	pancreatic	head	tumours	is	improved	by	better	visualization	of	the	
ampullary	 region	 (342,	343).	The	use	of	 a	neutral	oral	 contrast	 is	 superior	 to	 the	use	of	
positive	oral	contrasts	with	high	attenuation,	which	might	interfere	with	the	assessment	of	
the	 peri-pancreatic	 vasculature	 masking	 underlying	 radiological	 signs	 of	 an	 early	
carcinoma	(332,	344).		
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An	 unenhanced	 pre-contrast	 scan	 of	 the	 liver,	 pancreas	 and	 kidneys	 should	 be	
obtained	to	allow	detection	of	hepatic	steatosis,	subtle	pancreatic	ductal	or	parenchymal	
calcifications	and	subtle	primary	or	metastatic	lesions	(345).	
Following	the	pre-contrast	scan,	rapid	intravenous	bolus	injections	of	100-150	ml	
of	 iodinated	 low	osmolality	contrast	at	a	rate	of	4	 to	5	ml/second	are	administered.	The	
dose	 of	 the	 intravenous	 contrast	 should	 be	 calculated	 and	 adjusted	 according	 to	 the	
patient	body	weight	(1.5-2.0	mg	I/kg)	and	the	contrast	should	be	injected	using	a	power	
injector	(346,	347).	The	acquisition	of	images	should	be	during	the	optimal	pancreatic	and	
hepatic	parenchymal	enhancement	phases.	
The	 pathophysiological	 explanation	 of	 the	 pancreatic	 protocol	 could	 be	
understood	by	considering	the	blood	supply	to	the	liver	and	pancreas.	As	the	blood	supply	
of	 the	 pancreas	 is	 through	 the	 splanchnic	 vessels,	 arising	 from	 coeliac	 axis	 and	 the	
superior	mesenteric	artery,	while	the	blood	supply	of	the	liver	is	mainly	through	the	portal	
vein,	 the	 peak	 pancreatic	 parenchymal	 enhancement	 occurs	 relatively	 earlier	 than	 the	
peak	hepatic	parenchymal	enhancement.	Following	the	same	principle,	the	peri-pancreatic	
venous	 structures	 may	 not	 enhance	 homogenously	 during	 the	 peak	 of	 pancreatic	
enhancement	 and	 enhances	 late	 near	 the	 peak	 of	 the	 hepatic	 enhancement	 instead.	
Therefore	a	dual	phase	protocol	 is	adopted	 incorporating	pancreatic	parenchymal	phase	
and	hepatic/portal	venous	phase	(345,	348,	349).	
In	 practical	 terms,	 for	 an	 ideal	 pancreatic	 imaging	 protocol	 based	 on	 16-64	
imaging	 detector,	 the	 acquisition	 of	 the	 images	 should	 ideally	 start	 50	 to	 55	 seconds	
following	the	injection	of	the	intravenous	contrast	for	creating	the	pancreatic	phase,	while	
for	 the	 hepatic	 phase,	 the	 imaging	 acquisition	 should	 start	 65-75	 seconds	 following	 the	
contrast	 injection	 (350).	This	 timing	of	 imaging	acquisition	 is	based	on	 the	use	of	16-64	
imaging	 detector,	 however	 the	 dose,	 injection	 rate	 and	 the	 imaging	 interval	 should	 be	
modified	 according	 to	 the	 patients	 and	 to	 comply	with	 the	 local	 institutional	 guidelines	
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bearing	in	mind	that	the	faster	the	scanner	speed,	the	shorter	the	acquisition	time	for	each	
phase	(351).	
The	dual	phase	imaging	acquisition	allows	simultaneous	scanning	of	the	pancreas	
at	 its	 optimal	 parenchymal	 enhancement	 allowing	 tumour	 detection	 along	 with	
identification	 of	 vascular	 invasion	 by	 homogenous	 opacification	 of	 the	 adjacent	 peri-
pancreatic	arteries	and	veins.	 In	a	similar	way,	 the	 liver	will	be	scanned	during	the	peak	
hepatic	parenchymal	phase	(324,	345,	350).	
During	 the	 pancreatic	 phase,	 the	 intravenous	 contrast	 will	 cause	 intense	
enhancement	 of	 the	 normal	 pancreatic	 parenchyma,	 improving	 lesion	 conspicuity	 by	
illustrating	 the	 difference	 in	 the	 vascular	 perfusion	 between	 a	 typically	 hypovascular,	
hypodense	 pancreatic	 adenocarcinoma	 and	 the	 background	 of	 normal	 pancreatic	
parenchyma	(332,	352).	Assessment	of	 the	 tumour-vascular	relationship	 is	 facilitated	by	
the	 enhancement	 of	 the	 coeliac	 axis,	 superior	mesenteric	 artery	 and	 pancreatic	 arteries	
(296).	
It	 is	 ideal	 to	 obtain	 the	 images	 of	 the	 whole	 abdomen	 and	 the	 pancreas	 in	 one	
breath-hold	 acquisition	 as	 it	 might	 demonstrate	 a	 thin	 peripheral	 enhancement	
surrounding	 subtle	 liver	 metastasis	 with	 perfusion	 abnormalities	 known	 as	 flow	
phenomena	(332).		
The	 hepatic-portal	 venous	 phase	 is	 optimum	 for	 visualizing	 liver	 metastases	 and	
assessing	the	peripancreatic	venous	status	including	the	portal	vein,	superior	mesenteric	
vein	and	splenic	vein	(331).		
4.6.5 Post	processing	
Following	 image	 acquisition	 phase,	 routine	 reconstructions	 and	 reformations	 are	
performed	as	part	of	 the	dedicated	pancreatic	 imaging	protocol.	This	will	 create	2D	and	
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3D	high	resolution	curved	planar	images	highly	effective	in	visualizing	the	peripancreatic	
vascular	structures	allowing	identification	of	vascular	involvement.	Furthermore	it	allows	
better	demonstration	of	the	fluid-filled	pancreatic	duct	which	will	be	extremely	useful	 in	
determining	sites	of	duct	interruption	or	obstruction	aiding	in	accurate	localisation	of	the	
site	of	the	primary	tumour	(10).	
The	process	of	reconstruction	entails	creation	of	3-4	mm	slice	width	images	in	both	
axial	 and	 coronal	 planes,	which	will	 be	 sent	 to	 the	 PACS	 system	 (Picture	 Archiving	 and	
Communication	 System).	Another	 sets	 of	 images	will	 be	 created	 as	 thin	 as	 0.6	mm	slice	
width	as	possible.	These	will	be	dealt	with	either	directly	at	the	CT	console	or	will	be	sent	
to	3D	workstation	for	multiplanar	reformatting,	3D	angiography,	CT	volume	rendering,	CT	
cholangiopancreatography	(CTCP)	(351).	
4.6.6 Characteristic	 imaging	 findings	 of	 Pancreatic	 ductal	 adenocarcinoma	
(solid	neoplasms)	
Pancreatic	adenocarcinoma	 is	 identified	 in	65%	of	cases	 in	 the	head	of	pancreas,	
15%	 body	 and	 tail	 while	 the	 remaining	 20%	 diffusely	 affect	 the	 pancreas	 (353,	 354).	
Pancreatic	adenocarcinoma	typically	manifests	in	the	pancreatic	phase	as	focal	ill-defined	
hypovascular,	 hypodense	 (hypoattenuating)	 poorly	 enhancing	mass	 in	 90-95%	 of	 cases	
when	compared	to	the	arterially	enhancing	normal	pancreatic	parenchyma	(327,	332,	337,	
355,	356).	On	average,	there	is	a	difference	of	40	HU	(Hounsfield	Unit	is	definition	for	CT	
scanners	which	is	calibrated	with	reference	to	water)	between	the	hypoattenuating	focal	
mass	lesion	and	the	background	of	normal	pancreatic	parenchyma	(345).	In	the	remaining	
5-10%	of	pancreatic	adenocarcinomas,	tumours	fail	to	demonstrate	attenuation	difference,	
especially	if	size	is	less	than	2	cm,	therefore	tumour	mass	will	be	identified	as	isodense	or	
isoattenuating.	 In	such	circumstances	 it	 is	essential	 to	pay	attention	to	the	 indirect	signs	
that	 might	 indicate	 the	 presence	 of	 malignancy	 including	 upstream	 duct	 dilatation	
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associated	with	pancreatic	 atrophy	and	double	duct	 sign	 in	 the	absence	of	 calculus	duct	
obstruction	(333,	355-358).		
Segmental	 dilatation	 of	 the	 pancreatic	 duct	 is	 highly	 suggestive	 of	 a	 neoplastic	
lesion.	Dilatation	of	the	main	pancreatic	duct	is	considered	the	earliest	sign	in	pancreatic	
cancer	 (359).	 Gangi	 et	 al.	 reported	 dilatation	 of	 pancreatic	 duct	 18	 months	 before	 the	
diagnosis	of	pancreatic	cancer	(360).		
The	 finding	 of	 a	 hyperattenuating	 lesion	 could	 be	 diagnostic	 for	 neuroendocrine	
tumour.	The	characteristic	identification	of	these	hypervascular	tumours	with	or	without	
hypervascular	 liver	 metastasis	 would	 be	 identified	 on	 images	 obtained	 during	 the	
pancreatic	phase	(361).		
Metastases	 to	 the	 pancreas	 are	 rare,	 most	 commonly	 secondary	 to	 renal	 cell	 or	
bronchogenic	 carcinoma	without	 any	 preference	 to	 any	 particular	 part	 of	 the	 pancreas.	
Vascular	involvement	is	uncommon.	Tissue	diagnosis	with	percutaneous	core	biopsy	may	
be	 necessary	 to	 confirm	 the	 histological	 nature	 of	 the	 tumour	 and	 to	 alleviate	 any	
diagnostic	uncertainty	(362).	
4.6.7 Characteristic	imaging	findings	of	Ampullary	cancer	
Patients	 with	 ampullary	 cancer	 usually	 present	 early	 with	 symptoms	 of	
obstructive	 jaundice	with	 small	 tumours	 that	 are	 often	 not	 apparent	 on	 CT	 scan	 (363).	
However,	 secondary	 radiological	 findings	 such	 as	 marked	 bile	 duct	 dilatation,	 in	
association	with	mild	to	moderate	dilatation	of	 the	pancreatic	duct,	could	be	seen	(364).	
These	small	tumours	are	difficult	to	distinguish	from	other	causes	of	bulging	papilla	such	
as	papillitis,	papillary	stenosis,	choledochocele,	Brunner	gland	adenoma,	lipoma,	fibroma,	
lymphangioma,	and	paraganglioma	(365).	
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Larger	ampullary	tumors	however,	usually	appears	as	polypoidal	or	an	infiltrative	
mass	with	approximately	62%	of	 lesions	manifest	at	 imaging	as	a	discrete	nodular	mass	
that	causes	an	irregular	filling	defect	at	the	distal	margin	of	the	pancreaticobiliary	junction	
(366,	367).		
At	non–contrast	CT,	 ampullary	 cancer	 typically	appears	as	 intraductal	 soft-tissue	
mass	 that	 is	 hypoattenuating	 relative	 to	 the	 hepatic	 parenchyma	with	 an	 attenuation	 of	
approximately	 40	HU	 (363).	 During	 arterial	 and	 portal	 venous	 phase,	 ampullary	 cancer	
usually	enhances	with	lobulated	or	infiltrating	borders	(368).	
For	 infiltrative	mass,	 it	manifests	as	an	 irregularly	 thickened	ductal	wall	 that	obliterates	
the	lumen	and	demonstrates	delayed	prolonged	enhancement	(363).		
4.6.8 Characteristic	imaging	findings	of	Bile	duct	cancer	
With	 the	 advances	 in	 scanning	 technology,	 MDCT	 has	 become	 the	 non-invasive	
diagnostic	 modality	 of	 choice	 for	 assessing	 and	 staging	 bile	 duct	 cancers.	 With	 the	
promising	 results	 of	 the	 CT	 cholangiography,	 this	 could	 be	 considered	 as	 an	 alternative	
diagnostic	tool	when	MR	cholangiography	is	contraindicated.	
Cholangiocarcinoma	 is	 classified	 as	 either	 intrahepatic	 (15%)	 or	 extra	 hepatic	 which	 is	
classified	as	nodular,	sclerosing,	or	papillary	types	(369)	(370).		
.	
The	 radiological	 features	 of	 cholangiocarcinomas	 vary	 depending	 on	 the	
anatomical	 location	 of	 the	 tumours	 in	 relation	 to	 the	 biliary	 tree	when	 examined	by	 CT	
scan.	 Features	 include	 tumour	 mass	 lesion	 associated	 with	 bile	 duct	 dilatation	 in	 the	
exophytic	 type,	 bile	 duct	wall	 thickening	 could	 be	 demonstrated	 in	 the	 infiltrative	 type,	
while	the	polypoidal	variety	could	present	as	intraductal	tissue	(371).	
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On	 non-contrast	 MDCT,	 cholangiocarcinoma	 usually	 appear	 as	 a	 hypo-	 or	
isoattenuating	lesion	in	relation	to	the	normal	hepatic	parenchyma.	The	tumours	usually	
stay	hypoattenuating	during	 the	arterial	 and	 the	portal	 venous	phases.	This	 radiological	
feature	 reflects	 the	 hypovascular	 nature	 of	 these	 tumours	 (372-374).	 However,	 a	 study	
has	 concluded	 that	 hyperenhancement	 of	 a	 stenosed	 bile	 duct	 during	 the	 portal	 venous	
phase	could	be	considered	a	sign	of	malignancy	(375);	this	however	has	a	low	specificity	
of	19%.	
The	development	of	 the	non-invasive	CT	 cholangiography	using	 IV	 contrasts	has	
helped	in	delineating	the	anatomical	details	of	the	biliary	tree	and	found	to	be	superior	to	
the	use	of	 the	oral	 contrast	as	 they	provide	high	quality	opacification	of	 the	biliary	 tree.	
However,	 the	 use	 of	 this	 modality	 could	 be	 limited	 in	 patients	 with	 high-grade	 biliary	
obstruction	as	it	is	dependent	on	the	secretory	function	of	the	biliary	system	(376).	
The	 MDCT	 and	 the	 CT	 cholangiography	 have	 limitations	 detecting	 early	 or	 small	
tumours	 especially	 the	 infiltrating	 stricture-forming	 variety,	 also	 benign	 strictures	 or	
benign	lesions	at	the	porta-hepatis	which	can	imitate	cholangiocarcinoma	(377).	Also,	the	
use	of	CT	cholangiography	could	be	limited	in	patients	with	high-grade	biliary	obstruction	
or	 significantly	 high	 serum	bilirubin	 as	 it	 is	 dependent	 on	 the	 secretory	 function	 of	 the	
biliary	 system	 (376).	This	 has	been	 resolved	by	 the	use	of	 PET/CT	 in	 the	diagnosis	 and	
staging	of	cholangiocarcinoma.	
	
4.6.9 Assessment	of	vascular	status	
Vascular	 involvement,	 determined	 by	 the	 extent	 the	 tumour	 involves	 the	 vessel’s	
cross	 sectional	 circumference	 (355),	 is	 the	 most	 important	 factor	 in	 the	 preoperative	
radiological	 assessment	 of	 resectability	 of	 periampullary	 cancers	 in	 absence	 of	 lymph	
node	or	distant	metastasis.	The	use	of	3D	reconstruction	images	makes	the	assessment	of	
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the	vascular	 involvement	more	apparent	 than	using	 the	axial	 images	alone.	MDCT	has	a	
reported	 sensitivity	of	77-90%	and	specificity	of	81-100%	 in	diagnosing	peri-pancreatic	
vascular	 infiltration	(330,	378).	The	following	major	vessels	were	reported	in	relation	to	
PHM:	 	 Superior	 Mesenteric	 Artery	 (SMA),	 Hepatic	 Artery	 (HA),	 Coeliac	 Trunk	 (CA),	
Superior	Mesenteric	vein	(SMV)	and	Portal	vein	(PV)	(352,	379).		
These	 following	 terms	 have	 been	 used	 to	 describe	 the	 degree	 of	 vascular	 involvement	
(259).	
Abutment:	 Less	 than	 180-degree	 vascular	 involvement	 or	 contiguity	 <50%	 i.e.	 Peri-
vascular	 fat	 planes	 partially	 obliterated	 with	 the	 vessel	 encompassing	 less	 than	 180	
degree	of	its	circumference.	
Encasement:	More	than	180-degree	vascular	involvement	or	contiguity	≥	50%	i.e.	Peri-
vascular	 fat	 planes	 completely	 obliterated	with	 the	 vessel	 encompassing	more	 than	180	
degree	of	its	circumference.	
The	degree	of	arterial	invasion	is	recognized	by	the	following	criteria	(325,	378,	380,	381)	
1. Obliteration	 of	 the	 normal	 fat	 between	 pancreatic	 margin	 and	 the	 adjacent	
arteries	(HA,	CA,	SMA).	
2. >	180-degree	contact	between	tumor	and	arteries.	
3. Morphologic	 changes	 in	 the	 artery	 including	 narrowing	 and	 contour	
abnormalities.	
The	criteria	of	venous	 involvement	that	preclude	surgery	are	different	 from	those	of	 the	
arterial	 involvement	 and	 subjected	 to	 a	 great	 debate	 in	 the	 literature.	 The	 degree	 of	
venous	invasion	is	recognized	by	any	of	the	following	(325,	378,	380,	381):	
I. Tumour-to-vessel	circumferential	contiguity	of	≥	50%.	
II. >180-degree	contact	between	the	tumor	and	the	vein.	
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III. Loss	of	a	patent	Porto-splenic	confluence.	
IV. 360°	encasement	of	the	PV	or	SMV.	
V. A	change	in	the	vessel	contour	or	calibre	regardless	the	degree	of	contact	between	
tumour	and	vessel.	
VI. The	“teardrop”	configuration	of	the	SMV	(382).	
Confirmation	 of	 venous	 invasion	 is	 best	 demonstrated	 in	 images	 obtained	 during	 the	
hepatic	phase	with	a	reported	specificity	as	high	as	100%	(324,	378).	
The	 recent	 advances	 in	 venous	 graft	 technology	 allowing	 reconstructible	 resection	 of	
limited	 venous	 invasion,	 has	 contributed	 to	 this	 debate.	 Ishkawa	 and	 his	 colleagues	
defined	 five	 types	of	 tumour	abutment	along	SMV-PV	confluence	 in	order	 to	standardize	
criteria	 for	 venous	 involvement	 (383).	 Type	 (I):	 normal,	 (II)	 smooth	 shift	 without	
narrowing,	 (III):	 unilateral	 narrowing,	 (IV)	 bilateral	 narrowing,	 (V)	 bilateral	 narrowing	
with	collateral	veins.	
4.6.10 Grading	systems	of	vascular	invasion		
Loyer	and	his	working	group	adopted	the	first	attempt	to	categories	tumour	vessel	
relationship	in	1996	(384).	Using	thin	section	CT	images,	A-F	grading	system	was	designed	
to	classify	the	vascular	involvement	in	patients	with	pancreatic	adenocarcinoma.		In	1997,	
Lu	 and	 his	 colleagues	 adopted	 a	 five-point	 scale	 system	 based	 on	 the	 circumferential	
contiguity	of	tumour	to	the	vessels	with	reported	a	sensitivity	of	84%,	specificity	of	98%,	
positive	 predictive	 value	 of	 95%	 and	 negative	 predictive	 value	 of	 93%	 for	 vessel	
unresectability	(385).			
In	Germany,	Klauss	and	his	working	group	developed	a	new	invasion	score	(0-6)	
depending	 on	 the	 length	 of	 the	 tumour	 contact	 and	 the	 circumferential	 tumour	
involvement	 separately	 (386).	 Invasion	 score	 of	 11	 or	 more	 is	 considered	 evidence	 of	
vascular	 infiltration.	 They	 reported	 a	 sensitivity	 of	 90.9%,	 specificity	 of	 98.7%	 positive	
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predictive	 value	 of	 99.4%,	 negative	 predictive	 value	 of	 99.4%	 and	 overall	 accuracy	 of	
98.2%	when	evaluating	the	degree	of	vascular	invasion.		
Fang	 and	 his	 colleagues	 (387)	 have	 implemented	 another	 classification	 system	
based	on	 the	gap	between	 the	 tumour	and	 the	blood	vessels	using	3D	 reconstructed	CT	
images.	 Five	 types	 have	 been	 described	 in	 determining	 the	 resectability.	 The	 vessels	
described	include	the	portal	vein,	superior	mesenteric	artery,	inferior	vena	cava,	superior	
mesenteric	 vein,	 left	 renal	 vein,	 right	 renal	 vein,	 hepatic	 artery,	 celiac	 trunk,	 and	
abdominal	aorta.	They	reported	a	sensitivity,	specificity,	positive	and	negative	predictive	
values	of	100%	in	assessing	resectability	of	pancreatic	and	peri-ampullary	tumours.		
4.6.11 Assessment	of	Lymph	node	status	
The	 accuracy	 of	 assessing	 nodal	 disease	 by	 different	 radiological	 modalities	 is	
limited	 with	 reported	 sensitivity	 of	 the	 CT	 to	 diagnose	 nodal	 deposits	 is	 14%,	 with	 a	
specificity	 of	 85%	 (388).	 The	 presence	 of	 positive	 lymph	 node	 metastases	 is	 a	 poor	
prognostic	indicator	whether	it	is	metastatic	deposits	or	via	direct	invasion.	A	size	greater	
than	10	mm	in	short	axis	(antero-posterior	diameter)	on	cross	section	imaging	modalities	
has	been	used	as	diagnostic	criteria	for	metastatic	lymphadenopathy	(259,	332,	337,	355).	
The	size	 is	not	however	a	discriminative	 feature	for	 lymph	node	metastasis	(329).	Other	
criteria	have	been	reported	including	morphological	nodal	changes	such	as	poorly	defined	
boundaries,	 rounded	 shape	 alteration,	 and	 hypodense	 conversion	 appearance	 are	more	
specific	but	less	sensitive	findings	(355).	
Involvement	of	pancreatic	and	peripancreatic	lymph	nodes	should	not	prevent	an	
attempt	at	curative	surgical	resection,	as	they	could	be	resected	en-block	with	the	primary	
tumour.	 Nevertheless,	 involvement	 of	 remote	 lymph	 nodes	 beyond	 the	 extent	 of	 the	
Whipple	operation	(e.g.	para	aortic,	mesenteric	or	porta	hepatis)	is	however	considered	a	
contraindication	for	curative	resections	(332,	389,	390).	The	use	of	PET/CT	as	adjunct	tool	
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in	 staging	 has	 aided	 the	 identification	 of	 suspicious	 nodes	 for	 biopsy	 with	 a	 reported	
sensitivity	 of	 46%-71%	 and	 specificity	 of	 63%-100%	 for	 detecting	 suspicious	 nodal	
disease	outside	the	conventional	surgical	 field	(391-393).	However	 it	 is	 limited	 in	small-
volume	 disease,	 as	 it	 cannot	 differentiate	 between	 inflammatory	 vs.	 metastatic	
lymphadenopathy.	
4.6.12 Assessment	of	distant	metastasis	
Pancreatic	 cancer	 commonly	 metastases	 to	 liver,	 peritoneum,	 lungs	 and	 less	
commonly	bones.	Pre-operative	evaluation	of	metastatic	deposits	 is	 a	 crucial	part	of	 the	
pre-operative	 work-up,	 as	 evidence	 of	 remote	 metastasis	 is	 a	 contraindication	 for	 an	
attempt	at	surgical	resection.	CT	has	a	reported	sensitivity	of	75%-80%	in	detecting	liver	
metastasis	 (313,	 327,	 394).	 	 The	hepatic	metastases	 are	 best	 evaluated	 on	MDCT	portal	
venous	 phase	 as	 solid	 hypovascular	masses	 (331).	 If	 these	 lesions	 are	 small	 (≤	 10mm),	
they	 often	 reported	 as	 “indeterminate”	 as	 it	 is	 difficult	 to	 identify	 their	 nature	 due	 to	
difficulty	in	measuring	their	attenuation,	which	could	be	caused	by	pseudo	enhancement	
and/or	partial	volume	averaging.	These	lesions	are	best	assessed	by	MRI	(390).		
Pancreatic	spread	to	the	peritoneum	is	usually	a	small	volume	disease	and	it	is	difficult	to	
be	detected	using	CT	and	better	assessed	by	laparoscopy.	In	advanced	disease,	peritoneal	
carcinomatosis	 is	 detected	 on	 MDCT	 images	 as	 peritoneal	 thickening	 with	 contrast	
enhancement	associated	with	ascites	(390).	Ascites	 is	a	common	manifestation	of	cancer	
end-stage	and	it	is	present	in	about	20%	of	pancreatic	cancer	patients	(395).		
4.6.13 Radiological	staging	systems	
The	widely	used	cancer	staging	system	known	as	TNM	(Tumour,	Node,	Metastasis)	
staging	system	describes	the	cancer	in	relation	to	its	anatomical	local,	regional	and	distant	
extension.	
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Pierre	Denoix	 (396)	 (France)	 between	 1943	 and	 1952	was	 the	 first	 to	 devise	 this	most	
widely	used	staging	system	(397).	
In	 1987,	 the	 TNM	 staging	 system	 was	 combined	 with	 the	 American	 Joint	
Committee	on	Cancer	 (AJCC)	 into	 the	most	widely	accepted	and	commonly	used	 staging	
system	 for	 pancreatic	 cancer	 (398,	 399).	 This	 staging	 system	 incorporates	 three	 main	
categories.	The	 (T)	 stage	describes	 the	primary	 tumour	 stage,	 size	and	extent.	The	 (N)	 -	
lymph	node	stage	describes	the	lymph	node	involvement.	The	(M)	-	metastases	describes	
the	presence	or	absence	of	regional	or	remote	metastatic	deposits.	The	staging	system	has	
undergone	several	 revisions	and	development	 till	 the	seventh	edition	 (Table	4.1),	which	
became	 effective	 in	 January	 2007	 (397,	 400).	 The	 eighth	 edition	 has	 been	 recently	
published	(401).	The	Peninsula	HPB	cancer	centre	is	currently	using	this	staging	system.	
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TNM	 Pancreatic	adenocarcinoma	 Bile	Duct	cancer	 Ampullary	cancer	
T	stage	
Tx	 Primary	tumour	cannot	be	assessed	
T0	 No	evidence	of	primary	tumour	
Tis	 Carcinoma	in	situ	
T1	 Limited	to	pancreas,	≤	2	cm	in	
its	greatest	dimension	
Confined	to	bile	duct	 Limited	to	ampulla	or	
sphincter	of	Oddi	
T2	 Limited	to	pancreas,	>	2	cm	in	
its	greatest	dimension	
Invades	beyond	bile	
duct	wall	
Invades	duodenal	wall	
T3	 Extends	beyond	pancreas	
without	involvement	of	coeliac	
axis	or	superior	mesenteric	
artery	
Invades	gallbladder,	
liver,	pancreas,	
duodenum,	or	other	
adjacent	organs	
Invades	pancreas	
T4	 Involves	coeliac	axis	or	
superior	mesenteric	artery	
Involves	the	coeliac	
axis	or	the	superior	
mesenteric	artery	
Invades	peripancreatic	
soft	tissues,	or	other	
adjacent	organs	or	
structures	
N	stage	
Nx	 Regional	lymph	node	cannot	be	assessed	
N0	 No	regional	nodal	metastasis	
N1	 Regional	nodal	metastasis	
M	stage	
M0	 No	Distant	metastasis	
M1	 Distant	metastasis	
	
Table	4.1	TNM	staging	system	
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Notes	
1. Anatomical	 sub-sites	of	 the	pancreas	 include	head,	body,	 tail,	pancreatic	duct	
and	Islets	of	Langerhans	(endocrine	pancreas).	
2. Tis	also	includes	the	‘PanIN–III’	classification.	
3. Tumours	of	 the	head	of	 the	pancreas	are	 those	arising	 to	 the	right	of	 the	 left	
border	of	the	superior	mesenteric	vein.		
4. Tumours	of	the	body	are	those	arising	between	the	left	border	of	the	superior	
mesenteric	vein	and	left	border	of	the	aorta.	
5. The	uncinate	process	is	considered	as	part	of	the	head.	
6. Tumours	of	the	tail	are	those	arising	between	the	left	border	of	the	aorta	and	
the	hilum	of	the	spleen.	
7. The	regional	(peripancreatic)	lymph	nodes	are	demonstrated	in	(Table	4.2).	
Superior	 Superior	to	head	and	body	
Inferior	 Inferior	to	head	and	body	
Anterior	 Anterior	 pancreatico-duodenal,	 pyloric	 (for	 tumours	 of	 head	 only),	 and	
proximal	mesenteric	
Posterior	 Posterior	 pancreatico-duodenal,	 common	 bile	 duct,	 and	 proximal	
mesenteric	
Splenic	 Hilum	of	spleen	and	tail	of	pancreas	(for	tumours	of	body	and	tail	only)	
Coeliac	 For	tumours	of	head	only	
	
Table	4.2	Regional	peripancreatic	lymph	nodes	distribution	(402)
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4.7 Definition	of	Resectability		
It	is	generally	agreed	that	tumour	resectability	is	classified	into	two	major	categories:		
(A)	 Potentially	 resectable	 group	 that	 includes	 the	 resectable	 and	 the	 borderline	
resectable	tumours.		
(B)	 Non	 resectable	 group	 which	 includes	 the	 locally	 advanced	 tumours	 and	
metastatic	tumours	(399).		
Several	 classification	 systems	 have	 been	 designed	 such	 as	 the	 National	 Comprehensive	
Cancer	Network	(NCCN)	group	system	based	on	the	tumour	location	(pancreatic	head	vs.	
body&	 tail),	 extent	 and	 the	 tumour-vessel	 relationship	 (403).	 Another	 classification	
system	 by	 the	 multidisciplinary	 pancreatic	 cancer	 group	 at	 the	 Medical	 College	 of	
Wisconsin	(MCW)	based	on	the	tumour-vessel	relationship	(399).	
The	American	Joint	Committee	on	Cancer	(AJCC)	has	defined	criteria	for	resection	(Table	
4.3)	 based	 on	 the	TNM	 classification	 system	 (398).	 This	 system	 is	 currently	 used	 at	 the	
Peninsula	HPB	cancer	centre.	
Classification	 Stage	 Median	Survival	in	Months	
Resectable	 IA	(T1	N0	M0)	 17-23	
IB	(T2	N0	M0)	
IIA	(T3	N0	M0)	
IIB	(T1-3	N1	M0)	
Borderline	resectable	 III	(T4	any	N	M0)	 Up	to	20	
Locally	advanced/	
unresectable	
III	(T4	any	N	M0)	 8-14	
III/	IV	(any	T	any	N	M1)	 4-6	
	
Table	4.3		AJCC	classification,	Staging	and	Prognosis,	adopted	from	Al-Hawary	et	al.	
2013(398).	
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4.8 Borderline	resectable	pancreatic	cancer	(BLR)	
The	term	“borderline	resectability”	which	was	first	introduced	in	an	article	by	Maurer	
and	 his	 colleagues	 in	 1999	 (404).	 There	 is	 a	 great	 debate	 in	 the	 literature	 about	 the	
definition	of	BLR	in	order	to	reach	an	agreement	that	might	shape	treatment	strategies.	
The	American	Joint	Committee	on	Cancer	(AJCC)	has	defined	BLR	based	on	the	TNM	stage	
with	median	survival	rate	of	20	months	(398).	
The	 NCCN	 defined	 BLR	 based	 on	 the	 tumour	 anatomical	 location	 (pancreatic	 head	 vs.	
body&	tail),	extent	and	the	tumour-vessel	relationship	(403).		
The	MD	Anderson	Cancer	 Centre	 group	 introduced	 a	 definition	 of	 borderline	 resectable	
tumour,	which	was	classified	into	three	groups	(Table	4.4)	(405,	406).	
Group	 Definition	
A	
Abutment	of	SMA,	coeliac	axis	
Abutment	or	short	segment	encasement	of	HA	
Short	segment	occlusion	of	SMV,	PV	or	SMV-PV	confluence	(amenable	to	
reconstructive	resection)	
B	
Known	lymph	node	involvement	
Findings	suggestive	of	metastatic	disease	
C	
Comorbid	conditions	requiring	preoperative	workup	
Improving	marginal	performance	status	
	
Table	4.4	M.D.	Anderson	classification	system	for	borderline	resectable	pancreatic	cancer	
	
In	2009,	Callery	 and	his	 colleagues	 (29)	defined	borderline	 resectability	 as	 abutment	or	
encasement	or	reconstructible	venous	occlusion	of	SMV	and	or	PV.	
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4.9 Reporting	CT	
With	 increasing	 centralization	 of	 the	 pancreatic	 cancer	 specialized	 centres,	 the	
demand	 for	 creating	 a	 standard	 descriptive	 universal	 reporting	 system	 for	 pancreatic	
malignant	 tumours	 that	 could	 be	 understood	 by	 different	 specialties,	 became	 crucially	
important.	 Several	 attempts	have	been	made	 to	design	and	 to	 create	a	unique	 reporting	
system	but	with	no	general	agreement	between	authors.	The	Radiologic	Society	of	North	
America	(RSNA)	published	a	guidance	template	for	reporting	the	primary	pancreatic	mass	
available	 from	 http://www.radreport.org/template/0000018	 (407).	 Another	 radiology	
reporting	 template	 is	 adopted	 by	 the	 radiology	 department	 at	 the	MD	Anderson	 cancer	
centre	(MDACC)	(408).		
The	ideal	reporting	template	should	include	full	description	of	the	primary	tumour	mass	
including	 tumour	 size,	 site,	 enhancement,	 local	 extent,	 assessment	 and	 grading	 of	 the	
vascular	 status	 clarifying	 any	 grade	 of	 vascular	 involvement	 and	 stating	 the	 grading	
system	that	has	been	used,	and	assessment	of	the	nodal	status	and	distant	metastasis.		
4.10 MDCT	interpretation	pitfalls	
Focal	 and	 autoimmune	 pancreatitis	 may	 present	 as	 discrete	 hypoattenuating	 or	
isoattenuating	 mass	 with	 or	 without	 secondary	 tumour	 features	 that	 mimic	 pancreatic	
ductal	 adenocarcinoma	 (409).	 Even	 pre-operative	 biopsies	 showing	 only	 inflammatory	
cells	 could	 be	 misleading	 because	 elements	 of	 pancreatitis	 are	 often	 associated	 with	
pancreatic	carcinoma	(409,	410).		Unless	recurrent	or	chronic,	the	focal	pancreatitis	rarely	
causes	upstream	duct	dilatation	of	the	pancreatic	duct.	The	radiological		“duct	penetrating”	
sign	 (non-dilated	 pancreatic	 duct	 passes	 through	 hypoattenuating	 pancreatic	 mass)	
supports	 the	benign	diagnosis	 such	 as	 acute	 or	mild	 chronic	pancreatitis	 (411).	 Chronic	
pancreatitis	 often	 causes	 smooth	 narrowing	 of	 both	 pancreatic	 and	 common	 pancreatic	
ducts,	 which	 could	 be	 depicted	 on	 MDCT	 result	 in	 a	 challenging	 radiological	 diagnosis.
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5 Methods	
5.1 Plan	of	investigations	
The	 Southwest	 Peninsula	 HPB	 Cancer	 Unit	 provides	 pancreatic	 cancer	 surgical	
services	 to	 the	 counties	 of	Devon	 and	 Cornwall.	 Referrals	 come	 from	 five	 hospitals	 in	 a	
cancer	network	with	a	population	of	1.7	million.	Data	relating	to	population	density	were	
obtained	from	the	Office	for	National	Statistics	(ONS)	(412).	The	size	of	the	catchment	area	
served	by	each	of	the	five	hospitals	in	the	Peninsula	was	obtained	from	South	West	Public	
Health	Observatory	(413),	based	on	the	referral	practice	of	general	practitioners.	
The	 study	 cohort	 included	 consecutive	 series	 of	 patients	 referred	 from	 the	 five	
hospitals	across	the	cancer	network	and	treated	at	Southwest	Peninsula	HPB	Cancer	Unit	
between	January	2006	and	May	2014	(Appendix-A).	
All	patients	were	discussed	at	the	regional	HPB	MDT	before	being	offered	surgery.	
The	surgical	workload	is	shared	non-selectively	by	four	surgeons	and	is	undertaken	using	
standardised	 surgical	 techniques.	 In-patient	 care	 follows	 a	 standard	Enhanced	Recovery	
After	 Surgery	 (ERAS)	 protocol.	 (Appendix-D)	 Precise	 characterisation	 of	 the	 tumour	 is	
undertaken	 and	 the	 information	 relayed	 to	 the	 clinical	 team.	 Patients	 with	 evidence	 of	
metastatic	spread	are	referred	for	non-operative	treatment.	Clinically	significant	features	
of	the	morphology	of	the	pancreatic	head	tumour	are	recorded	in	the	patients’	notes.		
Initially	 a	 dataset	was	 compiled	 including	 patients’	 demographics,	 referral	 details,	
imaging	 characteristics,	 laboratory	 investigations	 results,	 operative	 details,	 pathological	
findings	and	follow	up	details.	These	information	were	obtained	from	patients’	case	notes,	
G.P	records,	electronic	information	systems	including	i	SOFT,	I	Lab	and	PACS	(Appendix-C)	
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The	 date	 of	 diagnosis	 of	 PHM	 was	 taken	 as	 the	 date	 of	 the	 first	 cross-sectional	
abdominal	 imaging	 which	 suggested	 this	 diagnosis.	 As	 the	 time	 of	 receipt	 of	 the	 initial	
referral	 is	variable	and	subject	 to	administrative	delays,	 the	 interval	 to	 surgery	 (IS)	was	
measured	 from	 the	 date	 of	 the	 first	 imaging	 modality	 undertaken	 which	 raised	 the	
possible	diagnosis	of	PHM	to	the	time	of	the	surgical	intervention.	The	travel	distance	by	
road	for	each	patient	was	obtained	from	the	AA	mileage	calculator	(414)(with	permission)	
using	the	post-code	data.	The	presence	of	pre-operative	biliary	obstruction	was	defined	as	
any	abnormality	in	liver	function	tests	sufficient	to	prompt	investigation	by	cross	sectional	
imaging	 or	 the	 requirement	 for	 pre-operative	 biliary	 drainage	 or	 clinically	 evident	
jaundice	 at	 time	 of	 surgery.	 Pre-operative	 diabetes	 was	 defined	 as	 the	 requirement	 for	
hypoglycaemic	medications.		The	American	Society	of	Anaesthesiologists	(ASA)	grade	was	
determined	at	the	time	of	surgery	by	the	responsible	anaesthetist.		
To	assess	 the	ability	of	 the	pre-operative	CT	scan	 to	determine	 the	 tumour	origin,	
stage	and	resectability,	all	pre-operative	CT	scans	of	 interest	were	retrieved	through	the	
Insignia	radiology	imaging	system	from	across	the	five	hospitals.	All	identifiable	data	were	
removed	 and	 images	were	 then	 anonymised	 and	 uploaded	 to	 the	 Picture	Archiving	 and	
Communication	 System	 (PACS)	 system.	 Two	 radiologists	 blinded	 to	 the	 final	 histology	
result	reviewed	all	scans	independently	in	the	same	manner	as	in	routine	clinical	practice	
using	a	specially	designed	focused	proforma	with	review	by	a	third	radiologist	in	cases	of	
discrepancy.	Final	radiological	re-reporting	results	were	correlated	with	the	operative	and	
histopathological	 outcome.	 Imaging	 other	 than	 of	 the	 primary	 tumour	 and	 the	
peripancreatic	area	was	not	reviewed.		
Resectability	was	defined	as	the	ability	to	resect	the	pancreatic	head	without	the	use	
of	 neoadjuvant	 chemotherapy.	 Surgical	 resection	 was	 performed	 by	 a	 classic	 Whipple	
resection	with	pancreatico-gastrostomy	reconstruction.		
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Tumours	were	 classified	according	 to	 the	histological	origin	 (pancreatic,	bile	duct,	
ampullary	 or	 duodenal).	 Pathological	 reporting	 was	 undertaken	 according	 to	 Royal	
College	 of	 Pathologists	 guidelines(23)	 with	 axial	 slicing	 of	 the	 resection	 specimen.	 The	
TNM	classification	 system	 for	malignant	 tumours	 (415,	416)	was	used	 to	determine	 the	
final	pathology	stage.		
Survival	 data	 were	 obtained	 from	 hospital	 and	 general	 practice	 records	 and	
included	all	 deaths	occurring	 after	 surgery,	 including	 in-hospital	mortality.	 Survival	was	
calculated	from	the	date	of	the	first	diagnosis.	Follow-up	was	completed	1st	May	2015.	
5.2 Study	participants	
5.2.1 Inclusion	criteria	
All	 patients	 who	 have	 undergone	 attempted	 surgical	 resection	 for	 presumed	
pancreatic	 head	 malignancy	 at	 Southwest	 Peninsula	 HPB	 Cancer	 Unit	 between	 January	
2006	and	May	2014	were	included.		
5.2.2 Exclusion	criteria	
The	following	patients	have	been	excluded:	
• All	patients	received	preoperative	neoadjuvant	chemo/chemo-radiotherapy.		
• All	patients	undergoing	surgical	resection	not	involving	the	pancreatic	head.		
• Patients	 with	 the	 final	 histology	 other	 than	 pancreatic,	 ampullary,	 bile	 duct	 or	
duodenal	cancer	were	excluded	from	the	final	analysis.		
• For	assessment	of	the	ability	of	the	staging	CT	scan	to	predict	the	resectability	of	
periampullary	 cancers,	 patients	 were	 excluded	 if	 the	 pre-operative	 CT	 scan	 of	
interest	could	not	retrieved.	
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5.3 Study	procedures	and	interventions	
No	 study-specific	 procedures	 or	 interventions	 were	 required.	 The	 study	 was	 a	
retrospective	 review	 of	 the	 Peninsula	 HPB	 cancer	 centre	 database	 with	 review	 of	 the	
preoperative	staging	CT	scan	for	patients	with	suspected	periampullary	cancers.	
5.4 Outcome	measures	
The	 outcome	 measures	 of	 interest	 were	 the	 resectability	 of	 the	 periampullary	
tumours	and	pathological	origin	of	the	resected	tumour.	
5.5 Study	questionnaires	and	forms	
A	proforma	was	designed	to	record	the	radiological	findings	of	interest	(Appendix-
B).	
5.6 Definition	of	end	of	the	study		
The	study	ended	by	completing	the	dataset,	retrieving	all	relevant	information	and	
analyzing	the	data.	
5.7 Source	data	
The	 Southwest	 Peninsula	 HPB	 Cancer	 Unit	 retains	 a	 prospectively	 maintained	
database	of	routinely	collected	clinical	information	including	demographics,	radiology	and	
pathology	reports.		Imagings	of	interest	were	retrieved	from	the	Insignia	radiology	system.		
5.8 Data	storage		
All	data	were	stored	on	NHS	password	protected	hard	drive.	Anonymised	data	was	
stored	on	a	project-specific,	encrypted	portable	hard	drive.		Data	will	be	kept	for	five	years	
after	the	study	ends.	
	
	 89	
5.9 Statistical	Analysis	
5.9.1 Statistical	tests	
The	following	statistical	tests	were	used	in	order	to	interpret	the	study	findings.	I	
undertook	the	descriptive	statistical	analysis,	which	were	rechecked	and	confirmed	by	Dr.	
Shahtahmassebi	whom	undertook	inferential	analyses.	
Pearson	 Chi	 square	 test	 (X2)	 was	 used	 to	 assess	 the	 significance	 in	 difference	
between	 discrete	 variables	 e.g.	 patients’	 travel	 distance,	 interval	 to	 surgery	 and	
pathological	outcomes.		This	was	to	test	whether	the	frequency	in	the	outcome	of	interest	
was	 significantly	 different	 between	 the	 different	 groups	 or	 it	 was	 due	 to	 chance.	 This	
significance	was	expressed	by	P	value.	
	
Kruskal-Wallis	 test,	 non-parametric	 test,	 was	 used	 to	 assess	 the	 significance	 of	
difference	between	continuous	variables	e.g.	radiological	tumour	size	between	two	groups	
e.g.	 resection	 vs.	 non-	 resections.	When	 comparing	 the	difference	 across	more	 than	 two	
groups	e.g.	the	five	referring	hospitals,	Mann–Whitney	U	test	was	used.	
	
To	 examine	 the	 strength	 of	 the	 relationship	 between	 variables	 (how	 closely	
related),	 correlation	 coefficient	 (r)	was	 used.	 This	 was	 to	 examine	 the	 strength	 of	 the	
relationship	 rather	 than	 the	 cause-effect	 relationship	 between	 variables,	 which	 ranges	
from	 -1	 to	 +1.	 A	 positive	 correlation	 coefficient	means	 that	 the	 value	 of	 one	 variable	 is	
increased	if	the	value	of	the	other	variable	is	increasing.	A	negative	correlation	coefficient	
means	 that	 if	 one	variable	 increased,	 the	other	variable	decreased.	A	perfect	 correlation	
could	 be	 +1	 or	 -1	 while	 the	 zero	 value	 indicates	 no	 correlation.	 	 Pearson’s	 correlation	
coefficient	was	 used	when	 both	 variables	were	 continuous	 e.g.	 patients’	 travel	 distance	
and	interval	to	surgery.	Spearman	correlation	coefficient	(non-parametric	test)	was	used	
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to	 test	 the	 strength	 of	 the	 relationship	 when	 one	 or	 both	 variables	 were	 non-normally	
distributed	 e.g.	 radiological	 features	 and	 final	 histological	 findings.	 Its	 significance	 was	
expressed	by	P	value.	
Kaplan–Meier	survival	curves	(non-parametric	test)	were	used	to	assess	patients’	
survival.	 Survival	 times	were	 calculated	 from	 time	of	 the	diagnosis	 (date	 of	 fist	 imaging	
modality	 that	 raised	 the	 suspicious	 of	 periampullary	 cancer	 was	 taken	 as	 a	 reference	
point)	till	May	2015.	Dates	of	death	(event)	were	determined	by	access	to	General	Practice	
records.	 
The	number	at	risk	(r)	at	given	time	period	was	calculated	by	subtracting	the	number	of	
patients	died	 and	 the	number	of	 those	who	 lost	 follow	up	 (censored)	 together	 from	 the	
total	number	of	risk	at	the	beginning	of	that	certain	time	period.	Probability	of	deaths	at	
specific	 time	 period	 was	 calculated	 by	 dividing	 the	 number	 of	 patients	 died	 (d)	 at	 this	
specific	period	by	the	number	at	risk	(r)	at	the	same	time	period.		
The	probability	of	survival	at	a	given	period	was	then	calculated	as	(1-	d/r).	
	
Kaplan-Meier	survival	probability	of	any	current	time	period	was	calculated	by	successive	
multiplication	 of	 all	 survival	 probabilities	 that	 preceding	 that	 specific	 period	 and	 the	
current	 time	 period.	 To	 examine	 the	 overall	 survival	 between	 any	 sets	 of	 two	 different	
groups	 e.g.	 resections	 vs.	 non-resections;	 log	 rank	 test	 was	 used.	 The	 significance	 was	
expressed	using	the	P	value.	
	
Cox	regression	analysis	(proportional	hazards)	was	used	to	explore	the	potential	
influence	of	more	than	one	variable	e.g.	age,	gender,	ASA	grade,	travel	distance	and	biliary	
obstruction	on	patient’s	survival.	It	provides	estimate	of	the	survival	time	and	confidence	
intervals	as	well	as	adjusts	the	effect	of	the	confounders.	
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Multivariate	logistic	regression	models	were	used	to	predict	a	categorical	outcome	
variable	e.g.	histological	tumour	stage	from	a	set	of	explanatory	variables	e.g.	preoperative	
variables	 (e.g.	 Interval	 to	 surgery	 as	 a	 binary	 variable	 <	 or	 ≥	 median),	 or	 radiological	
parameters.	
Cohen’s	 Kappa	 test	 was	 used	 to	 assess	 the	 concordance	 of	 responses	 (inter	
observer	 agreement)	 between	 the	 two	 radiologists	 re-reporting	 the	 scans	 (recording	
categorical	 data)	 in	 excess	 of	 the	 agreement	 that	 would	 occur	 by	 chance.	 The	 K	 value	
ranges	from	zero	to	one.	A	value	of	zero	means	no	significant	agreement	more	than	would	
have	been	expected	by	chance,	a	value	of	0.5	means	a	good	agreement,	0.7	means	a	very	
good	agreement	and	a	value	of	1	means	a	perfect	agreement.		
5.9.2 Statistical	software	
The	following	statistical	programs	have	been	used:	
§ IBM®	SPSS®	21	
§ The	R	statistical	program	
§ Analyse-it	program	
5.9.3 Number	of	participants	
As	no	previous	studies	have	been	undertaken	to	address	the	outcomes	of	the	two	
studies,	 formal	 power	 calculations	 were	 not	 possible	 to	 undertake	 at	 the	 time	 of	
conducting	 this	 study.	 	 Thus,	 an	 interim	 analysis	 was	 undertaken	 after	 50	 reports	 to	
identify	 likely	 positive	 radiology	 features	 to	 power	 the	 remainder	 of	 the	 study	 (421	
patients).
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5.9.4 First	and	second	studies	
To	 address	 the	 primary	 objective	 of	 the	 study,	 continuous	 variables	 were	
compared	with	Mann-Whitney	U	test	and	categorical	variables	by	Chi	square	test.	
In	 the	 demonstration	 of	 potential	 association	 between	 the	 travel	 distance	 to	 the	
regional	HPB	centre	and	interval	to	surgery	a	logarithmic	scale	was	used	to	accommodate	
the	wide	spread	of	intervals	to	surgery.	Correlation	was	assessed	by	Spearman	correlation	
coefficient	
Kaplan-Mayer	 survival	 curves	 were	 constructed	 for	 patients	 according	 to	 the	
resectability	and	the	pathology	subsets.	 	This	allowed	comparison	of	outcomes	according	
to	tumour	origin,	resection	margin	status	and	pathological	stage	for	the	entire	cohort.			
Kaplan-Meier	survival	analysis	and	Cox	Proportional	Hazard	models	were	used	to	
assess	the	effect	of	potential	influence	of	preoperative	variables	including	age,	gender,	ASA	
grade,	biliary	 interventions,	referring	hospital,	 travel	distance	and	 interval	 to	surgery	on	
the	post-operative	survival.			
Multivariate	 logistic	 models	 were	 then	 used	 to	 examine	 potential	 associations	
between	pre-operative	variables	with	the	histological	tumour	stage.	
5.9.5 Third	and	fourth	studies	
Contingency	tables	were	drawn	up	for	each	radiologist	comparing	continuous	and	
categorical	 radiology	 outcomes	 with	 pathology	 reports	 and	 surgical	 outcomes.		
Concordance	between	radiologists	was	assessed	using	inter-rate	reliability	measures	such	
as	Cohen’s	kappa	test.		
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Discrepancy:	 In	 the	 case	 of	 discrepancy	 in	 reporting	 between	 two	 consultant	
radiologists,	 a	 third	 consultant’s	 opinion	 was	 sought	 to	 review	 the	 scan	 and	 to	 discuss	
until	final	agreement	is	reached	
The	accuracy	of	the	preoperative	CT	scan	in	determining	the	origin	of	PHM	and	the	
resectability	was	assessed	using	Positive	predictive	value	(PPV),	Negative	predictive	value	
(NPV).	 The	PPV	 is	 identified	 as	 a	 group	of	 patients	with	CT	 scan	 suggesting	 the	 tumour	
organ	of	origin	and	they	have	confirmed	diagnosis	histologically.	The	NPP	is	identified	as	
patients	with	CT	diagnosis	of	certain	tumour	type,	in	whom	this	diagnosis	has	been	ruled	
out	by	the	histological	examination.	
5.9.6 Level	of	statistical	significance	
An	outcome	probability	of	5%	(P<0.05)	was	taken	as	being	statistically	significant.	
5.10 Criteria	for	termination	of	the	study	
None	
5.11 Procedure	for	accounting	for	missing,	unused,	and	spurious	data	
Staging	 images	were	not	 available	 for	 ten	patients.	 	 These	patients	were	 excluded	
from	the	final	analysis.	
5.12 Ethics	
Southwest	 Peninsula	 HPB	 Cancer	 Unit	 records	 many	 aspects	 of	 each	 patient’s	
journey	 from	 referral	 to	 follow-up	 including	 imaging	 and	 relevant	 findings	 from	 MDT	
discussion.	 Patient	 details	 were	 taken	 from	 the	 HPB	 database,	 which	 is	 currently	
maintained	 on	 NHS	 Trust	 password	 secured	 hard-drive.	 The	 director	 of	 studies	 was	
responsible	for	data	anonymisation	using	an	investigator-identifiable	sequential	number.		
These	data	were	then	recorded	on	an	encrypted	hard-drive.		Relevant	anonymised	images	
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were	 stored	 on	 NHS	 Trust	 radiology	 PACS.	 These	 images	 were	 reviewed	 by	 reporting	
radiologists	and	the	outcomes	were	recorded	on	password-secured	encrypted	hard-drive.		
Confirmation	was	obtained	from	the	South	West	Health	Research	Authority	that	under	the	
harmonised	Guidance	Approval	for	Research	Ethics	Committees	(REC),	neither	formal	REC	
review	nor	patient	consent	was	required	for	this	study.	Ethical	approval	was	granted	from	
NRES	Committee	South	Central	-	Hampshire	B	for	the	re-reporting	of	imaging	component	
of	the	study,	with	the	following	details:	
• REC	reference:	14/SC/1391	
• Protocol	number:	14/P/090		
• IRAS	project	ID:	167874		
• Ethical	approval	date:	17.11.2014	
• ClinicalTrials.gov	Identifier:	NCT02296736		
• ClinicalTrials.gov	registration:	18.11.2014	
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6 Results	
In	order	to	address	the	study	objectives,	this	MD	study	was	sub-divided	into	four	research	
questions.	
The	 results	 provided	 in	 this	 chapter	 are	 presented	 in	 a	 journal	 paper	 format	
corresponding	to	each	individual	study.	
Published	papers	could	be	found	at	the	end	of	the	thesis.		
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6.1 Variation	in	survival	after	surgery	for	peri-ampullary	cancer	in	a	
regional	cancer	network	
6.1.1 Abstract	
Background:	 Centralisation	 of	 specialist	 surgical	 services	 requires	 that	 patients	 are	
referred	to	a	regional	centre	for	surgery.	This	process	may	disadvantage	patients	who	live	
far	 from	the	regional	centre	or	are	referred	 from	other	hospitals	by	making	referral	 less	
likely	 and	 by	 delaying	 treatment,	 thereby	 allowing	 tumour	 progression.	 The	 aim	 of	 this	
study	is	to	explore	the	outcome	of	surgery	for	peri-ampullary	cancer	(PC)	with	respect	to	
referring	 hospital	 and	 travel	 distance	 for	 treatment	 within	 a	 network	 served	 by	 five	
hospitals.	
Materials	and	Methods:	Review	of	a	unit	database	was	undertaken	of	patients	undergoing	
surgery	for	PC	between	January	2006	and	May	2014.	
Results:	394	patients	were	studied.	Although	both	the	median	travel	distance	for	patients	
from	the	five	hospitals	(10.8,	86,	78.8,	54.7	and	89.2	kilometres)	(p<0.05),	and	the	annual	
operation	 rate	 for	 PC	 (2.99,	 3.29,	 2.13,	 3.32	 and	 3.07	 per	 100,000)	 (p=0.044)	 were	
significantly	 different,	 no	 correlation	 was	 noted	 between	 patient	 travel	 distance	 and	
population	operation	rate	at	each	hospital.	No	difference	was	noted	between	patients	from	
each	hospital	 in	 terms	of	 resection	completion	rate	or	pathological	 stage	of	 the	 resected	
tumours.	The	median	survival	after	diagnosis	for	patients	referred	from	different	hospitals	
ranged	 from	 1.2	 to	 1.7	 years	 and	 regression	 analysis	 revealed	 that	 increased	 travel	
distance	to	the	regional	centre	was	associated	with	a	small	survival	advantage.	
Conclusion:	Although	variation	 in	 the	provision	and	outcome	of	 surgery	 for	PC	between	
regional	hospitals	is	noted,	this	is	not	adversely	affected	by	geographical	isolation	from	the	
regional	centre.		
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6.1.2 Introduction	
Since	publication	of	the	Improving	Outcomes	Document	in	September	2000	(417)	
surgery	 for	 periampullary	 cancer	 (PC)	 in	 the	 UK	 has	 been	 centralised	 into	 designated	
regional	 Hepato-Pancreatico-Biliary	 (HPB)	 centres,	 each	 serving	 a	 population	 of	
approximately	 two	million.	 This	 process	 requires	 that	most	 hospitals	 do	 not	 undertake	
pancreatic	 resection,	 but	 perform	 the	 initial	 treatment	 and	 assessment	 of	 patients	with	
potential	PC,	before	referral	 to	 the	regional	 tertiary	centre.	This	separation	of	secondary	
from	tertiary	care	in	different	hospitals	has	the	potential	to	disadvantage	patients	referred	
from	hospitals	other	than	the	regional	centre,	as	the	referral	process	is	 likely	to	be	more	
complex	than	when	secondary	and	tertiary	care	are	provided	on	the	same	site.	Inevitably	
provision	 of	 pancreatic	 surgical	 services	 in	 a	 single	HPB	 centre	within	 a	 large	 area	will	
impose	greater	difficulty	and	inconvenience	for	some	patients	in	travelling	to	the	regional	
centre,	 which	 may	 adversely	 affect	 referral	 for	 treatment	 for	 patients	 with	 PC.	
Furthermore	 delays	 in	 treatment	 for	 patients	 residing	 further	 from	 the	 regional	 centre	
may	allow	tumour	progression	and	have	an	adverse	effect	on	outcomes.	
The	potential	influence	of	referral	between	hospitals	and	geographical	isolation	on	
the	outcome	of	surgery	for	PC	has	not	been	assessed	and	the	aim	of	this	study	is	to	assess	
associations	 between	 referring	 hospital	 of	 origin	 and	 traveling	 distance	 to	 the	 regional	
HPB	 surgical	 centre	with	 the	 population	 rate	 of	 surgery	 for	 PC,	 the	 interval	 to	 surgery,	
pathological	 outcome	 and	 long-term	 survival	 after	 diagnosis	 of	 PC	 within	 a	 cancer	
network.	
6.1.3 Materials	and	Methods	
The	 Peninsula	 HPB	 cancer	 unit	 provides	 pancreatic	 surgical	 services	 to	 the	
Peninsula	 Cancer	 Network,	 which	 serves	 the	 largely	 rural	 UK	 counties	 of	 Devon	 and	
Cornwall,	 ranking	 the	 7th	 and	 12th	 least	 densely	 populated	 of	 the	 90	 English	 local	
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government	areas	(418).	 	The	population	of	 the	 two	counties	(1.67	million)	 is	served	by	
four	hospitals	providing	secondary	care	only,	and	one	hospital,	which	provides	secondary	
care	and	also	hosts	the	regional	tertiary	HPB	surgery	centre.	Surgery	and	immediate	post-
operative	 care	 are	 provided	 by	 the	 regional	 centre.	 All	 other	 treatment	 including	 stent	
insertion,	adjuvant	chemotherapy	and	long-term	follow-up	are	provided	by	local	hospitals.	
All	hospitals	 are	 linked	by	a	weekly	audio-visual	MDT	with	 the	 regional	 centre.	Referral	
and	transfer	of	patients	follows	agreed	protocols	and	is	coordinated	by	nurse	specialists.	
Details	 of	 a	 consecutive	 series	 of	 patients	 having	 surgery	 at	 the	 Peninsula	HPB	 unit	
between	 January	 2006	 and	 May	 2014	 were	 studied.	 Demographic,	 operative	 and	
pathology	data	were	retrieved	from	the	unit	database.	Included	patients	were	those	who	
underwent	 surgery	 for	 PC	 where	 final	 histology	 revealed	 a	 diagnosis	 of	 pancreatic,	
ampullary,	distal	bile	duct	or	duodenal	 adenocarcinoma,	or	 those	where	 resection	could	
not	be	completed	and	intra-operative	biopsy	confirmed	the	presence	of	adenocarcinoma.	
Patients	receiving	neo-adjuvant	chemotherapy	were	excluded.	The	size	of	 the	catchment	
area	served	by	each	of	the	hospitals	in	the	Peninsula	was	obtained	from	South	West	Public	
Health	Observatory	(413).	The	travel	distance	by	road	for	each	patient	was	obtained	from	
the	AA	mileage	 calculator	 (with	permission)	using	post-code	data	 (419).	The	 interval	 to	
surgery	was	calculated	from	the	date	of	diagnosis	of	PC,	which	was	taken	as	the	date	of	the	
first	 cross-sectional	 abdominal	 imaging	which	 suggested	 this	 diagnosis.	 The	presence	 of	
biliary	obstruction	was	defined	as	either	clinically	evident	jaundice	at	the	time	of	surgery	
or	the	requirement	for	pre-operative	biliary	drainage.	Pre-operative	diabetes	was	defined	
as	 the	 requirement	 for	 hypoglycaemic	 medication.	 	 The	 workload	 in	 the	 HPB	 surgical	
centre	 is	 shared	 non-selectively	 by	 four	 surgeons	 and	 is	 undertaken	 using	 standardised	
techniques,	 and	 in-patient	 care	 follows	 a	 standard	 protocol.	 The	 American	 Society	 of	
Anaesthesiologists	(ASA)	grade	was	determined	at	the	time	of	surgery	by	the	responsible	
anaesthetist.	Resected	specimens	were	analysed	according	to	Royal	College	of	Pathologists	
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guidelines	 (23)	 and	 the	 TNM	 classification	 systems	 (402)	 was	 used	 to	 describe	
pathological	stage.	Survival	data	were	obtained	from	hospital	and	general	practice	records	
and	 included	 all	 deaths	 occurring	 after	 surgery,	 including	 in-hospital	mortality.	 Survival	
times	were	 calculated	 to	 include	 the	 interval	 prior	 to	 surgery	 and	 therefore	were	 taken	
from	the	date	of	the	first	cross-sectional	image,	which	raised	the	suspicion	of	PC.	Survival	
data	for	the	whole	group	of	patients	referred	from	each	hospital	is	given	as	single	outcome	
of	interest	and	is	reported	as	median	and	range.	Follow-up	was	completed	1st	May	2015.	
Differences	 in	demographics,	 operation	 rates,	 travel	 distance,	 interval	 to	 surgery	
and	pathology	outcome	were	compared	between	hospitals	(pathology	results	for	patients	
with	 duodenal	 cancer	 were	 not	 included	 due	 to	 low	 numbers).	 Difference	 in	 discrete	
variables	was	assessed	by	Pearson	Chi	square	 test	and	continuous	variables	by	Kruskal-
Wallis	 test.	 Correlation	 was	 assessed	 by	 Spearman	 correlation	 coefficient.	 To	 explore	
potential	 associations	 with	 patient	 survival	 a	 Cox	 regression	 analysis	 of	 pre-operative	
factors	 including	 age,	 gender,	 ASA	 grade,	 travel	 distance	 and	 the	 presence	 of	 biliary	
obstruction	 at	 presentation	 was	 undertaken.	 In	 addition,	 patient	 survival	 across	 five	
hospitals	was	compared	using	Kaplan–Meier	 survival	 curves	and	between	hospital	pairs	
by	Cox	regression	analysis.		
6.1.4 Results	
During	 the	 study	 period	 394	 patients	 fulfilling	 the	 study	 criteria	 underwent	
surgery	to	attempt	resection	of	PC	at	the	regional	HPB	surgery	centre	(hospital	A)	(Figure	
6-1).	 	The	median	age	(66.7	years,	range	39.4-	86.4)	and	gender	mix	(56.3%	male)	of	the	
whole	 group	 did	 not	 vary	 between	 patients	 referred	 from	 hospital	 A,	 or	 from	 hospitals	
providing	secondary	care	only	(hospital	B	to	E)	(Table	6.1).	
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Figure	6-1	Patients	undergoing	surgery	for	periampullary	cancer	at	Peninsula	HPB	Centre	
between	January	2006	and	May	2014	
The	number	of	operations	 for	PC	undertaken	as	a	proportion	of	 the	 local	population	
however	varied	significantly	between	referring	hospitals	(Table	6.1).		The	median	distance	
patients	were	required	to	travel	for	care	was	61.4	kilometers	and	was	significantly	less	for	
patients	 referred	 from	within	 the	 catchment	 area	 of	 the	 regional	HPB	 surgery	 centre	 to	
that	 for	 patients	 referred	 from	 all	 other	 hospitals	 in	 the	 Peninsula.	 No	 correlation	 was	
noted	 between	 the	 median	 travel	 distance	 to	 the	 regional	 centre	 of	 patients	 from	 the	
referring	hospitals	and	 the	operation	 rate	at	 that	hospital	 (p	=	 .855).	The	second	 lowest	
population	operation	rate	was	noted	 from	the	population	receiving	secondary	care	 from	
the	hospital	hosting	the	regional	HPB	centre.		
 Study Group 
n= 394 
Resected 
n= 273 
Duodenal 
adenocarcinoma 
n= 8  
(2.9%) 
Unresectable at 
surgery 
n= 121 
Bile Duct 
adenocarcinoma 
n= 46  
(16.8%) 
Ampullary 
adenocarcinoma 
n= 70  
(25.6%) 
Pancreatic 
adenocarcinoma 
n= 149  
(54.6%) 
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Referring	hospital	 (A)	 (B)	 (C)	 (D)	 (E)	 P	
n=394	(%)	 111(28.2)	 97(24.6)	 70(17.8)	 74	(18.8)	 42	
(10.6)	
	
Population	served	 464,437	 368,313	 410,213	 278,555	 171,227	
Annual	operation	
rate	for	PC	per	
100000	
2.99	 3.29	 2.13	 3.32	 3.07	 0.04	
Median	Travel	
Distance	
(kilometres)	
(range)	
10.8	(2.4-
112)	
85.9	
(45.2-
155.8)	
78.8	
(10.1-
130.3)	
54.7	(2.4-
96.2)	
98.3(63
-138.6)	
.000	
Median	age	(range)	 65.7	(41.2-
82.0)	
68.4	
(41.7-
84.0)	
65.5	
(39.4-
78.6)	
65.6	
(45.9-
86.4)	
70.2	
(50.7-
84.4)	
.105	
Gender	(%	Male)	 53.2	 58.8	 58.6	 58.1	 52.4	 .880	
ASA	
Grade	
(%)	
1	 8	(7.2)	 8	(8.2)	 8	(11.4)	 7	(9.5)	 0	 .416	
2	 56(50.5)	 53(54.6)	 39(55.7)	 41(55.4)	 22(52.4
)	
3	 28	(25.2)	 26	(26.8)	 18	(25.7)	 18	(24.3)	 14(33.3
)	
4	 2	(1.8)	 1	(1)	 0	 0	 0	
Missing	 17	(15.3)	 9	(9.3)	 5	(7.1)	 8	(10.8)	 6	(14.3)	
Diabetes	 Yes	(%)	 13	(11.7)	 10	(10.3)	 7	(10.0)	 6	(8.1)	 5	(11.9)	 .987	
Missing		 12	(10.8)	 17	(17.5)	 14	(20.0)	 15	(20.3)	 4	(9.5)	
Jaundice	at	
Presentation	(%)	
91	(82.0)	 82	(84.5)	 56	(80)	 65	(87.8)	 36	
(85.7)	
.641	
Median	interval	to	
surgery	(days)	
(range)	
47	
(5-551)	
52	
(1-459)	
56.5	
(16-379)	
47	
(16-246)	
51.5	
(6-477)	
.108	
Resection	
completed	(%)	
73	(65.7)	 68		(70)	 51	(72.8)	 51	(68.9)	 30	
(71.4)	
.880	
30-day	mortality	
(%)	
4	(3.6)	 1	(1)	 2	(2.8)	 1	(1.3)	 2	(4.7)	 .610	
	
Table	6.1	Details	of	394	patients	undergoing	surgery	for	peri-ampullary	cancer	between	
January	2006	and	May	2014,	displayed	by	referring	hospital	of	origin.	Hospital	A	hosts	the	
regional	HPB	cancer	centre.	
The	 distribution	 of	 ASA	 grades,	 the	 proportion	 of	 patients	 with	 diabetes,	 biliary	
obstruction	 at	 the	 time	 of	 surgery	 and	 pre-operative	 biliary	 intervention	 did	 not	 differ	
between	hospitals	 (Table	 6.1).	 The	median	 interval	 from	 first	 investigation	 suggesting	 a	
diagnosis	of	PC	to	surgery	was	49	days	(interquartile	range	34-69	days)	and	was	similar	
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between	 referring	 hospitals.	 Correlation	 analysis	 revealed	 no	 association	 between	 the	
travel	distance	to	the	regional	HPB	surgery	centre	and	the	interval	to	surgery	(p	=	0.15).	
In-patient	 30-day	 mortality	 occurred	 in	 10	 (2.5%)	 patients	 and	 did	 not	 differ	 between	
hospitals.		
Tumour	resection	was	completed	in	273	patients	(69.3%)	and	the	completion	rate	did	
not	differ	between	hospitals	(Table	6.2).	In	121	patients	the	tumour	was	inoperable	at	the	
time	of	surgery	either	due	to	the	presence	of	vascular	invasion	(70)	or	distant	metastases	
(47).	 In	 four	 patients	 the	 reason	 for	 irresectability	 was	 not	 recorded.	 	 Histological	
diagnoses	of	the	resected	specimens	are	shown	in	(Figure	6-1).		
Analysis	 of	 pathological	 outcomes	 revealed	no	difference	 between	patients	 from	 the	
referral	zone	of	the	regional	centre	and	those	from	other	hospitals	in	the	region,	in	terms	
of	resection	completion	rate,	tumour	size,	nodal	status	and	resection	margin	status	(Table	
6.2).	Similarly	the	distribution	of	the	main	diagnoses	of	PC	did	not	differ	between	patients	
from	the	regional	centre	and	those	from	other	hospitals.		
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N=	265	
A	
111	
B	
97	
C	
70	
D	
74	
E	
42	
P	
Pancreatic	cancer	
(n	=149)	
40	 38	 22	 28	 21	 	
T	size	(mm)	(range)	
30	
(15-48)	
31.5	
(16-60)	
30.5	
(15-70)	
32.5	
(12-50)	
30	
(18-65)	
.620	
N1disease	(%)	
35	
(87.5)	
33	
(86.8)	
19	
(86.4)	
23			
(82.1)	
17	
(81)	
.940	
R1	resection	(%)	
34	
(85)	
24	
(63.1)	
18	
(81.8)	
24			
(85.7)	
19	
(90.5)	
.052	
Ampullary	cancer	
(n=	70)	
21	 18	 12	 13	 6	 	
T	size	(mm)	(range)	
25	
(12-80)	
22.5	
(5-65)	
23.5	
(15-60)	
22	
(11-65)	
28	
(8-50)	
.933	
N1disease	(%)	
14	
(66.6)	
10	
(55.5)	
6	
(50)	
5	
(38.5)	
4	
(66.6)	
.551	
R1	resection	(%)	
7	
(33.3)	
1	
(5.5)	
2	
(16.6)	
2	
(15.4)	
2	
(33.3)	
.230	
Bile	duct	cancer	
(n=46)	
10	 10	 13	 10	 3	 	
T	size	(mm)	(range)	
25.5	
(10-70)	
27	
(10-45)	
25	
(10-40)	
20			
(12-50)	
15			
(12-20)	
.216	
N1disease	(%)	 7	(70)	 7	(70)	 4	(30.7)	 7	(70)	 1	(33.3)	 .172	
R1	resection	(%)	 5	(50)	 6	(60)	 5	(38.5)	 5	(50)	 2	(66.6)	 .839	
	
Table	6.2	Histopathological	stage	for	265	patients	undergoing	resection	of	pancreatic,	
ampullary	and	distal	bile	duct	cancer	at	the	regional	HPB	centre	(A)	displayed	by	referring	
hospital	of	origin	
After	 a	median	 follow-up	of	 4.5	 years	 (1.3-9.5	 years)	 the	median	 survival	 (range)	 of	
the	study	group	was	1.45	(0.11	–	9.4)	years	and	was	similar	in	males	(1.44,	0.13-9.3	years)	
and	 females	 (1.45,	 0.11-8.7	 years).	 Two	 patients	 were	 lost	 to	 follow-up.	 Survival	 was	
greater	 in	 patients	 where	 resection	was	 completed	 (1.85,	 0.14-9.4	 years)	 than	 in	 those	
where	 the	 tumour	 could	 not	 be	 removed	 (0.9,	 0.11-2.8	 years).	 The	 median	 survival	 of	
patients	travelling	more	than	the	median	distance	for	treatment	was	1.5	(0.14-8.7)	years	
compared	to	1.4	(0.11-9.4)	years	for	those	travelling	less	than	the	median	travel	distance	
(p=0.234).	Cox	regression	analysis	of	the	association	of	pre-operative	variables	including	
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individual	 patient	 travel	 distance	 however	 revealed	 a	 significant	 survival	 advantage	
associated	with	increased	travel	distance	to	the	regional	HPB	centre	(Table	6.3).	
	 Hazard	Ratio	 Lower	.95	 Upper	.95	 P-value	
Gender	 0.956	 0.744	 1.229	 0.728	
Age	 1.009	 0.995	 1.022	 0.217	
Distance	(km)	 0.996	 0.993	 0.999	 0.029	
Jaundice	 0.967	 0.686	 1.364	 0.852	
ASA	 1	vs.	2	 0.945	 0.678	 1.317	 0.739	
2	vs.	3&4	 1.117	 0.888	 1.407	 0.344	
	
Table	6.3	Cox	regression	analysis	of	potential	association	of	pre-operative	factors	including	
travel	distance	to	regional	HPB	centre	with	survival	after	diagnosis	for	394	patients	
undergoing	surgery	for	periampullary	cancer	
	
Further	survival	analysis	revealed	that	the	referring	hospital	of	origin	was	associated	
with	 outcome	 (Figure	 6-2),	 with	 median	 survival	 ranging	 from	 1.2	 (0.14-6.4)	 years	
(patients	from	hospital	D)	to	1.5	(0.3-8.8)	years	(patients	from	hospital	B).		
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Number	at	risk	
Hospital/years	 0	 2	 4	 6	 8	
A	 111	 37	 9	 7	 4	
B	 97	 38	 18	 7	 2	
C	 70	 30	 13	 7	 2	
D	 74	 17	 4	 1	 0	
E	 42	 18	 6	 1	 0	
	
Figure	6-2	Survival	from	diagnosis	of	394	patients	undergoing	surgery	for	periampullary	
cancer	at	Peninsula	HPB	surgery	centre	between	January	2006	and	May	2014,	according	to	
hospital	of	referral	(P	=	0.032)	
	
Pair	 by	 pair	 regression	 analysis	 comparing	 patients	 from	 the	 catchment	 area	 of	 the	
regional	HPB	 centre	 revealed	 no	 difference	 in	 survival	 from	diagnosis	 for	 patients	 from	
three	hospitals	C,	D	and	E,	but	confirmed	the	significantly	decreased	hazard	ratio	of	death	
of	patients	referred	from	hospital	B	(Table	6.4).		
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A	vs.	 Hazard	Ratio	 lower	.95	 upper	.95	 P-value	
B	 0.6934	 0.5011	 0.9594	 0.0271*	
C	 0.7042	 0.4952	 1.0013	 0.0508	
D	 1.1121	 0.7983	 1.5493	 0.5299	
E	 0.8228	 0.5435	 1.2456	 0.3565	
	
Table		6.4	Paired	regression	analysis	of	association	of	hospital	of	referral	(B	to	E)	with	
survival	compared	to	referral	from	Hospital	A	among	394	patients	undergoing	surgery	for	
peri-ampullary	cancer	
6.1.5 Discussion	
The	main	findings	of	this	study	are:		
1)	 Within	 the	 Peninsula	 Cancer	 Network	 the	 population	 operation	 rate	 for	 PC	
varies	 significantly	between	hospital	 catchment	areas	but	 this	variation	 is	not	 related	 to	
travel	distance	to	the	regional	HPB	surgical	centre	and		
2)	 Individual	 patient	 travel	 distance	 to	 the	 regional	 centre	 does	 not	 adversely	
affect	the	time	to	surgery,	pathological	outcome	or	survival	in	patients	with	PC.		
3)	 The	 provision	 of	 secondary	 and	 tertiary	 care	 in	 different	 hospitals	 does	 not	
adversely	affect	patient	outcomes.	
Centralisation	of	pancreatic	surgical	services	has	led	to	improved	outcomes	including	
higher	 resection	 rates	 (34,	 35),	 lower	 operative	 mortality	 (36,	 37)	 and	 improved	 long-
term	 survival	 (38).	 Similar	 improvements	with	 centralisation	 have	 been	 noted	 for	 liver	
(420),	 oesophageal	 (421),	 complex	urological	 (422)	 and	vascular	 surgery	 (423).	Despite	
these	findings	the	population	benefits	of	regionalisation	are	more	difficult	to	demonstrate.	
Although	 studies	 using	 hospital	 data	 have	 demonstrated	 improved	 outcomes	 associated	
with	centralisation	of	 surgical	 services	 for	patients	who	receive	 treatment	 (35,	45,	424),	
these	studies	may	be	biased	by	selection	of	patients	at	the	regional	centres	and	do	not	take	
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into	account	patients	who	are	not	referred	for	treatment.	Studies	demonstrating	improved	
population	outcomes	as	a	result	of	regionalisation	of	complex	surgery	are	more	difficult	to	
undertake.	 The	 potential	 disadvantages	 of	 centralisation	 of	 services	 include	 a	 more	
complex	 referral	 pathway	 when	 secondary	 and	 tertiary	 care	 are	 provided	 in	 different	
hospitals,	 and	 an	 increased	 burden	 of	 travel	 for	 patients	 living	 further	 from	 the	 centre,	
which	 may	 discourage	 referral	 and	 attendance	 for	 treatment.	 These	 consequences	 of	
centralisation	 have	 been	 noted	 (425,	 426)	 and	 the	 potential	 risk	 is	 greatest	 in	 areas	 of	
dispersed	 population.	 This	 has	 led	 to	 controversy	 over	 the	 implementation	 of	
centralisation	of	surgical	services	in	rural	communities	(427),	where	the	risk	of	limitation	
of	access	due	to	distance	may	outweigh	the	benefit	of	 improved	technical	outcomes.	The	
observation	that	operation	rates	are	not	adversely	affected	by	distance	to	the	HPB	surgical	
centre,	 or	 by	 referral	 from	 a	 different	 hospital,	 and	 that	 travel	 distance	 itself	 does	 not	
influence	the	outcome	of	surgery	for	PC	are	important,	as	they	show	that	regionalisation	of	
surgical	 services	 does	 not	 necessarily	 lead	 to	 limitations	 in	 access	 or	 increased	 patient	
selection	at	the	HPB	surgical	centre.	
The	 small	 variation	 in	 operation	 rate	 noted	 between	 hospitals	 may	 reflect	
differences	in	levels	of	comorbidity	and	suitability	for	surgery,	but	may	be	due	to	different	
referral	 practices	 within	 each	 hospital.	 	 The	 observation	 that	 the	 referring	 hospital	 of	
origin	 is	 also	 associated	 with	 long-term	 survival	 after	 surgery	 for	 PC	 is	 therefore	 an	
interesting	 new	 finding.	Many	 factors	 contribute	 to	 variation	 in	 local	 survival	 rates	 and	
levels	of	comorbidity	are	likely	to	play	a	major	role.	It	is	interesting	to	note	however	that	
long-term	survival	is	lowest	in	patients	from	the	hospital	with	the	highest	population	rate	
of	 surgery	 for	 PC.	 This	 may	 result	 from	 referral	 of	 more	 marginal	 cases,	 which	 is	 not	
revealed	by	the	measures	of	comorbidity	and	tumour	burden	used	in	this	study.		Variation	
in	 population	 operation	 rate	 for	 PC	 may	 also	 explain	 some	 of	 the	 variation	 noted	 in	
outcome	between	high-volume	hospitals	undertaking	pancreatic	surgery	(428).		
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The	 strength	 of	 this	 analysis	 lies	 in	 the	 accurate	 collection	 of	 individual	 travel	
distance	to	the	regional	HPB	surgery	centre	in	a	 large	consecutive	series	of	patients,	and	
its	 correlation	 with	 prospectively	 audited	 outcomes.	 In	 this	 study	 a	 single	 measure	 of	
survival	 of	 all	 patients	 has	 been	 used,	 without	 division	 by	 diagnosis,	 to	 allow	 simple	
comparison	between	hospitals.	This	figure	includes	deaths	due	to	surgical	complications,	
which	accounts	for	the	short	survival	in	some	patients.	A	weakness	of	the	study	lies	in	the	
characterisation	 of	 comorbidity.	 A	 more	 discriminating	 scoring	 system	 is	 required	 to	
investigate	 the	 potential	 association	 of	 comorbidity	 with	 variations	 in	 population	
operation	rate	 for	PC.	The	relatively	 long	median	 interval	 to	surgery	noted	 in	 this	study,	
even	 for	 patients	 with	 biliary	 obstruction	 (47	 days),	 is	 accounted	 for	 by	 the	 increasing	
complexity	in	the	patient	pre-operative	pathway.	This	pathway	however	imposes	a	similar	
interval	 to	 surgery	 on	 patients	 regardless	 of	 geographical	 isolation	 from	 the	 regional	
centre.	In	a	small	number	of	patients	a	long	interval	to	surgery	was	due	to	investigations	
being	undertaken	in	patients	with	self-resolving	 jaundice,	which	was	not	pursued	due	to	
patient	improvement.	The	studied	group	is	limited	to	those	who	have	been	referred	to	the	
centre	 for	 being	 potential	 resectable,	 however	 it	 does	 not	 capture	 those	 who	 have	 not	
been	referred	and	deemed	unfit	or	unresectable	at	the	referral	hospital.	The	resection	rate	
is	 lower	 in	 this	 series	 partly	 due	 to	 a	 low	 resection	 rate	 at	 the	 beginning	 of	 the	 decade	
which	is	now	been	resolved	with	improved	radiological	techniques	and	improved	surgical	
techniques,	the	current	non	resection	rate	is	less	than	10%.	
6.1.6 Conclusion	
This	 study	 confirms	 that	 centralisation	 of	 HPB	 surgical	 services	 can	 be	
implemented	 without	 imposing	 disadvantage	 in	 surgical	 outcomes	 on	 patients	 due	 to	
travel	distance	to	the	HPB	surgical	centre	or	referral	between	hospitals	for	treatment.	
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6.2 Assessment	of	the	effect	of	interval	from	presentation	to	surgery	on	
outcome	in	patients	with	peri-ampullary	malignancy	
6.2.1 Abstract	
Background:	 Delay	 between	 diagnosis	 of	 peri-ampullary	 cancer	 (PC)	 and	 surgery	 may	
allow	 tumour	 progression	 and	 affect	 outcome.	 The	 aim	 of	 this	 study	 was	 to	 explore	
associations	of	interval	to	surgery	(IS)	with	pathological	outcomes	and	survival	in	patients	
with	PC.	
Method:	 A	 database	 review	 of	 all	 patients	 undergoing	 surgery	 between	 2006	 and	 2014	
was	 undertaken.	 IS	 was	 measured	 from	 diagnosis	 by	 imaging.	 Potential	 association	
between	IS	and	survival	was	measured	using	Cox	regression	analysis,	and	between	IS	and	
pathological	outcome	with	multivariate	logistic	analysis.	
Results:	388	patients	underwent	 surgery.	The	median	 IS	was	49	days	 (1-551	days),	 and	
was	not	associated	with	any	of	the	evaluated	outcomes	in	patients	with	pancreatic	(149)	
or	 distal	 bile	 duct	 (46)	 cancer.	 For	 patients	 with	 ampullary	 cancer	 (71)	 longer	 IS	 was	
associated	 with	 improved	 survival,	 with	 median	 survival	 of	 27.5	 months	 for	 patients	
waiting	 ≤	 median	 IS	 (35)	 and	 38.3	 months	 for	 patients	 waiting	 >	 median	 IS	 (36)	 for	
surgery	 (p=0.041).	 A	 higher	 rate	 of	 margin	 positivity	 (31.4%)	 was	 also	 noted	 among	
patients	who	waited	 less	 than	the	median	IS	compared	to	 those	waiting	 longer	 than	this	
interval	(11.4%)	(p=0.032).	
Conclusion:	 For	 patients	 with	 ampullary	 cancer	 there	 is	 a	 paradoxical	 improvement	 in	
outcome	 among	 those	 with	 a	 longer	 IS,	 which	 may	 be	 explained	 by	 progression	 to	
inoperability	of	more	aggressive	lesions.	
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6.2.2 Introduction	
Peri-ampullary	 cancer	 (PC)	 most	 commonly	 originates	 within	 the	 pancreas,	 the	
distal	 common	 bile	 duct,	 or	 the	 duodenal	 ampulla.	 The	 organ	 of	 origin	 of	 PC	 is	 usually	
determined	 by	 pathological	 examination	 after	 resection	 and	 has	 important	 implications	
for	 prognosis.	 Five-year	 survival	 after	 surgical	 resection	 varies	 from	 6.5%-20%	 for	
pancreatic	cancer	(3-9),	19.2%-30%	for	bile	duct	cancer	(3,	5,	7,	8,	17,	18)	and	33%-45%	
for	ampullary	cancer	(3,	5,	7,	8).	For	many	patients	their	disease	is	inoperable	at	the	time	
of	presentation	due	to	local	invasion	or	the	presence	of	distant	metastases.	For	those	with	
operable	 tumours	 there	 will	 usually	 be	 an	 interval	 between	 radiological	 diagnosis	 and	
surgery,	 to	 allow	 referral,	 assessment	 and	 operative	 planning.	 In	 England,	 the	 National	
Cancer	Plan	stipulates	a	maximum	interval	of	62	days	from	primary	referral	to	treatment	
for	most	 solid	 cancers	 (429),	 although	 this	 figure	 is	 not	 based	 on	 evidence	 of	 safety	 for	
each	 tumour	 type.	 Tumour	 progression	 may	 take	 place	 during	 this	 interval,	 rendering	
tumours	inoperable	and	long-term	survival	may	potentially	be	affected.	
Within	 any	 patient	 cohort	 there	 is	 likely	 to	 be	 a	 range	 of	 intervals	 between	
diagnosis	 and	 surgery,	 with	 some	 patients	 undergoing	 surgery	 very	 quickly,	 and	 some	
waiting	many	months.	 As	 PC	 is	 an	 aggressive	malignancy,	 this	 period	may	 constitute	 a	
significant	part	of	the	natural	history	of	the	disease.	Analysis	of	the	potential	association	of	
interval	 to	 surgery	 with	 pathological	 and	 surgical	 outcomes	 may	 reveal	 aspects	 of	 the	
behaviour	of	these	tumours,	and	determine	if	the	62	day	target	to	surgery	disadvantages	
patients	by	allowing	tumour	progression.	
This	 study	aimed	 to	 investigate	 the	 interval	 to	 surgery	 in	a	 consecutive	 series	of	
patients	undergoing	surgery	with	the	intention	to	resect	PC	and	to	explore	the	association	
of	IS	to	resectability,	tumour	stage	and	overall	survival.	
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6.2.3 Material	and	methods	
Review	of	a	prospectively	maintained	database	of	consecutive	patients	undergoing	
surgical	 exploration	 for	 suspected	 PC	 between	 January	 2006	 and	 May	 2014	 was	
undertaken.	Referrals	came	from	five	hospitals	 in	a	cancer	network	with	a	population	of	
1.7	million.	The	study	cohort	included	patients	with	a	histological	diagnosis	of	pancreatic,	
bile	 duct	 or	 ampullary	 cancer,	 or	 those	where	 the	 tumour	was	 unresectable	 and	 biopsy	
confirmed	the	presence	of	adenocarcinoma.	Patients	receiving	neoadjuvant	chemotherapy	
were	excluded.	No	patients	were	excluded	from	surgery	due	to	disease	progression	in	the	
interval	between	referral	and	surgery.	Demographic	and	clinical	data	were	retrieved.	Pre-
operative	 biliary	 obstruction	 was	 defined	 as	 any	 abnormality	 in	 liver	 function	 tests	
sufficient	to	prompt	investigation	by	cross	sectional	imaging.	As	the	time	of	receipt	of	the	
initial	referral	is	variable	and	subject	to	administrative	delays,	the	interval	to	surgery	(IS)	
was	measured	 from	 the	 date	 of	 the	 first	 imaging	modality	 undertaken	which	 raised	 the	
possible	diagnosis	of	pancreatic	head	malignancy	to	the	time	of	the	surgical	intervention,	
by	 review	of	 individual	 radiology	 records.	Surgical	 resection	was	performed	by	a	 classic	
Whipple	 resection	 with	 reconstruction	 by	 pancreatico-gastrostomy.	 Pathological	
reporting	was	undertaken	according	to	Royal	College	of	Pathologists	guidelines(23)	with	
axial	slicing	of	 the	resection	specimen.	Tumours	were	classified	according	to	histological	
origin	(pancreatic,	bile	duct	or	ampullary)	and	nodal	status	and	margin	involvement	status	
were	retrieved	from	histology	reports.		
Continuous	 variables	 were	 compared	 with	 Kruskal-Wallis	 test	 and	 categorical	
variables	 by	 Chi	 square	 test.	 The	 mean	 and	 variance	 of	 tumour	 size	 across	 different	
tumour	types	were	compared	using	Bayesian	double	generalised	linear	models.			
Dates	of	death	were	determined	by	access	to	General	Practice	records	and	survival	
times	 calculated	 from	 the	 time	 of	 diagnosis.	 Kaplan-Meier	 survival	 analysis	 and	 Cox	
Proportional	Hazard	models	were	used	to	assess	the	effect	of	interval	to	surgery	on	post-
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operative	 survival.	 	 Multivariate	 logistic	 regression	 models	 were	 then	 used	 to	 explore	
potential	associations	between	pre-operative	variables	including	IS	as	a	binary	variable	(<	
or	≥	median)	with	histological	tumour	stage.		
6.2.4 Results	
388	 patients	 (223	 (57%)	 males)	 with	 a	 median	 (range)	 age	 67	 (41-86)	 years	
fulfilling	 the	 study	 criteria	 underwent	 surgical	 exploration	 during	 the	 study	 period	 and	
resection	was	completed	in	266	patients	(69%)	(Table	6.5).		
n=266	(%)	
Cancer	Origin	
p	Pancreas	
n=149	
(56%)	
Bile	duct	
n=46	
(17%)	
Ampulla	
n=71			
(27%)	
Median	age	
(range)	
67.9	
(41.3-	82.1)	
65.7	
(43.7-84.1)	
66.2	
(411.2-86.4)	
.312	
Gender	(%	male)	 55	 69.6	 53.5	 .171	
ASA	
(%)	
1	 6	(4)	 4	(8.7)	 9	(12.7)	
.056	
2	 84	(56.4)	 22	(47.8)	 42	(59.2)	
3	 44	(29.5)	 15	(32.6)	 14	(19.7)	
4	 1	(0.7)	 0	 0	
Missing	 14	(9.4)	 5	(10.8)	 6	(8.4)	
Median	IS	
(range)	(days)	 48	(1-551)	 50	(5-294)	 51	(14-477)	 .881	
Median	tumour	
size	(range)	
(mm)	
30	(12-70)	 22	(10-70)	 25	(5-80)	 .002	
Involved	lymph	
nodes	(%)	
127	(85.2)	 26	(56.5)	 40	(56.3)	 .0001	
Involved	
resection	margin	
(%)	
119	(79.9)	 23	(50)	 15	(21.1)	 .0001	
30	day	post-
operative	
mortality	
3	(2)	 0	 3	(4.2)	 0.275	
	
Table	6.5	Interval	to	surgery	and	pathological	outcome	among	266	patients	undergoing	
resection	of	peri-ampullary	cancer.	
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In	122	(31%)	patients	the	tumour	was	found	to	be	inoperable	due	to	local	invasion	
of	 vascular	 structures	 (n=70	 (57%))	 or	 the	 development	 of	 distant	 metastases	 (n=47	
(63%)).	 Operative	 details	 could	 not	 be	 retrieved	 in	 three	 (1%)	 patients,	 tumour	 mass	
could	 not	 be	 identified	 in	 one	 patient	 and	 one	 patient	 did	 not	 tolerate	 surgery.	 Lateral	
resections	of	a	small	venous	patch	were	undertaken	in	32	(12%)	patients.	The	median	IS	
for	388	patients	was	49	(1-551)	days,	and	was	similar	in	groups	undergoing	resection	(49	
days,	range	1-551)	or	surgical	exploration	only	(50	days,	range	11-512)	(P=0.940).	The	IS	
in	331	patients	(85.3%)	with	biliary	obstruction	at	the	time	of	initial	presentation	was	47	
days	 (1-512)	 compared	 to	 69	 (14-551)	 in	 those	 without	 this	 complication	 (p=0.001).	
Pancreatic	 tumours	were	noted	 to	be	 larger	 than	both	ampullary	and	bile	duct	 tumours	
(Table	6.5).		
In	regression	analysis	 the	variance	 in	size	of	ampullary	tumours	was	noted	to	be	
greater	 than	 both	 pancreatic	 tumours	 (coefficient	 =	 -1.075;	 credible	 interval	 -1.441	 to	 -
0.704)	and	bile	duct	tumours	(coefficient	=	-0.63;	credible	interval	-1.096	to	-0.165).			
After	 minimum	 follow-up	 of	 12	 months	 the	 median	 survival	 (range)	 from	
diagnosis	of	the	whole	cohort	was	17.2	months	(1.4-114.6)	and	was	significantly	longer	in	
patients	undergoing	surgical	resection	(23.7	months,	range	1.5-114.6)	compared	to	those	
having	 surgical	 exploration	 only	 (11.2	 months,	 range	 1.4-75.7)	 The	 median	 survival	
(range)	of	patients	undergoing	resection	of	pancreatic,	bile	duct	and	ampullary	cancer	was	
17.3	 (1.5-114.6),	 28.1	 (5.8-104)	 and	 33.3	 (2.1-107.1)	 months	 respectively.	 No	 patients	
were	 lost	 to	 follow-up.	 Pre-operative	 IS	 was	 not	 associated	 with	 survival	 for	 patients	
undergoing	 resection	 of	 pancreatic	 or	 bile	 duct	 cancer,	 but	 a	 positive	 association	 was	
noted	for	patients	with	ampullary	cancer	(Figure	6-3).		
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Number	at	risk	(Pancreatic	cancer)	
IS/Years	 0	 2	 4	 6	 8	
0-49	days	 77	 25	 9	 4	 2	
>	49	days	 72	 30	 6	 1	 1	
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Number	at	risk	(Bile	duct	cancer)	
IS/Years	 0	 2	 4	 6	 8	
0-49	days	 22	 13	 4	 4	 0	
>	49	days	 24	 18	 6	 3	 1	
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Number	at	risk	(Ampullary	cancer)	
IS/Years	 0	 2	 4	 6	 8	
0-49	days	 35	 18	 9	 3	 2	
>	49	days	 36	 25	 13	 4	 1	
	
Figure	6-3	Survival	curves	of	patients	undergoing	pancreatic	head	resection	for	a)	
pancreatic	(149),	b)	bile	duct	(46)	and	c)	ampullary	cancer	(71),	divided	into	subsets	
determined	by	the	median	interval	to	surgery	from	initial	investigation.	P	=	.419,	.321	
and	.043*	respectively.	
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Cox	 regression	 analysis	 of	 survival	 data	 confirmed	 the	 reduced	 hazard	 of	 death	
associated	with	a	longer	IS	in	patients	with	ampullary	cancer	only	(Table	6.6).		
Tumour	type	 Hazard	Ratio	 95%	CI	 P	
Pancreas	(149)	 0.679	 0.314-1.467	 0.324	
Bile	duct	(46)	 0.855	 0.584-1.251	 0.419	
Ampulla	(71)	 0.506	 0.259-0.991	 0.047*	
	
Table	6.6	Cox	regression	analysis	of	association	of	interval	to	surgery	with	survival	of	
patient	cohorts,	determined	by	tumour	origin.	
Multivariate	analysis	of	potential	 associations	between	pre-operative	 factors	and	
histological	outcomes	and	survival	confirms	the	reduced	risk	of	positive	resection	margin	
in	patients	with	a	longer	interval	to	surgery	(Table	6.7).		
	
Tumour	Size	 Nodal	status	
Resection	margin	
status	
Coeffi
cient	
95%	CI	 p	
Odds	
Ratio	
95%	
CI	
p	
Odds	
Ratio	
95%	
CI	
p	
IS	
(</>	
49)	
-0.14	
-0.403	
0.123	
0.232	 0.604	
0.221	
1.654	
0.326	 0.226	
0.058	
0.877	
.032	
Gender	 -0.51	
-0.743	
-0.277	 0.000	 0.512	
0.183	
1.432	 0.202	 0.795	
0.224	
2.818	 .722	
Age	 -0.017	
-0.029	
-0.005	 0.005	 0.996	
0.947	
1.048	 0.878	 0.996	
0.934	
1.063	 .912	
Bilary	
obstruc
tion	at	
present
ation	
-0.161	
-0.484	
0.162	
0.312	 2.330	
0.589	
9.225	
0.228	 0.413	
0.081	
2.118	
.289	
	
Table	6.7		Multivariate	analysis	of	potential	associations	with	tumour	size,	nodal	status	and	
resection	margin	status	among	71	patients	undergoing	resection	of	ampullary	cancer	
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The	 proportion	 of	 ampullary	 cancer	 specimens	 removed	 within	 less	 than	 the	
median	 IS	 (49	 days)	with	 involved	margins	was	 31%,	 compared	 to	 11.4%	among	 those	
removed	after	this	interval	from	diagnosis	(p=0.032).		An	association	between	tumour	size	
with	age	and	female	gender	is	also	noted	(Table	6.7).	
6.2.5 Discussion	
Patients	with	PC	may	suffer	significant	delays	between	presentation	and	surgery.	
This	may	be	contributed	to	by	the	vague	nature	of	symptoms	at	the	time	of	presentation	
(430,	431),	the	need	for	biliary	drainage	(268),	delays	incurred	during	referral	to	regional	
centres	 and	 capacity	 issues	 restricting	 access	 to	 operating	 time.	 	 Because	 of	 perceived	
delays	in	the	treatment	of	cancer	cases	NHS	guidelines	introduced	a	target	of	62	days	from	
referral	to	treatment	for	most	solid	tumours	in	2000	(429).	Concerns	may	be	raised	that	
this	 delay	 will	 reduce	 the	 operability	 of	 the	 pancreatic	 head	 lesion,	 allow	 tumour	
progression	 and	 impair	 long-term	 survival.	 The	 main	 finding	 of	 this	 study	 is	 that	 no	
association	is	noted	between	delay	to	surgery	and	any	outcome	in	patients	with	pancreatic	
or	distal	bile	duct	cancer,	but	that	a	longer	interval	to	surgery	is	paradoxically	associated	
with	 improved	 outcome	 in	 patients	 with	 ampullary	 cancer.	 A	 proportional	 increase	 in	
survival	is	noted	with	each	extra	months	delay	prior	to	surgery	associated	with	a	hazard	
ratio	of	death	of	0.55	after	surgical	resection.	In	corroboration	of	this	finding	the	chance	of	
an	involved	resection	margin	is	also	reduced	for	patients	with	ampullary	cancer	who	wait	
longer	for	surgery.	
In	this	series	a	high	percentage	of	resected	patients	were	shown	to	have	ampullary	
cancer	 (26%).	 This	 is	 consistent	 with	 the	 adoption	 of	 a	 standardised	 pathological	
reporting	protocol,	which	has	led	to	higher	rates	of	diagnoses	other	than	pancreatic	cancer	
in	 peri-ampullary	 malignancy	 (24,	 432).	 PC	 usually	 presents	 with	 biliary	 obstruction	
caused	 by	 mass	 effect	 and	 operability	 is	 determined	 by	 the	 sequence	 of	 invasion,	 as	
vascular	invasion	is	a	major	cause	of	irresectability	(352,	433,	434).	Lesions	of	the	ampulla	
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lie	 furthest	 from	 the	 vascular	 structures	 and	 may	 be	 less	 likely	 to	 be	 inoperable	 than	
lesions	 of	 the	 pancreatic	 parenchyma,	 which	 encases	 the	 junction	 between	 superior	
mesenteric	 and	 portal	 vein.	 Surgery	 is	 offered	 to	 patients	 who	 do	 not	 have	 invasion	 of	
vascular	structures	or	distant	metastases	detected	on	pre-operative	imaging,	though	these	
findings	are	often	encountered	at	the	time	of	surgery.	This	may	be	caused	by	understaging	
by	CT	scan	(435)	or	by	tumour	progression	in	the	interval	to	surgery,	which	is	more	likely	
in	aggressive	tumours.	These	results	suggest	that	for	pancreatic	and	bile	duct	tumours	the	
timing	of	 surgery	 in	 relation	 to	pre-operative	 imaging	within	 the	 range	measured	 in	 the	
study	has	no	effect	on	resectability,	tumour	stage	or	survival	after	diagnosis.	This	implies	
that	 the	 operative	 findings	 and	 surgical	 outcome	 are	 determined	 before	 imaging	 takes	
place	 and	 these	 tumours	 change	 little	 in	 the	 interval	 to	 surgery.	 For	 ampullary	 tumours	
however	 it	 appears	 that	 a	 longer	 wait	 for	 surgery	 results	 in	 selection	 of	 a	 subset	 of	
patients	 whose	 tumours	 remain	 resectable,	 with	 better	 prognostic	 characteristics,	 as	
shown	 by	 the	 reduced	 risk	 of	 an	 involved	 resection	 margin	 and	 improved	 long-term	
survival.	 This	 may	 be	 explained	 by	 the	 progression	 of	 a	 more	 aggressive	 subset	 of	
ampullary	 tumours	 in	 the	 interval	 to	 surgery	 leading	 to	 inoperability.	 This	 more	
aggressive	subset	probably	includes	older	patients;	in	whom	resected	ampullary	tumours	
are	shown	to	be	larger.	In	support	of	this	concept	we	have	noted	a	greater	variance	in	size	
of	 ampullary	 tumours	 than	pancreatic	and	bile	duct	 tumours.	Less	aggressive	ampullary	
tumours	 remain	 confined	 to	 the	 region	 of	 the	 ampulla	 while	 others	 progress	 to	 invade	
vascular	 structures.	 As	 ampullary	 tumours	 are	 located	 a	 greater	 distance	 from	 the	
vascular	structures	than	pancreatic	and	bile	duct	tumours	they	are	likely	to	cause	vascular	
obstruction	as	a	relatively	delayed	event	compared	to	biliary	obstruction.		Results	for	the	
whole	 cohort	 however	 do	 not	 show	 an	 association	 between	 interval	 to	 surgery	 and	
resectability.	 It	 is	 probable	 that	 the	 small	 proportion	 of	 patients	with	 ampullary	 cancer	
who	progress	 to	 inoperability	 is	masked	 in	 the	 larger	 group	of	 patients	with	pancreatic	
and	bile	duct	cancer,	where	IS	is	shown	to	have	no	effect	on	resectability	and	outcome.		
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	In	 the	 event	 of	 inoperability	 usually	 a	 biopsy	 is	 taken	 and	 the	 presence	 of	
malignancy	 confirmed.	 Determining	 the	 organ	 of	 origin	 in	 this	 situation	 is	 difficult	
however,	as	this	requires	examination	of	the	spatial	relationship	of	periampullary	lesions	
(23).	 Histological	 tissue	 stains	 have	 low	 specificity	 in	 determining	 precise	 tumour	
phenotype	 (25).	 Usually	 in	 this	 situation	 a	 diagnosis	 of	 adenocarcinoma	 is	 made	 and	
patients	often	referred	for	palliative	treatment	with	chemotherapy	targeted	at	pancreatic	
cancer.	Our	results	provide	indirect	evidence	that	among	this	patient	group	there	will	also	
be	patients	with	ampullary	cancer,	which	has	progressed	to	involve	vascular	structures.		
A	 potential	 weakness	 of	 this	 study	 is	 the	 variable	 timing	 of	 the	 initial	 imaging.	
Often	this	was	performed	after	the	development	of	progressive	jaundice,	so	there	was	an	
uninterrupted	time	line	from	presentation	to	surgery.	In	some	patients	however	an	initial	
presentation	 with	 spontaneously	 resolving	 biliary	 obstruction	 was	 investigated	 which	
revealed	potential	PC,	but	 the	 issue	was	not	 taken	 forward	due	 to	clinical	 improvement.	
This	presentation	accounts	for	the	very	long	IS	in	some	patients.	Although	spontaneously	
resolving	biliary	obstruction	has	been	reported	previously	in	ampullary	cancer	(436),	we	
have	noted	a	similar	phenomenon	in	pancreatic	and	bile	duct	cancer	in	this	study.	Another	
potential	weakness	 is	 the	 lack	 of	 discrimination	of	 ampullary	 tumours	 into	 intestinal	 or	
pancreatico-biliary	 phenotype.	 These	 two	 tumours	 have	 different	 anatomical	 and	
morphological	 characteristics,	 in	 addition	 to	 different	 prognosis.	 It	 is	 possible	 that	 the	
phenomenon	we	have	observed	occurs	differentially	in	these	two	subsets.	Distinguishing	
between	 these	 two	 phenotypes	 however	 does	 not	 form	 part	 of	 the	 Royal	 College	 of	
Pathologists’	dataset	(23).		
Previous	 evidence	 has	 shown	 that	 delayed	 diagnosis	 and	 a	 prolonged	 interval	 to	
surgery	 have	 an	 adverse	 outcome	 in	 other	 tumour	 types	 including	 breast	 cancer	 (437),	
non-small	cell	lung	cancer	(438),	and	urological	cancer	(439).	There	is	little	data	available	
however	on	what	constitutes	a	safe	interval	to	surgery	after	diagnosis.	The	62	day	interval	
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adopted	 as	 a	 target	 for	 treatment	 of	 most	 solid	 tumours	 in	 England	 was	 selected	 as	 a	
pragmatic	 figure	 without	 evidence	 of	 beneficial	 effect	 for	 each	 tumour	 type.	 Although	
there	is	evidence	that	late	diagnosis	has	a	negative	effect	on	outcome	in	pancreatic	cancer,	
as	 shown	 by	 the	 low	 resection	 rate	 (440),	 the	 study	 shows	 that	 following	 symptomatic	
presentation	delay	of	up	to	two	months	prior	to	resection	has	no	further	effect	on	outcome	
in	 pancreatic	 and	 bile	 duct	 cancer.	 For	 ampullary	 cancer	 however	 a	 delay	 to	 surgery	
within	the	62-day	target	period	has	a	measurable	effect,	with	some	lesions	progressing	to	
inoperability,	 and	 improved	 outcome	 of	 the	 selected	 patients	 whose	 tumours	 remain	
resectable.	This	 finding	has	significant	 implications	for	planning	surgery	 in	patients	with	
PC,	as	the	final	histological	tumour	type	is	not	known	until	surgery	is	completed,	and	early	
surgery	for	these	patients	is	therefore	preferable.	Also	these	findings	suggest	that	in	some	
patients	with	inoperable	PC	the	tumour	may	originate	within	the	ampulla,	rather	than	the	
pancreas.	This	may	have	 implications	for	the	selection	of	palliative	chemotherapy	in	this	
patient	group.	
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6.3 Systematic	evaluation	of	radiological	findings	in	the	assessment	of	
resectability	of	peri-ampullary	cancer	by	CT	using	different	contrast	
phase	protocols	
6.3.1 Abstract		
Aims:	 To	 determine	 the	 relative	 significance	 of	 radiological	 signs	 in	 determining	 the	
resectability	of	peri-ampullary	cancer	(PC)	and	to	assess	the	value	of	multi-phase	imaging	
in	detecting	these	findings.	
Materials	 and	Methods:	 Blinded,	 double	 re-reporting	 of	 pre-operative	 imaging	 from	 five	
hospitals	was	undertaken	of	 411	patients	 undergoing	 surgery	 for	 PC	 over	 an	 eight	 year	
period,	of	whom	119	patients	were	found	to	be	inoperable	at	the	time	of	surgery.	
Results:	The	median	tumour	size	was	26.7	mm	and	the	proportion	of	patients	reported	to	
have	 regional	 lymphadenopathy	 (RL),	 venous	 (VI)	 and	 arterial	 involvement	 (AI)	 was	
24.7%,	11.5%	and	3.9%	respectively	and	was	similar	regardless	of	the	number	of	contrast	
phases	undertaken.	Significant	associations	were	however	noted	between	individual	risk	
factors:	VI	was	closely	associated	with	tumour	size	(p=0.002)	and	AI	(p<	0.0001).	In	multi-
variable	analysis	AI,	VI	and	RL	were	independently	associated	with	resectability	(relative	
risk	 of	 resection	 =0.05,	 0.31	 and	 0.51	 respectively).	 Tumour	 size	 however	 was	 not	
associated	with	resectability	when	VI	was	included	in	the	multivariate	model.		
Conclusions:	The	use	of	multiple	vascular	contrast	phases	has	no	measureable	impact	on	
the	rate	of	determination	of	tumour	resectability	of	PC.	In	pre-operative	staging	AI	is	the	
most	significant	adverse	finding	for	resectability.	Large	tumour	diameter	is	not	an	adverse	
finding	in	isolation	from	other	risk	factors.		
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6.3.2 Introduction	
Determination	 of	 tumour	 resectability	 is	 a	major	 aspect	 of	 the	 interpretation	 of	
pre-operative	 imaging	 of	 peri-ampullary	 cancer	 (PC).	 The	 findings	 of	 distant	metastases	
and	local	invasion	resulting	in	occlusion	of	major	arteries	or	veins	are	contraindications	to	
attempted	 surgical	 resection,	 whereas	 lesser	 degrees	 of	 arterial	 involvement	 (AI)	 and	
venous	involvement	(VI),	including	abutment	and	tapering,	are	relative	contraindications,	
as	imaging	can	sometimes	be	inaccurate	in	determining	these	findings	(441-444),	and	vein	
resection	 can	 be	 undertaken	 where	 incomplete	 venous	 occlusion	 is	 noted	 (445-447).	
Tumour	size	(448)	and	regional	lymphadenopathy	(RL)	(332,	449)	have	also	been	shown	
to	be	associated	with	unresectability,	 although	RL	 is	 a	 relative	 contraindication	as	 these	
nodes	are	removed	as	part	of	a	Whipple	procedure	(240).	This	finding	may	however	be	a	
surrogate	 marker	 of	 an	 aggressive	 malignancy,	 which	 will	 progress	 rapidly	 to	 become	
inoperable.	
Despite	 pre-operative	 imaging	 to	 exclude	 patients	 with	 contraindications	 to	
surgery	 a	 proportion	 of	 patients	 with	 PC	 proceeding	 to	 operation	 are	 found	 to	 be	
inoperable,	either	due	 to	unresectable	 invasion	of	vascular	structures	or	 the	presence	of	
metastatic	 disease.	 This	 may	 result	 from	 either	 understaging	 by	 CT	 or	 rapid	 tumour	
progression	in	the	interval	between	imaging	and	surgery.		
Pre-operative	 staging	 of	 PC	 is	 commonly	 undertaken	 by	 contrast-enhanced	 CT	
scan.	Some	authorities	recommend	tri-phasic	imaging	(324),	including	pre-contrast	phase,	
arterial	 phase	 and	 portal	 phase;	 although	 the	 benefits	 of	 this	 over	 monophasic	 scans	
(portal	venous	phase	only)	and	biphasic	scans	(arterial	and	portal	phases)	have	not	been	
demonstrated.	 This	 has	 implications	 in	 terms	 of	 radiation	 exposure	 and	 resource	
utilisation.	 There	 have	 also	 been	 major	 improvements	 in	 CT	 scan	 technology	 in	 recent	
years	with	the	development	of	multi-detector	imaging	(450),	which	would	be	expected	to	
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lead	to	a	reduction	in	the	proportion	of	false	negative	findings,	and	may	have	reduced	the	
need	for	multi-phase	imaging.	
The	 principal	 study	 aim	 is	 to	 determine	 a	 hierarchy	 of	 radiological	 findings	 in	
predicting	 the	 resectability	 of	 PC	 in	 patients	 undergoing	 surgery	 at	 a	 regional	 centre	
within	 a	 Cancer	 Network	 serving	 five	 hospitals	 (A-E)	 and	 to	 investigate	 the	 cause	 of	
unresectability	 (local	 invasion	 or	 metastatic	 disease)	 associated	 with	 these	 findings.	
Secondary	aims	were	to	explore	the	effect	of	varied	imaging	protocols	in	the	detection	of	
these	 findings	 to	 determine	 potential	 advantages	 of	 multi-phase	 imaging	 in	 clinical	
practice.	
6.3.3 Material	and	Methods	
Details	 of	 consecutive	 patients	 undergoing	 surgical	 exploration	 for	 suspected	PC	
between	 January	 2006	 and	 January	 2014	 were	 collected	 in	 a	 prospective	 database.	
Patients	were	offered	surgery	following	review	of	imaging	at	a	specialist	HPB	MDT	and	all	
scans	 were	 performed	 on	 64-slice	 multi-detector	 CT	 (MDCT).	 Relevant	 abdominal	 CT	
scans	were	 retrieved	 from	 referring	hospitals,	 anonymised	 and	uploaded	 to	 a	 dedicated	
research	 hard-drive.	 Images	 were	 then	 re-reported	 independently	 by	 two	 radiologists	
with	 higher	 training	 in	 pancreatico-biliary	 imaging	 using	 standard	 criteria	 (451).	 The	
number	of	vascular	contrast	phases	was	recorded	for	each	patient	and	the	proportion	of	
patients	 having	 mono,	 bi	 and	 tri-phasic	 imaging	 in	 each	 of	 the	 referring	 hospitals	 was	
determined,	 along	 with	 the	 association	 of	 the	 number	 of	 scan	 phases	 with	 the	 main	
radiological	 findings.	 Specific	 data	 fields	were	 created	 to	 collect	 information	 relating	 to	
hospital	of	origin,	 the	presence	of	a	biliary	stent	 inserted	at	ERCP,	 tumour	size,	 regional	
nodal	 status	 (presence	 of	 lymph	 nodes	 >1cm	 in	 transverse	 diameter)	 and	 vascular	
involvement	status.	Radiological	evidence	of	arterial	and	venous	involvement	(Figure	6-4	
and	6-5)	was	defined	according	to	published	criteria	(451).			
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Figure	6-4	MDCT	imaging	demonstrating	SMA	involvement	by	PC	(Arrow)	
	
	
Figure	6-5	MDCT	imaging	demonstrating	SMV	involvement	by	PC	(Arrow)	
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In	 the	 assessment	 of	 binary	 variables	 (e.g.	 nodal	 status)	 a	 positive	 outcome	was	
recorded	only	when	both	radiologists	agreed	on	the	finding.	For	tumour	size	the	mean	of	
the	two	findings	was	taken.		
At	 surgery	 initially	 a	 search	 for	 metastatic	 disease	 was	 undertaken	 before	 an	
attempt	 at	 dissection	 of	 the	 primary	 tumour.	 The	 tumour	 was	 considered	 to	 be	
unresectable	due	 to	 local	 invasion	when	 the	operating	surgeon	was	unable	 to	 resect	 the	
tumour	 after	 trial	 dissection	without	 undertaking	 arterial	 resection	 or	where	 there	was	
occlusion	or	extensive	 invasion	of	 the	portal	or	superior	mesenteric	vein.	Data	retrieved	
from	the	database	included	the	operative	finding	of	either	unexpected	distant	metastases	
or	local	invasion	by	tumour	into	vascular	structures.	The	proportion	of	resectable	tumours	
was	recorded	for	consecutive	quartiles	(two	year	intervals)	of	the	study	period.	To	explore	
further	the	predictive	value	of	radiological	findings	the	operative	outcome	among	patients	
where	 the	 tumours	were	 found	 to	 be	 unresectable	were	 categorised	 into	 the	 finding	 of	
metastatic	disease	or	local	invasion.	
Discrete	variables	and	interdependence	of	radiological	 findings	were	analysed	by	
Chi-square	test	and	continuous	variables	by	Mann-Whitney.	Estimates	of	the	relative	value	
of	 radiological	 parameters	 in	 the	 prediction	 of	 resectability	 of	 PC	 were	 determined	 by	
logistic	regression	analysis.	
6.3.4 Results		
Operative	 details	 and	 relevant	 pre-operative	 imaging	 were	 available	 in	 409	
patients	(Figure	6-6),	of	median	age	66.9	(28-86)	years,	of	whom	55.8%	were	male.	The	
median	age	(66.7	v	67.5	years),	percentage	of	male	patients	(54.5%	v	59.8%)	and	median	
interval	 between	 imaging	 and	 surgery	 (42	 v	 39	 days,	 p=0.419)	 did	 not	 differ	 between	
patients	proceeding	to	resection	and	those	where	the	lesion	was	found	to	be	unresectable.	
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Figure	6-6	Flow	chart	of	patients	undergoing	surgery	for	PC	between	January	2006	and	
January	2014	
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Analysis	 of	 images	 revealed	 a	 similar	 proportion	 of	mono-,	 bi-	 and	 tri-phasic	 scans.	
There	was	variation	in	the	number	of	vascular	contrast	phases	undertaken	in	scans	from	
different	hospitals;	however	the	rate	of	detection	of	the	main	radiological	end-points	did	
not	differ	according	to	the	number	of	contrast	phases	undertaken	(Table	6.8).	
n	=	409	
Monophasic	
(134,	32.7%)	
Biphasic	
(149,	36.4%)	
Triphasic	
(126,	31%)	
P	
Hospital	
A	(119)	 20	(16.8)	 52	(43.7)	 46	(38.6)	
0.0001	
B	(97)	 45	(46.4)	 50	(51.5)	 2	(2.1)	
C	(78)	 24	(30.7)	 9	(11.5)	 45	(57.7)	
D	(71)	 24	(33.8)	 21(29.5)	 26	(36.6)	
E	(44)	 21	(47.7)	 17	(38.6)	 6	(13.6)	
AI	(16)	 3	(2.4)	 8	(5.4)	 5	(4)	 0.398	
VI	(47)	 20	(15)	 11	(7.4)	 16	(12.7)	 0.122	
RL	(101)	 28	(21)	 42	(28.2)	 31	(24.6)	 0.83	
Tumour	visible	(250)	 72	(53.7)	 99	(66.4)	 79	(62.7)	 0.83	
Median	 tumour	 size	
(range)	
25.25	
(11.5-70)	
26.25	
(10.5-58)	
27.75	
(8-64.5)	
0.39	
Resection	 completed	
(292)	
102	(76.1)	 107	(71.8)	 83	(65.8)	 0.187	
	
Table	6.8	Radiological	findings	and	surgical	resection	rate	according	to	the	number	of	CT	
scan	phases	for	409	patients	undergoing	attempted	surgical	resection	for	PC	
	In	particular	 the	proportion	of	 patients	noted	 to	have	AI	did	not	differ	 between	
patients	where	 only	 portal	 venous	 imaging	was	 performed	 (3	 of	 134)	 and	 those	where	
additional	 arterial	 phase	 imaging	 (bi-	 and	 tri-phasic	 scans)	 was	 also	 performed	 (13	 of	
275)	 (p=0.223).	 The	 primary	 tumour	 was	 visible	 in	 250	 patients	 (61.1%),	 with	 no	
difference	 in	 the	 rate	 of	 detection	 in	 patients	 having	 different	 contrast	 phase	 protocols	
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(Table	 6.8).	 Similarly	 the	 median	 tumour	 size	 was	 26.7	 (8-70)	 mm	 and	 did	 not	 differ	
between	patients	having	different	scan	phases	(p=	0.39).	Where	a	tumour	was	visible	RL,	
VI	and	AI	were	noted	in	101	(40.4%),	47	(18.8%)	and	16	(6.4%)	of	patients	respectively.	
Among	the	159	patients	where	no	primary	tumour	was	visible,	RL	was	noted	in	40	(25%)	
patients.	Tumour	size	was	noted	to	be	greater	in	patients	with	RL	(28.5mm	v	26mm),	AI	
(30.7mm	v	26.5mm)	and	VI	 (33mm	v	25.5mm)	than	 in	 those	without	 these	 findings	(p=	
0.02,	0.03	and	0.0001	respectively).	In	evaluation	of	interdependence	of	pre-operative	risk	
factors	VI	was	noted	to	be	strongly	associated	with	AI	(p=0.000).	Of	the	16	patients	with	
AI,	8	(50%)	also	were	noted	to	have	VI.	The	finding	of	RL	was	not	significantly	associated	
with	either	AI	(p=0.472)	or	VI	(p=0.108).	
Biliary	 stents	 had	 been	 inserted	 prior	 to	 CT	 scan	 in	 73	 (17.8%)	 patients.	 The	
proportion	of	patients	with	radiologically	detectable	RL	did	not	differ	between	those	who	
had	(17/72,	23.6%)	and	those	who	had	not	(84/337,	25%)	had	a	stent	inserted	prior	to	CT	
scan	(p=0.814).		
Surgical	resection	of	the	PC	was	completed	in	292	patients	(71.4%).	Resection	was	
completed	 more	 commonly	 among	 the	 159	 patients	 where	 no	 lesion	 was	 visible	 (126,	
79%)	than	among	the	250	patients	where	the	tumour	was	visible	(166,	66.4%)	(p=0.005).	
Among	the	155	patients	with	a	visible	tumour	and	no	adverse	risk	factors	(RL,	AI	or	VI)	on	
pre-operative	 imaging,	 the	median	 tumour	 size	 did	 not	 differ	 between	 the	 121	 patients	
where	 the	 tumour	was	resectable	 (24.5	mm,	 IQR	20.5-30.42)	and	 the	34	patients	where	
the	tumour	was	not	resectable	(26.7mm,	IQR	20-28.5mm)	(p=0.55).	
Of	 the	 17	 patients	 with	 VI	 on	 pre-operative	 imaging	 where	 resection	 was	
completed,	 partial	 venous	 resection	 was	 necessary	 in	 three	 (17.6%)	 patients.	 Vein	
resection	was	also	required	in	five	of	the	348	patients	(1.4%)	where	VI	was	not	noted	pre-
operatively.		
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The	final	pathological	diagnosis	of	resected	specimens	is	shown	in	(Table	6.9).	
Tumour	origin	 N	(%)	 Median	tumour	
size	(range)	mm	
Histological	lymph	
node	involvement	(%)	
Pancreatic	adenocarcinoma	 132	(45.2)	 30	(12-65)	 122	(92.4)	
Ampullary	adenocarcinoma	 66	(22.6)	 25	(5-80)	 37	(56)	
Bile	duct	adenocarcinoma	 47	(16.1)	 25	(10-70)	 25	(53.2)	
Duodenal	adenocarcinoma	 7	(2.4)	 40	(30-55)	 4	(47)	
Tubulo-villous	adenoma	 15	(5.1)	 30	(24-55)	 	
Inflammatory	disease	 12	(4.1)	 	 	
Neuroendocrine	tumour	 6	(2)	 18	(10-25)	 3	(50)	
Metastasis	 4	(1.4)	 35	(25-45)	 	
Gastro	 Intestinal	 Stromal	
cell	tumour	(GIST)	
1	(0.03)	 	 0	(0)	
Others	(Benign)	 2	(0.6)	 	 	
	
Table	6.9	Histological	outcome	of	292	patients	undergoing	surgical	resection	for	presumed	
periampullary	cancer.	
	
In	univariate	analysis	the	presence	of	a	visible	tumour,	tumour	size,	RL,	AI	and	VI	
on	pre-operative	imaging	were	all	associated	with	unresectability	of	the	tumour	(Table	
6.10).	However	in	multivariate	analysis	the	strongest	association	with	tumour	
resectability	was	with	the	presence	of	AI	(Table	6.10).	Tumour	size	and	VI	were	found	to	
be	mutually	exclusive	for	significance	in	the	multi-variate	model.
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Imaging	
characteristic	
Tumour	resectability	 UVA	 MVA	
Yes	
(292)	
No	
(117)	 p	 Exponent	
95%	CI	of	
Exponent	 P	
Median	
tumour	 size	
(mm)(range)	
25.5	
(8-70)	
28	
(11.5-64.5)	
	
0.01	
	
0.46	
	
(0.193-1.084)	
	
0.076	
RL	(101)	
(%)	
63	
(21.6)	
39	
(32.8)	
	
0.017	
	
0.51	
	
(0.272-0.949)	
	
0.047	
AI	(16)	
(%)	
2	
(0.68)	
14	
(11.7)	
	
0.000	
	
0.05	
	
(0.007-0.445)	
	
0.007	
VI	(47)	
(%)	
17	
(5.82)	
30	
(25.2)	
	
0.000	
	
0.31	
	
(0.152-0.638)	
	
0.001	
	
Table	6.10	Univariate	and	multivariate	analysis	of	the	association	of	the	preoperative	
radiological	risk	factors	and	surgical	resectability	of	PC	in	409	patients	
In	the	117	patients	where	the	tumour	was	not	resected	this	was	due	to	the	finding	of	
hepatic	metastatic	disease	in	45	patients	(37.8%)	or	local	invasion	of	vascular	structures	
in	72	patients	 (60.5%).	The	proportion	of	patients	with	unresectable	disease	was	16/67	
(23.8%),	 35/93	 (37.6%),	 32/119	 (26.2%)	 and	 34/130	 (26.1%)	 (p=0.17)	 in	 consecutive	
time	 quartiles	 of	 the	 study.	 No	 difference	 was	 noted	 in	 the	 reasons	 for	 unresectability	
(local	 invasion	 or	 metastatic	 disease)	 among	 patients	 with	 different	 pre-operative	
radiological	findings	(Table	6.11).	
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n=117	 Local	invasion	
(n=	72,	61.5%)	
Metastatic	
disease	
(n=45,	38.5%)	
Chi	Sq	 P	
Radiological	finding	
Tumour	visible	(84,	71.8%)	 49	(58.3)	 35	(41.6)	 1.3	 0.256	
Median	 tumour	 size	 (mm)		
(range)	
28.25	
(11.5-64.5)	
27.75	
(16.5-55.5)	
	
0.838	
	
0.36	
RL	(38,	32.5%)	 23	(60.5)	 15	(39.5)	 0.024	 0.876	
AI	(16,	13.7%)	 9	(56.2)	 5	(31.25)	 0.051	 0.822	
VI	(30,	25.6%)	 22	(73.3)	 8	(26.6)	 2.37	 0.123	
No	 adverse	 radiological	 findings	
(54,	46.1%)	
32	(59.2)	 22	(40.7)	 0.22	 0.639	
	
Table	6.11	Reasons	for	non-resection	(local	invasion	or	metastatic	disease)	among	117	
patients	undergoing	attempted	surgical	resection	for	periampullary	cancer	with	different	
pre-operative	radiological	findings	
6.3.5 Discussion	
This	study	allows	the	determination	of	a	hierarchy	of	relative	contraindications	to	
resection	 of	 peri-ampullary	 cancer,	 based	 on	 a	 systematic	 assessment	 of	 radiological	
findings.	 In	 multivariable	 analysis	 the	 likelihood	 of	 completing	 surgical	 resection	 was	
reduced	 by	 a	 factor	 of	 0.05,	 0.31	 and	 0.51	 by	 a	 finding	 of	 AI,	 VI	 and	 RL	 respectively,	
compared	to	a	patient	with	none	of	these	findings.	In	the	absence	of	these	findings	tumour	
size	 was	 not	 associated	 with	 resectability.	 The	 study	 also	 revealed	 significant	
interdependence	 of	 radiological	 signs,	 with	 VI	 closely	 associated	 with	 tumour	 size	
(p<0.0001)	and	with	AI	(p=0.000).	The	study	demonstrated	that	the	proportion	of	patients	
with	 unresectable	 disease	 at	 the	 time	 of	 surgery	 has	 not	 declined	 over	 the	 eight-year	
period	of	the	study,	and	that	the	radiological	findings	are	similar	regardless	of	the	number	
of	scan	phases	undertaken.	In	addition	pre-operative	radiological	findings	were	not	able	to	
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predict	 the	 reason	 the	 pancreatic	 tumour	 was	 not	 resectable	 at	 the	 time	 of	 surgery	
(metastatic	disease	or	local	progression).		
Many	 studies	 have	 shown	 that	 AI	 and	 VI	 are	 risk	 factors	 for	 non-resection	 of	
pancreatic	tumours	(352,	403,	452).	Most	have	focused	on	assessing	the	accuracy	of	MDCT	
in	 identifying	these	risk	 factors	 in	comparison	with	operative	 findings	or	histology	(329,	
453,	454).	This	study	has	used	a	structured	reporting	protocol	to	assess	the	relative	risk	
that	pre-operative	identification	of	these	findings	entails	for	individual	patients	in	terms	of	
tumour	resectability.	AI	is	shown	to	be	the	most	significant	adverse	finding,	with	a	relative	
risk	of	resection	of	0.05	compared	to	a	patient	without	this	finding.	This	may	be	due	to	the	
hepatic	 and	 superior	mesenteric	 arteries	 lying	 further	 from	 the	 duodenal	 ampulla	 than	
venous	 structures,	 denoting	 a	 greater	 degree	 of	 invasion.	 The	 observation	 that	 the	
radiological	 findings	 of	 AI	 and	 VI	 are	 associated	 with	 each	 other	 may	 also	 reflect	 the	
spatial	relationship	of	these	structures,	with	VI	occurring	first	followed	by	AI.		
The	 significance	 of	 radiological	 evidence	 of	 RL	 has	 been	 less	 well	 investigated	
previously.	 It	 is	 interesting	 to	 note	 that	 the	 presence	 of	 RL	 was	 not	 influenced	 by	 the	
insertion	of	biliary	stents,	so	this	finding	should	be	attributed	to	a	malignant,	rather	than	
inflammatory	 process.	 RL	 was	 also	 not	 associated	 with	 other	 signs	 of	 local	 tumour	
progression,	and	is	only	weakly	associated	with	primary	tumour	size.	The	development	of	
lymph	node	metastases	 in	PC	may	 therefore	depend	on	different	biological	processes	 to	
primary	 tumour	 enlargement	 and	 local	 invasion.	 RL	 was	 however	 independently	
associated	with	tumour	irresectability.	This	is	probably	due	to	this	finding	being	a	marker	
of	a	more	aggressive	malignancy.	In	a	large	proportion	(69%)	of	patients	with	RL	however	
the	tumour	remains	resectable	at	surgery.	
Our	 study	 confirms	 that	 although	 tumour	 size	 is	 associated	 with	 invasion	 of	
vascular	structures,	 size	alone	does	not	 lead	 to	an	 increased	risk	of	non-resection	 in	 the	
	
	 134	
absence	of	other	 adverse	 findings.	This	 is	 significant	 as	 some	centres	have	used	 tumour	
size	alone	as	a	factor	in	the	decision	to	offer	surgery	for	PC	(448).	
The	observation	that	20%	of	patients	with	no	detectable	tumour	radiologically	are	
found	to	be	inoperable	at	the	time	of	surgery	is	an	interesting	finding.	This	suggests	that	
although	the	interval	from	imaging	to	surgery	has	only	a	small	 impact	on	resectability	in	
large	 series(455)	 there	 may	 be	 a	 more	 aggressive	 subset	 where	 progression	 proceeds	
rapidly.	 Similarly	 among	 the	 271	 patients	 where	 no	 adverse	 radiological	 signs	 were	
identified	 54	 (19.9%)	were	 still	 found	 to	 be	 inoperable	 at	 the	 time	 of	 surgery.	 Caution	
must	be	exercised	therefore	in	the	interpretation	of	radiological	findings	when	counseling	
patients.	In	addition	although	vein	resection	was	required	in	17.6%	of	patients	undergoing	
resection	where	VI	was	noted	on	pre-operative	 imaging	 it	was	also	necessary	 in	1.4%	of	
cases	without	VI	on	pre-operative	imaging.	These	observations	emphasize	the	limitations	
of	pre-operative	imaging	in	planning	surgery	for	PC.	
The	 weaknesses	 of	 this	 study	 mainly	 relate	 to	 the	 non-standardised	 imaging	
protocols	 undertaken	 in	 different	 centres,	 and	 its	 retrospective	 nature.	 This	 study	
however	 represents	 an	 analysis	 of	 the	 value	of	 pre-operative	 imaging	 in	 routine	 clinical	
practice,	 rather	 than	 under	 trial	 conditions,	 and	 the	 results	 are	 therefore	 likely	 to	 be	
relevant	 to	 other	 centres	 undertaking	 this	 type	 of	 surgery.	 Of	 particular	 interest	 is	 the	
finding	 that	 the	 radiological	 findings	 and	 resection	 rate	 are	 similar	 regardless	 of	 the	
number	 of	 contrast	 phases.	 Although	multi-phase	 pancreatic–protocol	 CT	 is	 considered	
the	 ‘gold-standard’	 in	 assessing	 resectability	 of	 PC	 (324),	 our	 results	 indicate	 that	 the	
resectability	 rate	 is	unaltered	by	 the	CT	 technique	used.	 It	 is	possible	 that	with	a	 larger	
study	the	use	of	arterial	phase	contrast	may	lead	to	greater	sensitivity	in	the	detection	of	
AI.	This	however	does	not	seem	necessary	in	patients	with	small	tumours	and	no	evidence	
of	 VI,	 where	 the	 risk	 of	 AI	 is	 very	 low.	 Another	 limiting	 point	 is	 lack	 of	 best	 imaging	
technique,	in	terms	of	CT	phases,	to	identify	resectability.	
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The	study	 is	also	 limited	by	 the	number	of	 radiologists	undertaking	 re-reporting	
(two).	The	agreement	between	radiologists	is	being	addressed	separately	and	it	is	possible	
that	the	results	have	been	biased	by	individual	radiologists	performance.		
The	analysis	of	 surgical	outcomes	has	revealed	 the	most	common	cause	 for	non-
resection	 was	 invasion	 of	 vascular	 structures	 (60.5%),	 with	 metastatic	 disease	 a	 less	
common	finding	(37.8%).	Patients	noted	to	have	AI	or	VI	on	pre-operative	imaging	had	a	
similar	 likelihood	 of	 being	 inoperable	 due	 to	metastatic	 disease	 or	 local	 invasion	 at	 the	
time	of	surgery,	suggesting	that	 these	 findings	are	markers	of	aggressive	malignancy.	CT	
has	a	high	 resolution	 for	hepatic	metastases,	which	has	 increased	 in	 recent	years	 (456).	
Despite	 this	 the	 proportion	 of	 patients	 with	 unresectable	 disease	 has	 remained	 largely	
unchanged	 over	 the	 period	 of	 study.	 This	 finding	 suggests	 that	 disease	 progression	
between	imaging	and	the	time	of	surgery	may	be	a	more	significant	cause	of	inoperability	
than	under-staging	by	CT.	There	may	therefore	be	an	irreducible	number	of	patients	with	
rapidly	progressive	disease	who	will	be	unresectable	at	the	time	of	surgery,	regardless	of	
the	quality	of	the	imaging	and	reporting	undertaken.		
The	strength	of	 this	study	 lies	 in	 its	 large	size	and	 in	the	assessment	of	 imaging	of	
heterogeneous	techniques	from	different	hospitals.	Other	studies	have	shown	similar	risk	
factors	for	non-resection	(250,	457),	and	a	similar	rate	of	non-resection	(250,	457)	at	the	
time	 of	 surgery,	 and	 there	 is	 little	 available	 evidence	 that	 this	 rate	 has	 declined	 with	
improved	imaging.	This	may	be	due	to	alterations	in	the	threshold	for	undertaking	surgery	
in	borderline	cases	and	 improvements	 in	 surgical	 technique.	The	study	however	 reveals	
significant	 limitations	 in	 the	 ability	 of	 MDCT	 to	 predict	 the	 presence	 of	 surgically	
significant	operative	findings.	
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6.4 Estimation	of	the	organ	of	origin	of	peri-ampullary	malignancy	by	
pre-operative	CT	scan	
6.4.1 Abstract	
Background:	 Tumours	 occurring	 within	 the	 pancreatic	 head	 commonly	 arise	 from	 the	
pancreas,	 duodenal	 ampulla,	 distal	 bile	 duct	 or	 duodenum.	 Because	 these	 lesions	 may	
cause	biliary	 obstruction	 they	often	present	with	painless	 jaundice.	 They	 are	difficult	 to	
distinguish	on	standard	pre-operative	imaging.	Treatment	of	these	lesions	was	previously	
surgical,	 therefore	 determination	 of	 organ	 of	 origin	 not	 important.	 Increasingly	 neo-
adjuvant	therapy	is	offered,	which	may	need	to	be	tailored	to	the	organ	of	origin.	
Aim:	We	wished	 to	assess	 the	ability	of	 specialist	 reporting	of	pre-operative	CT	scans	 to	
determine	the	organ	of	origin	of	PC.	
Methods:	 Blinded	 re-reporting	 of	 pre-operative	 imaging	 from	 five	 hospitals	 was	
undertaken	 of	 consecutive	 cohort	 of	 411	 patients	 undergoing	 surgery	 for	 PC	 between	
January	 2006	 and	 May	 2014	 were	 undertaken.	 A	 modified	 reporting	 template	 was	
designed	featuring	the	radiological	findings	of	interest	for	PC.	Radiological	identification	of	
tumour	 site	 was	 determined	 by	 the	 presence	 of	 the	 main	 tumour	 bulk	 within	 the	
pancreatic	head	parenchyma.	Radiologists	made	an	estimate	of	 the	pathological	organ	of	
origin	of	the	PC	based	on	all	the	reported	features.	Cohen’s	Kappa	statistic	test	was	used	to	
determine	the	inter-observer	agreement	between	radiologists.	
Results:	 Each	pathological	 tumour	 type	was	noted	 to	 have	distinct	 radiological	 features.	
Localisation	 of	 a	 visible	 tumour	 within	 the	 pancreatic	 parenchyma	 was	 seen	 most	
commonly	in	pancreatic	cancer	(92%)	than	other	tumour	types	(p<0.0001).	Local	invasion	
into	 the	duodenum	was	 a	 characteristic	 feature	 seen	 in	79%	of	patients	with	 ampullary	
tumours	and	isolated	dilation	of	the	bile	duct	without	dilation	of	the	pancreatic	duct	was	
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seen	most	commonly	in	patients	with	ampullary	or	bile	duct	cancer.	In	the	assessment	of	
tumour	origin	good	agreement	(kappa=0.6,	0.51-0.68)	was	noted	between	the	consensus	
radiology	 opinion	 and	 the	 final	 histology	 result.	 Overall	 accuracy	 was	 greatest	 for	
ampullary	cancer	(88.1%)	and	lowest	for	pancreatic	cancer	(83.2%).	
Conclusion:	Radiological	 assessment	 of	 pre-operative	 imaging	provides	 a	 high	degree	 of	
accuracy	in	predicting	the	organ	of	origin	of	peri-ampullary	cancer.	
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6.4.2 Introduction	
With	 the	 introduction	 of	 standardised	 reporting	 of	 pancreaticoduodenectomy	
specimens	(23)	a	larger	number	of	patients	have	been	diagnosed	with	tumours	other	than	
pancreatic	 cancer,	 than	 was	 the	 case	 previously	 (24).	 This	 is	 significant	 as	 trials	 of	
adjuvant	chemotherapy	are	stratified	and	targeted	at	the	specific	tumour	origin	(245,	458).	
The	development	and	popularisation	of	neoadjuvant	chemotherapy	for	pancreatic	cancer	
requires	accurate	pre-operative	prediction	of	 the	organ	of	origin	of	PC,	 to	allow	directed	
therapy.	We	wished	to	assess	the	ability	of	focused	re-reporting	of	pre-operative	CT	scans	
of	patients	undergoing	Whipple’s	pancreaticoduodenectomy	to	predict	the	organ	of	origin	
of	the	resected	tumour,	by	comparison	with	final	pathology.		
6.4.3 Methods	
A	consecutive	series	of	patients	undergoing	Whipple’s	pancreaticoduodenectomy	
(PD)	procedure	for	PC	between	January	2006	and	May	2014	were	examined.	Preoperative	
CT	 images	 were	 retrieved	 from	 Insignia	 PACS	 (Picture	 Archiving	 and	 Communication	
System).	All	images	were	anonymised	and	kept	on	a	secure	encrypted	hard	drive.	Relevant	
scans	were	re-reported	by	three	radiologists	with	specialist	training	in	pancreatico-biliary	
imaging.	
A	template	of	relevant	radiological	features	was	constructed	based	largely	on	the	
Radiology	Reporting	Template	 of	 the	 Society	 of	Abdominal	Radiology	 and	 the	American	
Pancreatic	Association	(451)	(Appendix	B).	Features	which	are	either	very	rare	or	unlikely	
to	 be	 related	 to	 tumour	 aetiology	 (e.g.	 the	 presence	 of	 venous	 collaterals	 and	 thrombus	
within	portal	or	mesenteric	veins)	were	not	 included.	The	 features	were	also	simplified.	
Each	feature	was	reported	as	a	binary	outcome,	regardless	of	the	degree	to	which	it	was	
noted	 (for	 example	 the	 degree	 of	 vascular	 invasion).	 Local	 invasion	 by	 tumour	 into	
duodenum,	 colon,	 stomach	 or	 adrenal	 gland	 was	 also	 noted.	 Features	 of	 biliary	
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morphology	were	recorded	only	in	patients	who	had	not	undergone	insertion	of	a	biliary	
stent	prior	 to	undertaking	CT.	The	 shape	of	bile	duct	 stricture	 (abrupt	or	 tapering)	was	
determined	by	3D	image	reconstruction.	
Surgery	was	undertaken	by	standard	techniques,	with	excision	of	the	pylorus	in	all	
patients.	Histological	examination	of	the	resected	specimen	was	undertaken	according	to	
Royal	College	of	Pathologists	guidelines	(23)	with	axial	slicing	of	the	resection	specimen.	
Determination	of	the	organ	of	origin	was	undertaken	by	the	reporting	pathologist	using	a	
combination	of	 tumour	 localisation	 and	histological	 features,	 including	 cellular	 atypia	 in	
adjacent	structures.	
CT	 scans	 were	 performed	 in	 the	 initial	 referring	 hospital	 and	 imported	 for	 re-
reporting.	 Scan	protocols	differed	between	 each	hospital,	 in	particular	 in	 relation	 to	 the	
number	of	contrast	phases	undertaken.	Scans	were	reported	by	radiologists	blinded	to	the	
clinical	details	 and	 the	 final	histopathology	 results.	Two	 radiologists	 recorded	outcomes	
for	 the	 features	noted	 in	Appendix	B.	Each	 feature	was	 recorded	as	present	only	 if	both	
radiologists	agreed	on	the	finding.	Where	there	was	agreement	on	the	features	these	were	
then	 categorised	 according	 to	 the	 final	 pathological	 tumour	 origin.	 For	 continuous	 data	
(size)	 the	mean	of	 the	 two	outcomes	was	recorded.	The	 tumour	site	was	determined	by	
estimating	the	site	of	the	main	tumour	bulk	within	the	pancreatic	head.	Local	invasion	was	
noted	 where	 tumour	 was	 seen	 in	 the	 stomach,	 duodenum,	 or	 adrenal	 gland.	 The	
radiologists	 then	made	a	prediction	of	 the	organ	of	origin	of	 the	peri-ampullary	 tumour.	
Where	 there	 was	 a	 discrepancy	 in	 this	 prediction	 a	 third	 PB	 radiologist	 gave	 a	 further	
independent	 opinion	 blinded	 to	 the	 previous	 reports,	 and	 the	 majority	 opinion	 (when	
achieved)	was	recorded.	Where	three	differing	opinions	were	made	of	the	tumour	origin	
the	outcome	‘other’	was	recorded.	
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Statistical	analysis	
Inter-observer	 agreement	 in	 recording	 categorical	 data	 was	 assessed	 by	 Cohen’s	
Kappa	 statistic.	 This	 method	 is	 commonly	 used	 to	 evaluate	 concordance	 in	 radiology	
reporting.	A	value	of	0	 indicates	agreement	purely	due	to	chance	and	1	 indicates	perfect	
agreement.	 The	 spectrum	 of	 values	 is	 arbitrarily	 divided	 into	 five	 categories	 for	
descriptive	purposes:	0-20	poor,	20-40	fair,	40-60	moderate,	60-80	good,	and	80-100	very	
good	 agreements.	 	 Categorical	 outcome	 data	 were	 then	 compared	 by	 the	 chi-square	
method.	 Inter-observer	 agreement	 in	 assessing	 continuous	 data	 (tumour	 size)	 was	
assessed	 by	 Spearman’s	 Correlation	 test	 and	 Mann-Whitney	 test.	 Analyses	 were	
performed	using	Analyse-It	software.	
6.4.4 Results	
During	the	study	period	411	patients	underwent	surgery	 for	PC.	The	median	age	
was	66	(27-86)	years	and	there	were	230	(56%)	males.	334	patients	(81.2%)	presented	
initially	with	features	of	biliary	obstruction,	five	with	duodenal	obstruction,	six	with	upper	
GI	bleeding	and	six	tumours	were	detected	as	an	incidental	finding.		Seventy-two	(17.5%)	
patients	underwent	ERCP	and	stent	insertion	prior	to	CT	scan.	Re-reported	pre-operative	
radiological	features	of	the	pancreatic	head	of	the	patients	undergoing	surgery	along	with	
Kappa	 estimates	 of	 radiologists’	 agreement	 are	 shown	 in	 (Table	 6.12)
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Table	6.12	Radiological	pancreatic	findings	among	411	patients	undergoing	surgery	for	PC.		
Agreement	 was	 reached	 on	 the	 presence	 of	 a	 visible	 tumour	 mass	 in	 254	 (62%)	
patients,	in	whom	arterial	phase	imaging	had	been	undertaken	in	170	patients.	In	10	cases	
there	was	no	radiological	agreement	regarding	the	number	of	contrast	phases	undertaken.	
In	 the	79	patients	where	 local	 invasion	was	noted	by	both	radiologists	 this	 involved	 the	
N=411	 Y/Y	 %	 Y/N	 %	 N/N	 %	 Kappa	
(95%	CI)	
Tumour	mass	visible	 254	 62	 105	 25.5	 52	 12.6	 0.35					
(0.25-0.46)	
Regional	LN	 102	 24.8	 133	 32.4	 176	 42.8	 0.35					
(0.25-0.44)	
Pancreatic	
calcification	
13	 3.2	 35	 8.5	 363	 88.3	 0.3										
(0.2-0.6)	
CBD	enhancement	(in	
non-stented	patients,	
n=339)	
39	 11.5	 140	 41.3	 159	 47	 0.18					
(0.08-0.2)	
CBD	wall	thickening	
(n=339)	
0	 0	 4	 1.2	 335	 98.8	 0	
CBD	
stricture	
morphol
ogy	
(n=339)	
Tapering	 49	 14.4	 131	 38.6	 159	 46.9	 0.22	
(0.05-0.23)	
Abrupt	 120	 35.4	 141	 41.6	 78	 23	 0.17	
(0.06-0.27	
Duct	Diameters	
	 Median	
(Radiologist	
A)	
Range	 Median	
(Radiologist	B)	
Range	 Correlation	
Median	PD	
diameter	mm	
6	 1-75	 5	 1-20	 0.538	
Median	CBD	
diameter	mm	
17	 4-38	 16	 2-31	 0.822	
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duodenum	 in	 76	 patients	 (96.2%).	 In	 two	 patients	 invasion	 of	 the	 stomach	 was	 noted	
(Table	6.13).	
N=254	 Concordant	
outcome	
%	 Kappa	
Gross	
local-
isation	of	
tumour	
mass	
Pancreas	 184	 44.7	 0.66	(0.55-0.77)	
Bile	duct	 2	 0.5	
Ampulla	 31	 7.5	
Duodenum	 5	 1.2	
No	agreement	 32	 12.6	
Arterial	enhancement	
(assessable	in	170	cases)	
4	 2.35	 0.38	(0.036-0.73)	
Venous	enhancement	
(assessable	in	244	cases)	
4	 1.63	 0.33	(0-0.67)	
Local	invasion	by	tumour	 79	 31.1	 0.165	(0.05-0.28)	
Arterial	invasion	 13	 5.1	 0.60	(0.41-0.8)	
Venous	invasion	 47	 18.5	 0.34	(0.22-0.47)	
	
Table		6.13	Radiological	features	reported	by	two	radiologists	among	254	patients	
undergoing	surgery	for	PC	where	tumour	mass	visible	
In	initial	reporting	of	the	images	by	two	radiologists	in	determining	the	organ	of	origin	
of	 PC	 agreement	 was	 reached	 on	 296	 occasions	 (72%)	 (Kappa=	 0.51,	 CI	 =0.44-57).	
Resection	 of	 the	 tumour	mass	was	 completed	 in	 292	 patients	 (71%)	 and	 a	 diagnosis	 of	
pancreatic,	 ampullary,	 bile	 duct	 or	 duodenal	 cancer	 noted	 in	 252	 patients	 (Figure	 6.7).		
The	 radiological	 findings	 associated	 with	 these	 diagnoses	 are	 shown	 in	 Table	 6.14
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Figure	6-7	Flow	chart	of	patients	undergoing	surgery	for	PC	between	January	2006	and	May	
2014	with	pathological	outcome	
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	 Pathological	tumour	origin	(For	resected	malignant	tumours)	
Pancreas	
(%)	
Ampulla	
(%)	
Bile	
duct	
(%)	
Duodenum	
(%)	
X2	 p	
N=	252	 132	
(52.3)	
66	(26.2)	 47	
(18.6)	
7	(2.7)	 	 	
Tumour	visible	(143)	 95	(71.9)	 29	(43.9)	 14	
(29.8)	
5	(71.4)	 31.4	 0.0001	
Median	tumour	size	(mm)	 27(12-70)	 22(12-
58)	
22(11-
43)	
40(14-54)	 	 0.724	
Gross	
localisation	of	
visible	tumour	
mass	(143)	
Pancreatic	
parenchyma	
(101)	
87	(91.6)	 2	(6.9)	 10	
(71.4)	
2	(40)	 113.5	 <.0001	
Ampulla	(18)	 1	(1.0)	 15	(51.7)	 1	(2.12)	 1	(20)	
Bile	duct	(2)	 0	 0	 2	(14.2)	 0	
Duodenum	
(3)	
0	 2	(6.9)	 0	 1	(20)	
No	agreement	
(19)	
7	(7.4)	 10	(34.5)	 1	(7.1)	 1	(20)	
Local	invasion	(48)	(Stomach	or	
Duodenum)	
19	(20)	 23	(79.3)	 3	(21.4)	 3	(60)	 37.5	 <.0001	
Arterial	invasion	(2)	 0	 0	 1	(7.1)	 1	(20)	 	 	
Venous	invasion	(15)	 12	(12.6)	 1	(3.4)	 1	(7.1)	 1	(20)	 2.6	 0.45	
Pancreatic	calcification	(5)	 4	(4.2)	 1	(3.4)	 1	(7.1)	 0	 0.636	 0.888	
Regional	lymphadenopathy	(57)	 32	(24.2)	 15	(22.7)	 9	(19.1)	 1	(20)	 0.800	 0.849	
Patients	where	bile	duct	
characteristics	assessable	(no	
stent)	(n=204)	
113	 51	 33	 7	 	 	
CBD	enhancement	(24)	 11(9.7%)	 5(9.8%)	 8(24.2
%)	
0/7	(0%)	 6.52	 0.089	
CBD	wall	thickening		 0	 0	 0	 0	 N/A	 N/A	
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Table	6.14		Radiological	features	among	252	patients	undergoing	pancreatic	head	resection	
for	peri-ampullary	malignancy	categorised	according	to	pathological	tumour	origin	
	
Radiological	 prediction	 by	 two	 radiologists	 of	 the	 tumour	 origin	 among	 all	 patients	 is	
shown	in	table	6.15	
N=411	 	 Radiology	1	
Tumour	
origin	
Pancreas	 Ampulla	 Bile	
duct	
Duodenum	 Others	
Radiolog
y	2	
Pancreas	 205	 13	 12	 4	 2	
Ampulla	 25	 54	 6	 3	 1	
Bile	duct	 18	 15	 29	 0	 4	
Duodenum	 3	 3	 2	 8	 2	
Others	 0	 0	 0	 1	 1	
	
Table	6.15	Radiological	prediction	of	the	pathological	tumour	origin	among	411	patients	
undergoing	surgery	for	PC,	Observed	agreement	0.72,	Kappa	0.51	(0.44-57)	
	
Third	 reporting	 of	 the	 115	 disputed	 cases	 allowed	 a	 majority	 opinion	 to	 be	
reached	in	a	further	104	cases.		In	the	remaining	eleven	cases	no	agreement	was	reached.	
Tapering	stricture	(%)	 20	(17.7)	 7	(13.7)	 2	(6)	 1	(14.2)	 4.638	 .098	
	Abrupt	stricture	(%)	 36	(31.8)	 21	(41.1)	 17	
(51.5)	
1	(14.2)	
CBD	diameter	(mm)	 17	(4-27)	 18	(7-25)	 18	(10-
30)	
9	(6-18)	 0.040	 0.573	
PD	diameter	mm	(all)	 6.8	(1.5-
24)	
5(2-15)	 3.5	
(1.5-11)	
2(2-2.5)	 0.347	 0.000	
PD	diameter	mm	(non-stented)		 7(1.5-24)	 5.5	(2-
15)	
4.5	(2-
11)	
2(2-5.5)	 0.312	 0.000	
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A	 radiological	 prediction	 of	 the	 organ	 of	 origin	 of	 PC	 was	 therefore	 possible	 in	 400	
(97.3%)	 patients,	 and	 of	 these	 surgical	 resection	 was	 completed	 in	 281,	 allowing	
correlation	 with	 histology.	 Among	 these	 patients	 244	 diagnoses	 of	 pancreatic	 (127),	
ampullary	 (65),	 bile	 duct	 (45)	 or	 duodenal	 cancer	 (7)	 were	 made	 by	 histological	
examination.	In	addition	in	37	patients	alternative	diagnoses	were	made	including	tubulo-
villous	adenoma	(15),	pancreatitis	(10),	renal	metastases	(4),	neuro-endocrine	tumour	(6),	
gastro-intestinal	 stromal	 tumour	 (1)	 and	 gallstones	 (1).	 Correlation	 of	 the	 radiological	
prediction	of	tumour	origin	with	the	findings	on	pathological	examination	after	resection	
is	shown	in	Table	6.16.	
N=244	 Consensus	Radiological	prediction	(244)	
Final	 pathological	
diagnosis	
Pancreas	
(140)	
Ampulla	
(60)	
Bile	duct	(37)	 Duodenum	(7)	
Pancreas	(127)	 113	 6	 7	 1	
Ampulla	(65)	 6	 48	 8	 3	
Bile	duct	(45)	 17	 5	 22	 1	
Duodenum	(7)	 4	 1	 0	 2	
PPV	 0.81	 0.8	 0.59	 0.28	
NPV	 0.86	 0.91	 0.89	 0.98	
Accuracy	(%)	 83.2	 88.1	 84.4	 	
	
Table	6.16	Correlation	of	radiological	prediction	of	tumour	origin	based	on	independent	
reporting	by	three	radiologists	with	pathological	outcome	in	244	patients	undergoing	
resection	for	malignant	tumours,	Observed	agreement	=0.758,	kappa=0.6	(0.51-0.68)	
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6.4.5 Discussion	
The	 main	 findings	 of	 this	 study	 are	 that	 the	 radiological	 features	 within	 the	
pancreatic	 head	 in	 cases	 of	 suspected	 peri-ampullary	malignancy	 used	 in	 the	 radiology	
reporting	template	vary	widely	in	frequency	depending	on	the	organ	of	origin	of	the	peri-
ampullary	tumour,	and	collective	evaluation	of	these	features	allows	an	estimation	of	the	
organ	of	origin	of	the	tumour	in	the	majority	of	cases	(97%).	Radiologists’	performance	in	
reporting	these	individual	features	varied	(kappa	0.2	-0.63),	with	a	median	kappa	value	of	
0.35	 (fair	 agreement).	Better	 agreement	 in	making	 an	overall	 assessment	of	 the	 tumour	
organ	of	origin	(kappa	=0.51)	was	noted,	suggesting	that	information	from	many	sources	
was	used	in	determining	this	opinion.	Where	agreement	or	majority	opinion	was	reached	
by	radiologists	a	high	degree	of	accuracy	was	noted	in	the	prediction	of	all	tumour	types	
except	duodenal	cancer,	with	a	good	level	of	concordance	noted	between	radiological	and	
pathological	 opinions	 (agreement=	 0.758,	 Kappa=0.6,	 CI=0.51-0.68).	 The	 PPV	 of	
radiological	estimation	was	highest	for	pancreatic	cancer	(0.84)	and	lowest	for	duodenal	
cancer	(0.4).		
This	 surgical	 series	 has	 reported	 a	 similar	 distribution	 of	 cases	 of	 pancreatic	
(45%),	ampullary	(22%),	bile	duct	(16%)	and	duodenal	(7%)	cancer	as	other	studies	(459,	
460).	The	proportion	of	patients	with	benign	disease	 is	also	 similar	 to	other	work	 (461,	
462).	Distinguishing	between	 these	malignant	 tumour	origins	has	not	previously	been	a	
clinical	or	radiological	priority,	as	the	mainstay	of	treatment	has	been	surgical	resection,	
which	 is	 undertaken	 in	 a	 similar	 fashion	 regardless	 of	 the	 final	 diagnosis.	 Increasingly	
however	 neoadjuvant	 treatment	 is	 being	 used	 to	 downsize	 tumours	 (463,	 464)	 and	 to	
improve	post-operative	survival	(465-467),	and	this	treatment	may	be	better	targeted	at	
the	 specific	 tumour	 of	 origin.	 Gemcitabine	 and	 platinum-based	 neo-adjuvant	
chemotherapy	has	been	used	in	cases	of	PC	(468)	as	these	treatments	have	been	evaluated	
as	adjuvant	chemotherapy	in	the	three	main	tumour	types	(466,	467)	However	differences	
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in	agent	effectiveness	when	used	in	the	adjuvant	and	neo-adjuvant	settings	has	been	noted	
(469)	and	evaluation	of	novel	neoadjuvant	therapies	stratified	according	to	tumour	origin	
may	reveal	differences	in	effectiveness..	
		 In	blinded	re-reporting	of	CT	images	many	radiological	features	were	detectable	in	
a	 significantly	 different	 proportion	 according	 to	 tumour	 type	 (Table	 6.14).	 Three	 main	
themes	were	noted:	
1) Tumour	 visibility	 (p=0.0001)	 and	 location	 within	 the	 parenchyma	 of	 the	
pancreatic	 head	 (p<0.0001)	 were	 strongly	 associated	 with	 pancreatic	 cancer.	
When	 visible	 however	 the	 tumour	 size	 did	 not	 differ	 between	 the	 three	 tumour	
types.		
2) Radiological	 evidence	 of	 local	 invasion	 was	 most	 commonly	 seen	 into	 the	
duodenum,	and	was	strongly	associated	with	ampullary	cancer	(p<0.0001).	
3) Dilation	 of	 the	 common	 bile	 duct	 without	 dilation	 of	 the	 pancreatic	 duct	 was	 a	
more	common	feature	of	bile	duct	and	duodenal	cancer	(=<0.0001).	
Other	 imaging	 characteristics	 of	 the	 individual	 tumour	 types	 were	 also	 noted.	
Despite	 commonly	 being	 reported	 as	 sclerosing	 tumours	 one-third	 of	 distal	 bile	 duct	
tumours	 were	 present	 as	 a	 visible	 mass,	 which	 was	 most	 commonly	 seen	 within	 the	
pancreatic	parenchyma,	 rather	 than	 localised	 to	 the	 intra-pancreatic	distal	 common	bile	
duct.	Although	common	bile	duct	enhancement	and	abrupt,	rather	than	tapering	bile	duct	
strictures,	have	previously	been	associated	with	bile	duct	tumours	(375,	470,	471),	these	
observations	did	not	reach	significance	in	this	study	(p=0.089	and	0.102	respectively),	and	
were	 also	 commonly	 noted	 in	 pancreatic	 and	 ampullary	 tumours.	 Venous	 invasion	was	
noted	 rarely	 but	 was	 seen	 in	 ampullary	 (3.4%)	 and	 bile	 duct	 cancer	 (7.1%)	 as	 well	 as	
pancreatic	cancer	(13%).	The	highest	degree	of	concordance	noted	was	in	the	reporting	of	
arterial	 invasion	 (0.63).	Very	 few	of	 these	 cases	were	however	 resectable	 at	 the	 time	of	
surgery	 to	 allow	 correlation	 with	 histology	 so	 no	 comment	 can	 be	 made	 regarding	
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association	 with	 different	 tumour	 types.	 On	 six	 occasions	 (1.4%)	 tumour	 enhancement	
during	a	 vascular	 contrast	phase	was	noted	 (2	venous,	2	 arterial	 and	2	 in	both	phases).	
Two	 of	 these	 were	 shown	 to	 be	 bile	 duct	 tumours;	 one	 ampullary	 tumour,	 one	 renal	
metastasis	and	two	were	not	resected.	This	feature	has	low	value	therefore	in	determining	
tumour	origin,	although	 it	may	have	value	 in	excluding	a	diagnosis	of	pancreatic	 cancer.	
Despite	the	fact	that	histological	evidence	of	lymph	node	involvement	is	more	common	in	
pancreatic	 than	 either	 ampullary	 or	 bile	 duct	 cancer	 (472),	 radiological	 evidence	 of	
regional	lymphadenopathy	was	seen	broadly	equally	in	all	tumour	types	and	concordance	
in	reporting	this	finding	was	fair	(kappa	=0.35).	CT	scan	is	known	to	have	low	sensitivity	
in	detecting	metastases	in	normal	sized	lymph	nodes	(473,	474).	
The	association	of	the	three	main	significant	radiological	features	with	pancreatic	
(475),	ampullary	(476)	and	bile	duct	cancer	(470)	have	been	reported	previously.	These	
associations	 however	 have	 been	 described	 largely	 within	 radiology	 teaching	 resources	
and	 large-scale	 correlation	 with	 pathological	 findings	 has	 not	 been	 undertaken.	 The	
strength	of	this	study	lies	in	a	systematic	evaluation	of	their	frequency	in	a	large	series	of	
cases	of	PC	and	a	demonstration	of	their	value	in	permitting	a	determination	of	the	organ	
of	origin	of	PC.	No	previous	attempt	has	been	made	to	quantify	the	accuracy	of	radiological	
estimation	of	the	organ	of	origin	of	PC	and	our	results	demonstrate	a	high	level	of	accuracy.	
Importantly	there	is	a	discriminating	feature	for	each	of	the	most	common	tumour	types.	
Other	investigations	may	be	useful	in	differentiating	rarer	tumours.	For	example	duodenal	
tumours	 often	 a	 have	 a	 characteristic	 clinical	 presentation	 and	 can	 be	 diagnosed	 by	
endoscopy,	and	neuroendocrine	tumours	can	be	diagnosed	by	serological	tests.	Similarly	
pancreatitis	 can	present	 a	 diagnostic	 challenge	when	 a	 pancreatic	mass	 is	 noted,	 and	 in	
this	 series	 twelve	 patients	 were	 noted	 to	 have	 this	 diagnosis	 on	 final	 histology.	 The	
radiological	features	of	these	lesions	have	not	been	assessed	in	detail	as	other	clinical	and	
serological	information	contribute	to	the	assessment	of	these	patients.	
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A	 potential	 weakness	 of	 the	 study	 is	 the	 lack	 of	 quality	 control	 of	 radiological	
reporting.	Although	the	concordance	rate	between	radiologists	in	determining	radiological	
features	 was	 not	 high,	 similar	 variation	 has	 been	 noted	 in	 describing	 findings	 in	 other	
tumour	 sites	 (477,	 478).	 Comparison	with	 reporting	 of	 PC	 from	other	 centres	would	be	
very	interesting.	Only	two	radiologists	were	undertaking	re-reporting	of	the	CT	scans,	one	
of	 them	 used	 to	 be	 a	member	 of	 the	MDT	meetings,	which	 is	 another	 limitation	 of	 this	
study.	
In	summary	although	this	study	reveals	a	high	degree	of	accuracy	in	determining	
tumour	origin	radiology	cannot	currently	by	itself	provide	the	degree	of	accuracy	required	
by	 oncologists	 in	 administering	 neo-adjuvant	 treatment,	 and	 chemotherapy	 is	 rarely	
administered	based	on	radiological	evidence	alone	without	a	tissue	diagnosis	(479).	This	
area	 of	 study	 may	 become	 more	 important	 as	 the	 use	 of	 neo-adjuvant	 chemotherapy	
expands	 and	 refinements	 in	 imaging	 technology	 could	 focus	 on	 these	 areas	 to	 improve	
differentiation	of	tumour	origin.	
With	 improvements	 in	 imaging	 and	 reporting,	 along	 with	 information	 from	 other	
sources,	 in	 the	 future	 it	 should	 be	 possible	 to	 determine	 the	 organ	 of	 origin	 of	 PC	 pre-
operatively	with	sufficient	accuracy	to	guide	pre-operative	treatments.	In	clinical	practice	
other	 findings	 can	 be	 taken	 into	 account.	 For	 example	 endoscopic	 assessment	 of	 the	
duodenum	and	ampulla	are	useful	in	defining	the	origin	of	tumours	from	these	sites,	and	
elevated	serum	tumour	markers	are	more	typically	seen	in	pancreatic	cancer	(77,	480).	A	
useful	 future	study	would	be	a	prospective	evaluation	of	 the	ability	of	multi-disciplinary	
teams	 to	 assess	 the	 organ	 of	 origin	 of	 PC	 by	 combining	 radiological	 with	 clinical	 and	
biochemical	 data.	 This	 may	 allow	 the	 elaboration	 of	 a	 scoring	 system	 that	 could	 be	
validated	in	different	centres.	
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7 Conclusion	
The	provision	of	 regionalised	pancreatic	cancer	services	 into	major	centres	does	not	
adversely	 affect	 patient	 outcomes.	 In	 this	 research	 study,	 we	 noted	 although	 there	 is	 a	
significant	 variation	 in	 the	patients’	 travel	distance	across	 the	 referring	hospitals	within	
the	 cancer	 network;	 however	 the	 individual	 patient’s	 travelling	 distance	 to	 the	 regional	
centre	did	not	adversely	affect	the	outcomes.		
There	was	no	association	between	delay	to	surgery	up	to	two	months	following	the	initial	
diagnosis	 and	 the	 outcome	 in	 patients	with	 pancreatic	 or	 bile	 duct	 cancer,	 however	we	
noted	slight	survival	improvement	in	small	cohort	of	patients	with	ampullary	cancer.	
While	 evaluating	 the	 role	 of	 CT	 scan	 in	 the	 preoperative	 assessment	 of	 tumour	
resectability	 in	patients	with	PHM,	we	have	noted	 that	 there	 is	no	additional	benefit	 for	
the	use	of	 the	arterial	phase.	Also,	 it	was	noted	 that	 the	 radiological	 tumour	size	has	no	
effect	on	resectability	in	the	absence	of	vascular	involvement.	
Using	 a	 focused	proforma	 is	 a	 good	 adjunct	 in	 reporting	CT	 scan	with	 a	 good	 reliability	
predicting	the	site	of	tumour	mass	in	patients	with	suspected	PHM.	
This	 project	 highlights	 important	 aspects	 in	 the	 preoperative	 pathway	 in	 patients	 with	
PHM	as	it	supports	the	regionalisation	of	pancreatic	cancer	services	as	part	of	the	British	
Government	 policy	 and	 we	 recommend	 using	 a	 standardised	 reporting	 template	 when	
reporting	CT	scan	for	suspecting	PHM.	
We	recommend	using	a	standard	pancreatic	protocol	CT	scan	 for	all	patients	referred	to	
the	 Peninsula	 HPB	 cancer	 centre.	 We	 also	 recommend	 using	 the	 proposed	 reporting	
template	while	interpreting	the	staging	CT	scans.	For	histological	assessment	of	ampullary	
carcinoma,	 we	 recommend	 incorporation	 of	 the	 histological	 differentiation	
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(pancreaticobiliary	vs.	intestinal)	into	the	final	histological	report,	as	this	is	an	important	
factor	 to	 consider	 while	 assessing	 survival	 in	 this	 group	 of	 patients.	
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8 Appendix	
8.1 Appendix	A:	The	study	flow	chart	
	
Figure	8-1	Flow	chart	showing	details	of	patient	population	included	in	HPB	database	for	use	
in	this	study.	Different	subsets	of	this	population	were	used	for	each	specific	research	
question
 
 
 
 
 
 
 
 
 
 
  
Number of patients 
n = 494 
Duodenal cancer 
n = 7 
Neoadjuvant therapy 
n = 6 
Resections not 
involving pancreatic 
head n = 67 
Exclusion 
n = 73 
Non resected 
n = 120 
Resections 
n = 301 
Total patients included 
n = 421 
Bile duct cancer 
n = 47 
Ampullary cancer 
n = 68 
PDA 
n =138 
Others  
n = 41 
TVA   
n = 15 
Metastases 
n = 5 
Pancreatitis 
n = 12 
NET 
n = 6 
Gallstones 
n = 1 
Duodenal diverticulum 
n = 1 
 
GIST 
n = 1 
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8.2 	 Appendix	B:	Radiology	reporting	template	
Type	of	scan	 Monophasic	
Biphasic	
Triphasic	
Visible	mass	 Yes	
No	
Site	 Pancreas	 Head	
Neck	
Uncinate	
Ampulla	
Bile	duct	
Duodenum	
Tumour	Size		 (mm)	
Enhancement	
phase	
Arterial	
Venous	
Arterial	&	Venous	
None	
Enhancement	
type		
Homogenous	
Heterogeneous/	patchy	
Rim/	peripheral	
Local	invasion	 Stomach	
Duodenum	
Transverse	colon	
Adrenal	
Pancreatic	and	
Common	bile	
duct	diameter		
(mm)	
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Bile	duct	wall	
enhancement	
Yes	
No	
Bile	duct	wall	
changes	
Tapering	
Abrupt	
Thickening	
None	
Calcifications	 Yes	 Ductal		
Parenchymal	
No	
Lymph	nodes	
Enlargement				
(I.e.	>	10	mm	in	
transverse	axis)	
Yes	 Anterior	
Posterior	
Superior	
Inferior	
No	
Arterial	vascular	
invasion	(HA,	
SMA,	Coeliac	
Trunk)	
Grade	0	
Grade	1	
Grade	2	
Venous	vascular	
invasion	(PV,	
SMV)	
	
	
Table	8.1	Radiology	reporting	proforma
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8.3 Appendix	C:	Recorded	data	included	in	the	study	
Preoperative	
• Age		 • Gender	 Male	
Female	
• Referring	Hospital	(A-E)	 • ASA	grade	 1	
2	
3	
4	
• Jaundice	at	
presentation	
Yes	 • DM	 Yes	
No	 No	
• Biliary	stent	 Yes	 • CT	scan	findings	(see	reporting	
template)	
No	
• Travel	distance	to	regional	centre	 • Interval	to	surgery	(Median	and	
range)	
Operative	
• Resectability	 Yes	 • Reason	for	
non-resection	
Local/vascular	
invasion	
No	 Metastatic	
disease	
Postoperative	
• Histological	
tumour	type		
Pancreatic	
adenocarcinoma	
• Lymph	node	
involvement	
Yes	
Ampullary	
carcinoma	
Bile	Duct	cancer	 No	
Duodenal	cancer	
Others	
• Resection	
margin	
involvement	
Yes	 • Survival	time	
No	
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Abstract
Background: Centralisation of specialist surgical services requires that patients are referred to a regional centre for
surgery. This process may disadvantage patients who live far from the regional centre or are referred from other
hospitals by making referral less likely and by delaying treatment, thereby allowing tumour progression. The aim of
this study is to explore the outcome of surgery for peri-ampullary cancer (PC) with respect to referring hospital and
travel distance for treatment within a network served by five hospitals.
Methods: Review of a unit database was undertaken of patients undergoing surgery for PC between January 2006
and May 2014.
Results: 394 patients were studied. Although both the median travel distance for patients from the five hospitals
(10.8, 86, 78.8, 54.7 and 89.2 km) (p < 0.05), and the annual operation rate for PC (2.99, 3.29, 2.13, 3.32 and 3.07 per
100,000) (p = 0.044) were significantly different, no correlation was noted between patient travel distance and
population operation rate at each hospital. No difference was noted between patients from each hospital in terms
of resection completion rate or pathological stage of the resected tumours. The median survival after diagnosis for
patients referred from different hospitals ranged from 1.2 to 1.7 years and regression analysis revealed that
increased travel distance to the regional centre was associated with a small survival advantage.
Conclusion: Although variation in the provision and outcome of surgery for PC between regional hospitals is
noted, this is not adversely affected by geographical isolation from the regional centre.
Trial registration: This study is part of post-graduate research degree project. The study is registered with
ClinicalTrials.gov (unique identifier NCT02296736) November 18, 2014.
Keywords: Ampulla, Bile duct, Pancreatic, Cancer, Centralized hospital services
Background
Since publication of the Improving Outcomes Document
in September 2000 [1] surgery for periampullary cancer
(PC) in the UK has been centralised into designated
regional Hepato-Pancreatico-Biliary (HPB) centres, each
serving a population of approximately two million. This
process requires that most hospitals do not undertake
pancreatic resection, but perform the initial treatment
and assessment of patients with potential PC, before re-
ferral to the regional tertiary centre. This separation of
secondary from tertiary care in different hospitals has
the potential to disadvantage patients referred from
hospitals other than the regional centre, as the referral
process is likely to be more complex than when sec-
ondary and tertiary care are provided on the same site.
Inevitably provision of pancreatic surgical services in a
single HPB centre within a large area will impose
greater difficulty and inconvenience for some patients
in travelling to the regional centre, which may adversely
affect referral for treatment for patients with PC.
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Furthermore delays in treatment for patients residing
further from the regional centre may allow tumour pro-
gression and have an adverse effect on outcomes.
The potential influence of referral between hospitals
and geographical isolation on the outcome of surgery for
PC has not been assessed and the aim of this study is to
assess associations between referring hospital of origin
and traveling distance to the regional HPB surgical
centre with the population rate of surgery for PC, the
interval to surgery, pathological outcome and long-term
survival after diagnosis of PC within a cancer network.
Methods
The Peninsula HPB unit provides pancreatic surgical
services to the Peninsula Cancer Network, which serves
the largely rural UK counties of Devon and Cornwall,
ranking the 7th and 12th least densely populated of 90
English local government areas [2]. The population of
the two counties (1.67 million) is served by four hospi-
tals providing secondary care only, and one hospital
which provides secondary care and also hosts the re-
gional tertiary HPB surgery centre. Surgery and imme-
diate post-operative care are provided by the regional
centre. All other treatment including stent insertion,
adjuvant chemotherapy and long-term follow-up are
provided by local hospitals. All hospitals are linked by a
weekly audio-visual MDT with the regional centre. Re-
ferral and transfer of patients follows agreed protocols
and is coordinated by nurse specialists.
Details of a consecutive series of patients having sur-
gery at the Peninsula HPB unit between January 2006
and May 2014 were studied. Demographic, operative
and pathology data were retrieved from the unit data-
base. Included patients were those who underwent sur-
gery for PC where final histology revealed a diagnosis
of pancreatic, ampullary, distal bile duct or duodenal
adenocarcinoma, or those where resection could not be
completed and intra-operative biopsy confirmed the
presence of adenocarcinoma. Patients receiving neo-
adjuvant chemotherapy were excluded. The size of the
catchment area served by each of the hospitals in the
Peninsula was obtained from South West Public Health
Observatory [3]. The travel distance by road for each
patient was obtained from the AA mileage calculator
(with permission) using post-code data [4]. The interval
to surgery was calculated from the date of diagnosis of
PC, which was taken as the date of the first cross-
sectional abdominal imaging which suggested this diag-
nosis. The presence of biliary obstruction was defined
as either clinically evident jaundice at the time of surgery
or the requirement for pre-operative biliary drainage. Pre-
operative diabetes was defined as the requirement for
hypoglycaemic medication. The workload in the HPB sur-
gical centre is shared non-selectively by four surgeons and
is undertaken using standardised techniques, and in-
patient care follows a standard protocol. The American
Society of Anaesthesiologists (ASA) grade was determined
at the time of surgery by the responsible anaesthetist.
Resected specimens were analysed according to Royal
College of Pathologists guidelines [5] and the TNM
classification systems [6] was used to describe patho-
logical stage. Survival data were obtained from hospital
and general practice records and included all deaths oc-
curring after surgery, including in-hospital mortality.
Survival times were calculated to include the interval
prior to surgery and therefore were taken from the date
of the first cross-sectional image which raised the
suspicion of PC. Survival data for the whole group of
patients referred from each hospital is given as single
outcome of interest and is reported as median and
range. Follow-up was completed 1st May 2015.
Differences in demographics, operation rates, travel
distance, interval to surgery and pathology outcome
were compared between hospitals (pathology results for
patients with duodenal cancer were not included due to
low numbers). Difference in discrete variables was
assessed by Pearson Chi square test and continuous vari-
ables by Kruskal-Wallis test. Correlation was assessed by
Spearman correlation coefficient. To explore potential
associations with patient survival a Cox regression ana-
lysis of pre-operative factors including age, gender, ASA
grade, travel distance and the presence of biliary ob-
struction at presentation was undertaken. In addition,
patient survival across five hospitals was compared using
Kaplan–Meier survival curves and between hospital
pairs by Cox regression analysis.
Results
During the study period 394 patients fulfilling the study
criteria underwent surgery to attempt resection of PC at
the regional HPB surgery centre (hospital A) (Fig. 1).
The median age (66.7 years, range 39.4- 86.4) and gen-
der mix (56.3% male) of the whole group did not vary
between patients referred from hospital A, or from hos-
pitals providing secondary care only (hospital B to E)
(Table 1). The number of operations for PC undertaken
as a proportion of the local population however varied
significantly between referring hospitals (Table 1). The
median distance patients were required to travel for care
was 61.4 km and was significantly less for patients re-
ferred from within the catchment area of the regional
HPB surgery centre to that for patients referred from all
other hospitals in the Peninsula. No correlation was
noted between the median travel distance to the regional
centre of patients from the referring hospitals and the
operation rate at that hospital (p = .855). The second
lowest population operation rate was noted from the
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population receiving secondary care from the hospital
hosting the regional HPB centre.
The distribution of ASA grades, the proportion of pa-
tients with diabetes, biliary obstruction at the time of
surgery and pre-operative biliary intervention did not
differ between hospitals (Table 1). The median interval
from first investigation suggesting a diagnosis of PC to
surgery was 49 days (interquartile range 34–69 days)
and was similar between referring hospitals. Correlation
analysis revealed no association between the travel
Study Group
n= 394
Resected
n= 273
Duodenal
adenocarcinoma
n= 8
(2.9%)
Unresectable at
surgery
n= 121
Bile Duct
adenocarcinoma
n= 46
(16.8%)
Ampullary 
adenocarcinoma
n= 70
(25.6%)
Pancreatic
adenocarcinoma
n= 149
(54.6%)
Fig. 1 Patients undergoing surgery for PC at Peninsula HPB Centre between January 2006 and May 2014
Table 1 Details of 394 patients undergoing surgery for peri-ampullary cancer between January 2006 and May 2014, displayed by
referring hospital of origin. Hospital A hosts the regional HPB cancer centre
Referring hospital (A) (B) (C) (D) (E) P
n = 394 (%) 111 (28.2) 97 (24.6) 70 (17.8) 74 (18.8) 42 (10.6)
Population served 464,437 368,313 410,213 278,555 171,227
Annual operation rate for PC per 100000 2.99 3.29 2.13 3.32 3.07 0.044
Median Travel Distance (kilometres) (range) 10.8 (2.4–112) 85.9 (45.2–155.8) 78.8 (10.1–130.3) 54.7 (2.4–96.2) 98.3 (63–138.6) .000
Median age (range) 65.7 (41.2–82.0) 68.4 (41.7–84.0) 65.5 (39.4–78.6) 65.6 (45.9–86.4) 70.2 (50.7–84.4) .105
Gender (% Male) 53.2 58.8 58.6 58.1 52.4 .880
ASA Grade (%) 1 8 (7.2) 8 (8.2) 8 (11.4) 7 (9.5) 0 .416
2 56 (50.5) 53 (54.6) 39 (55.7) 41 (55.4) 22 (52.4)
3 28 (25.2) 26 (26.8) 18 (25.7) 18 (24.3) 14 (33.3)
4 2 (1.8) 1 (1) 0 0 0
Missing 17 (15.3) 9 (9.3) 5 (7.1) 8 (10.8) 6 (14.3)
Diabetes Yes (%) 13 (11.7) 10 (10.3) 7 (10.0) 6 (8.1) 5 (11.9) .987
Missing data 12 (10.8) 17 (17.5) 14 (20.0) 15 (20.3) 4 (9.5)
Jaundice at Presentation (%) 91 (82.0) 82 (84.5) 56 (80) 65 (87.8) 36 (85.7) .641
Median interval to surgery (days) (range) 47 (5–551) 52 (1–459) 56.5 (16–379) 47 (16–246) 51.5 (6–477) .108
Resection completed (%) 73 (65.7) 68 (70) 51 (72.8) 51 (68.9) 30 (71.4) .880
30-day mortality (%) 4 (3.6) 1 (1) 2 (2.8) 1 (1.3) 2 (4.7) .610
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distance to the regional HPB surgery centre and the
interval to surgery (p = .15). In-patient 30-day mortality
occurred in 10 (2.5%) patients and did not differ be-
tween hospitals.
Tumour resection was completed in 273 patients
(69.3%) and the completion rate did not differ between
hospitals (Table 2). In 121 patients the tumour was inop-
erable at the time of surgery either due to the presence
of vascular invasion (70) or distant metastases (47). In
four patients the reason for irresectability was not re-
corded. Histological diagnoses of the resected specimens
are shown in Fig. 1. Analysis of pathological outcomes
revealed no difference between patients from the referral
zone of the regional centre and those from other hospi-
tals in the region, in terms of resection completion rate,
tumour size, nodal status and resection margin status
(Table 2). Similarly the distribution of the main diagno-
ses of PC did not differ between patients from the re-
gional centre and those from other hospitals.
After a median follow-up of 4.5 years (1.3–9.5 years)
the median survival (range) of the study group was
1.45 (0.11 – 9.4) years and was similar in males (1.44,
0.13–9.3 years) and females (1.45, 0.11–8.7 years).
Two patients were lost to follow-up. Survival was
greater in patients where resection was completed
(1.85, 0.14–9.4 years) than in those where the tumour
could not be removed (0.9, 0.11–2.8 years). The me-
dian survival of patients travelling more than the me-
dian distance for treatment was 1.5 (0.14–8.7) years
compared to 1.4 (0.11–9.4) years for those travelling less
than the median travel distance (p = 0.234). Cox regression
analysis of the association of pre-operative variables in-
cluding individual patient travel distance however revealed
a significant survival advantage associated with increased
travel distance to the regional HPB centre (Table 3).
Further survival analysis revealed that the referring
hospital of origin was associated with outcome (Fig. 2),
with median survival ranging from 1.2 (0.14–6.4) years
(patients from hospital D) to 1.5 (0.3–8.8) years (patients
from hospital B). Pair by pair regression analysis com-
paring patients from the catchment area of the regional
HPB centre revealed no difference in survival from diag-
nosis for patients from three hospitals C, D and E, but
confirmed the significantly decreased hazard ratio of
death of patients referred from hospital B (Table 4).
Discussion
The main findings of this study are: 1) within the Penin-
sula Cancer Network the population operation rate for
PC varies significantly between hospital catchment areas
but this variation is not related to travel distance to the
regional HPB surgical centre and 2) individual patient
travel distance to the regional centre does not adversely
affect the time to surgery, pathological outcome or sur-
vival in patients with PC and 3) the provision of second-
ary and tertiary care in different hospitals does not
adversely affect patient outcomes.
Table 2 Histopathological stage for 265 patients undergoing resection of pancreatic, ampullary and distal bile duct cancer at the
regional HPB centre (A) displayed by referring hospital of origin
N = 265 A
111
B
97
C
70
D
74
E
42
P
Pancreatic cancer (n = 149) 40 38 22 28 21
T size (mm) (range) 30 (15–48) 31.50 (16–60) 30.5 (15–70) 32.5 (12–50) 30 (18–65) .620
N1disease (%) 35 (87.5) 33 (86.8) 19 (86.4) 23 (82.1) 17 (81) .940
R1 resection (%) 34 (85) 24 (63.1) 18 (81.8) 24 (85.7) 19 (90.5) .052
Ampullary cancer (n = 70) 21 18 12 13 6
T size (mm) (range) 25 (12–80) 22.5 (5–65) 23.5 (15–60) 22 (11–65) 28 (8–50) .933
N1disease (%) 14 (66.6) 10 (55.5) 6 (50) 5 (38.5) 4 (66.6) .551
R1 resection (%) 7 (33.3) 1 (5.5) 2 (16.6) 2 (15.4) 2 (33.3) .230
Bile duct cancer (n = 46) 10 10 13 10 3
T size (mm) (range) 25.5 (10–70) 27 (10–45) 25 (10–40) 20 (12–50) 15 (12–20) .216
N1disease (%) 7 (70) 7 (70) 4 (30.7) 7 (70) 1 (33.3) .172
R1 resection (%) 5 (50) 6 (60) 5 (38.5) 5 (50) 2 (66.6) .839
Table 3 Cox regression analysis of potential association of pre-
operative factors including travel distance to regional HPB
centre with survival after diagnosis for 394 patients undergoing
surgery for periampullary cancer
Hazard Ratio Lower .95 Upper .95 P-value
Gender 0.956 0.744 1.229 0.728
Age 1.009 0.995 1.022 0.217
Distance (km) 0.996 0.993 0.999 0.029
Jaundice 0.967 0.686 1.364 0.852
ASA 1 vs 2 0.945 0.678 1.317 0.739
2 vs 3 & 4 1.117 0.888 1.407 0.344
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Centralisation of pancreatic surgical services has led
to improved outcomes including higher resection rates
[7, 8], lower operative mortality [9, 10] and improved
long-term survival [11]. Similar improvements with cen-
tralisation have been noted for liver [12], oesophageal [13],
complex urological [14] and vascular surgery [15]. Despite
these findings the population benefits of regionalisation
are more difficult to demonstrate. Although studies
using hospital data have demonstrated improved out-
comes associated with centralisation of surgical services
for patients who receive treatment [8, 16, 17], these
studies may be biased by selection of patients at the
regional centres and do not take into account patients
who are not referred for treatment. Studies demonstrat-
ing improved population outcomes as a result of re-
gionalisation of complex surgery are more difficult to
undertake. The potential disadvantages of centralisation
of services include a more complex referral pathway
when secondary and tertiary care are provided in differ-
ent hospitals, and an increased burden of travel for
patients living further from the centre, which may dis-
courage referral and attendance for treatment. These
consequences of centralisation have been noted [18, 19]
and the potential risk is greatest in areas of dispersed
population. This has led to controversy over the imple-
mentation of centralisation of surgical services in rural
communities [20], where the risk of limitation of access
due to distance may outweigh the benefit of improved
technical outcomes. The observation that operation
rates are not adversely affected by distance to the HPB
surgical centre, or by referral from a different hospital,
and that travel distance itself does not influence the
outcome of surgery for PC are important, as they show
that regionalisation of surgical services does not neces-
sarily lead to limitations in access or increased patient
selection at the HPB surgical centre.
The small variation in operation rate noted between
hospitals may reflect differences in levels of comorbidity
and suitability for surgery, but may be due to different re-
ferral practices within each hospital. The observation that
the referring hospital of origin is also associated with
long-term survival after surgery for PC is therefore an in-
teresting new finding. Many factors contribute to variation
in local survival rates and levels of comorbidity are likely
to play a major role. It is interesting to note however that
long-term survival is lowest in patients from the hospital
with the highest population rate of surgery for PC. This
may result from referral of more marginal cases, which is
not revealed by the measures of comorbidity and tumour
burden used in this study. Variation in population oper-
ation rate for PC may also explain some of the variation
noted in outcome between high-volume hospitals under-
taking pancreatic surgery [21].
The strength of this analysis lies in the accurate collection
of individual travel distance to the regional HPB surgery
centre in a large consecutive series, and its correlation with
prospectively audited outcomes. In this study a single
measure of survival of all patients has been used, without
division by diagnosis, to allow simple comparison between
hospitals. This figure includes deaths due to surgical com-
plications, which accounts for the short survival in some
patients. A weakness of the study lies in the characterisa-
tion of comorbidity. A more discriminating scoring system
is required to investigate the potential association of co-
morbidity with variations in population operation rate for
PC. The relatively long median interval to surgery noted in
this study, even for patients with biliary obstruction
(47 days), is accounted for by the increasing complexity in
the patient pre-operative pathway. This pathway however
imposes a similar interval to surgery on patients regardless
of geographical isolation from the regional centre. In a
small number of patients a long interval to surgery was due
Number at risk
hospital/years 0 2 4 6 8
A 111 37 9 7 4
B 97 38 18 7 2
C 70 30 13 7 2
D 74 17 4 1 0
E 42 18 6 1 0
Fig. 2 Survival from diagnosis of 394 patients undergoing surgery
for periampullary cancer at Peninsula HPB surgery centre between
January 2006 and May 2014, according to hospital of referral (p = 0.032)
Table 4 Paired regression analysis of association of hospital of
referral (B to E) with survival compared to referral from Hospital
A among 394 patients undergoing surgery for peri-ampullary
cancer
A vs Hazard Ratio Lower .95 Upper .95 P-value
B 0.6934 0.5011 0.9594 0.0271
C 0.7042 0.4952 1.0013 0.0508
D 1.1121 0.7983 1.5493 0.5299
E 0.8228 0.5435 1.2456 0.3565
The data bolded shows a significant findings
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to investigations being undertaken in patients with self-
resolving jaundice, which was not pursued due to patient
improvement.
Conclusion
This study confirms that centralisation of HPB surgical ser-
vices can be implemented without imposing disadvantage
in surgical outcomes on patients due to travel distance to
the HPB surgical centre or referral between hospitals for
treatment.
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Assessment of the effect of interval from presentation to
surgery on outcome in patients with peri-ampullary
malignancy
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PL6 8BU, and 3School of Science and Technology, Nottingham Trent University, Nottingham, NG1 4BU, UK
Abstract
Background: Delay between diagnosis of peri-ampullary cancer (PC) and surgery may allow tumour
progression and affect outcome. The aim of this study was to explore associations of interval to surgery
(IS) with pathological outcomes and survival in patients with PC.
Method: A database review of all patients undergoing surgery between 2006 and 2014 was undertaken.
IS was measured from diagnosis by imaging. Potential association between IS and survival was
measured using Cox regression analysis, and between IS and pathological outcome with multivariate
logistic analysis.
Results: 388 patients underwent surgery. The median IS was 49 days (1–551 days), and was not asso-
ciated with any of the evaluated outcomes in patients with pancreatic (149) or distal bile duct (46) cancer.
For patients with ampullary cancer (71) longer IS was associated with improved survival, with median
survival of 27.5months for patients waitingmedian IS (35) and 38.3months for patients waiting >median
IS (36) for surgery (p = 0.041). A higher rate of margin positivity (31.4%)was also noted among patients who
waited less than the median IS compared to those waiting longer than this interval (11.4%) (p = 0.032).
Conclusion: For patients with ampullary cancer there is a paradoxical improvement in outcome among
those with a longer IS, which may be explained by progression to inoperability of more aggressive
lesions.
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Introduction
Peri-ampullary cancer (PC) most commonly originates within
the pancreas, the distal common bile duct, or the duodenal
ampulla. The organ of origin of PC is usually determined by
pathological examination after resection and has important
implications for prognosis. Five-year survival after surgical
resection varies from 6.5%–20% for pancreatic cancer,1–7
19.2%–30% for bile duct cancer1,3,5,6,8,9 and 33%–45% for
ampullary cancer.1,3,5,6 For many patients their disease is
inoperable at the time of presentation due to local invasion or the
presence of distant metastases. For those with operable tumours
there will usually be an interval between radiological diagnosis
and surgery, to allow referral, assessment and operative planning.
In England, the National Cancer Plan stipulates a maximum
interval of 62 days from primary referral to treatment for most
solid cancers,10 although this figure is not based on evidence of
safety for each tumour type. Tumour progression may take place
during this interval, rendering tumours inoperable and long-
term survival may potentially be affected.
Within any patient cohort there is likely to be a range of in-
tervals between diagnosis and surgery, with some patientsThe abstract was presented at the World Pancreatic Forum, Bern,
Switzerland 18–19 June 2015.
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undergoing surgery very quickly, and some waiting many
months. As PC is an aggressive malignancy, this period may
constitute a significant part of the natural history of the disease.
Analysis of the potential association of interval to surgery with
pathological and surgical outcomes may reveal aspects of the
behaviour of these tumours, and determine if the 62 day target to
surgery disadvantages patients by allowing tumour progression.
This study aimed to investigate the interval to surgery in a
consecutive series of patients undergoing surgery with the
intention to resect PC and to explore the association of IS to
resectability, tumour stage and overall survival.
Material and methods
Review of a prospectively maintained database of consecutive
patients undergoing surgical exploration for suspected PC be-
tween January 2006 and May 2014 was undertaken. Referrals
came from five hospitals in a cancer network with a population
of 1.7 million. The study cohort included patients with a histo-
logical diagnosis of pancreatic, bile duct or ampullary cancer, or
those where the tumour was unresectable and biopsy confirmed
the presence of adenocarcinoma. Patients receiving neoadjuvant
chemotherapy were excluded. No patients were excluded from
surgery due to disease progression in the interval between
referral and surgery. Demographic and clinical data were
retrieved. Pre-operative biliary obstruction was defined as any
abnormality in liver function tests sufficient to prompt investi-
gation by cross sectional imaging. As the time of receipt of the
initial referral is variable and subject to administrative delays, the
interval to surgery (IS) was measured from the date of the first
imaging modality undertakenwhich raised the possible diagnosis
of PC to the time of the surgical intervention, by review of in-
dividual radiology records. Surgical resection was performed by a
classic Whipple resection with reconstruction by pancreatico-
gastrostomy. Pathological reporting was undertaken according
to Royal College of Pathologists guidelines11 with axial slicing of
the resection specimen. Tumours were classified according to
histological origin (pancreatic, bile duct or ampullary) and nodal
status and margin involvement status were retrieved from his-
tology reports.
Continuous variables were compared with Kruskal–Wallis test
and categorical variables by Chi square test. The mean and
variance of tumour size across different tumour types were
compared using Bayesian double generalised linear models.
Dates of death were determined by access to General Practice
records and survival times calculated from the time of diagnosis.
Kaplan–Meier survival analysis and Cox Proportional Hazard
models were used to assess the effect of interval to surgery on
post-operative survival. Multivariate logistic regression models
were then used to explore potential associations between pre-
operative variables including IS as a binary variable (<
or  median) with histological tumour stage.
Results
388 patients (223 (57%) males) with a median (range) age 67
(41–86) years fulfilling the study criteria underwent surgical
exploration during the study period and resection was completed
in 266 patients (69%). In 122 (31%) patients the tumour was
found to be inoperable due to local invasion of vascular struc-
tures (n = 70 (57%)) or the development of distant metastases
(n = 47 (63%)). Operative details could not be retrieved in three
(1%) patients, tumour mass could not be identified in one pa-
tient and one patient did not tolerate surgery. Lateral resections
of a small venous patch were undertaken in 32 (12%) patients.
The median IS for 388 patients was 49 (1–551) days, and was
similar in groups undergoing resection (49 days, range 1–551) or
surgical exploration only (50 days, range 11–512) (p = 0.940).
Table 1 Interval to surgery and pathological outcome among 266 patients undergoing resection of peri-ampullary cancer
n [ 266 (%) Cancer Origin p
Pancreas n [ 149 (56%) Bile duct n [ 46 (17%) Ampulla n [ 71 (27%)
Median age (range) 67.9 (41.3–82.1) 65.7 (43.7–84.1) 66.2 (411.2–86.4) 0.312
Gender (% male) 55 69.6 53.5 0.171
ASA (%) 1 6 (4) 4 (8.7) 9 (12.7) 0.056
2 84 (56.4) 22 (47.8) 42 (59.2)
3 44 (29.5) 15 (32.6) 14 (19.7)
4 1 (0.7) 0 0
Missing 14 (9.4) 5 (10.8) 6 (8.4)
Median IS (range) (days) 48 (1–551) 50 (5–294) 51 (14–477) 0.881
Median tumour size (range) (mm) 30 (12–70) 22 (10–70) 25 (5–80) 0.002
Involved lymph nodes (%) 127 (85.2) 26 (56.5) 40 (56.3) 0.0001
Involved resection margin (%) 119 (79.9) 23 (50) 15 (21.1) 0.0001
30 day post-operative mortality 3 (2) 0 3 (4.2) 0.275
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The IS in 331 patients (85.3%) with biliary obstruction at the
time of initial presentation was 47 days (1–512) compared to 69
(14–551) in those without this complication (p = 0.001).
Pancreatic tumours were noted to be larger than both ampullary
and bile duct tumours (Table 1). In regression analysis the
variance in size of ampullary tumours was noted to be greater
than both pancreatic tumours (coefficient = −1.075; credible
interval −1.441 to −0.704) and bile duct tumours (coeffi-
cient = −0.63; credible interval −1.096 to −0.165).
After minimum follow-up of 12 months the median survival
(range) from diagnosis of the whole cohort was 17.2 months
(1.4–114.6) and was significantly longer in patients undergoing
surgical resection (23.7 months, range 1.5–114.6) compared to
those having surgical exploration only (11.2 months, range
1.4–75.7) The median survival (range) of patients undergoing
resection of pancreatic, bile duct and ampullary cancer was 17.3
(1.5–114.6), 28.1 (5.8–104) and 33.3 (2.1–107.1) months
respectively. No patients were lost to follow-up. Pre-operative IS
was not associated with survival for patients undergoing resec-
tion of pancreatic or bile duct cancer, but a positive association
was noted for patients with ampullary cancer (Fig. 1). Cox
regression analysis of survival data confirmed the reduced hazard
of death associated with a longer IS in patients with ampullary
cancer only (Table 2). Multivariate analysis of potential associ-
ations between pre-operative factors and histological outcomes
and survival confirms the reduced risk of positive resection
margin in patients with a longer interval to surgery (Table 3).
The proportion of ampullary cancer specimens removed within
less than the median IS (49 days) with involved margins was
31%, compared to 11.4% among those removed after this in-
terval from diagnosis (p = 0.032). An association between
tumour size with age and female gender is also noted (Table 3).
Discussion
Patients with PC may suffer significant delays between presen-
tation and surgery. This may be contributed to by the vague
nature of symptoms at the time of presentation,12,13 the need for
biliary drainage,14 delays incurred during referral to regional
centres and capacity issues restricting access to operating time.
Because of perceived delays in the treatment of cancer cases NHS
guidelines introduced a target of 62 days from referral to treat-
ment for most solid tumours in 2000.10 Concerns may be raised
that this delay will reduce the operability of the pancreatic head
Figure 1 Survival curves of patients undergoing pancreatic head
resection for a) pancreatic (149), b) bile duct (46) and c) ampullary
cancer (71), divided into subsets determined by the median interval to
surgery from initial investigation. p = 0.419, 0.321 and 0.043*
respectively
Table 2 Cox regression analysis of association of interval to surgery
with survival of patient cohorts, determined by tumour origin
Tumour type Hazard Ratio 95% confidence p
Pancreas (149) 0.679 0.314–1.467 0.324
Bile duct (46) 0.855 0.584–1.251 0.419
Ampulla (71) 0.506 0.259–0.991 0.047*
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lesion, allow tumour progression and impair long-term survival.
The main finding of this study is that no association is noted
between delay to surgery and any outcome in patients with
pancreatic or distal bile duct cancer, but that a longer interval to
surgery is paradoxically associated with improved outcome in
patients with ampullary cancer. A proportional increase in sur-
vival is noted with each extra months delay prior to surgery
associated with a hazard ratio of death of 0.55 after surgical
resection. In corroboration of this finding the chance of an
involved resection margin is also reduced for patients with
ampullary cancer who wait longer for surgery.
In this series a high percentage of resected patients were shown
to have ampullary cancer (26%). This is consistent with the
adoption of a standardised pathological reporting protocol,
which has led to higher rates of diagnoses other than pancreatic
cancer in peri-ampullary malignancy.15,16 PC usually presents
with biliary obstruction caused by mass effect and operability is
determined by the sequence of invasion, as vascular invasion is a
major cause of irresectability.17–19 Lesions of the ampulla lie
furthest from the vascular structures and may be less likely to be
inoperable than lesions of the pancreatic parenchyma, which
encases the junction between superior mesenteric and portal
vein. Surgery is offered to patients who do not have invasion of
vascular structures or distant metastases detected on pre-
operative imaging, though these findings are often encountered
at the time of surgery. This may be caused by understaging by CT
scan20 or by tumour progression in the interval to surgery, which
is more likely in aggressive tumours. These results suggest that
for pancreatic and bile duct tumours the timing of surgery in
relation to pre-operative imaging within the range measured in
the study has no effect on resectability, tumour stage or survival
after diagnosis. This implies that the operative findings and
surgical outcome are determined before imaging takes place and
these tumours change little in the interval to surgery. For
ampullary tumours however it appears that a longer wait for
surgery results in selection of a subset of patients whose tumours
remain resectable, with better prognostic characteristics, as
shown by the reduced risk of an involved resection margin and
improved long-term survival. This may be explained by the
progression of a more aggressive subset of ampullary tumours in
the interval to surgery leading to inoperability. This more
aggressive subset probably includes older patients, in whom
resected ampullary tumours are shown to be larger. In support of
this concept we have noted a greater variance in size of ampullary
tumours than pancreatic and bile duct tumours. Less aggressive
ampullary tumours remain confined to the region of the ampulla
while others progress to invade vascular structures. As ampullary
tumours are located a greater distance from the vascular struc-
tures than pancreatic and bile duct tumours they are likely to
cause vascular obstruction as a relatively delayed event compared
to biliary obstruction. Results for the whole cohort however do
not show an association between interval to surgery and
resectability. It is probable that the small proportion of patients
with ampullary cancer who progress to inoperability is masked in
the larger group of patients with pancreatic and bile duct cancer,
where IS is shown to have no effect on resectability and outcome.
In the event of inoperability usually a biopsy is taken and the
presence of malignancy confirmed. Determining the organ of
origin in this situation is difficult however, as this requires ex-
amination of the spatial relationship of periampullary lesions.11
Histological tissue stains have low specificity in determining
precise tumour phenotype.21 Usually in this situation a diagnosis
of adenocarcinoma is made and patients often referred for
palliative treatment with chemotherapy targeted at pancreatic
cancer. Our results provide indirect evidence that among this
patient group there will also be patients with ampullary cancer
which has progressed to involve vascular structures.
A potential weakness of this study is the variable timing of the
initial imaging. Often this was performed after the development
of progressive jaundice, so there was an uninterrupted time line
from presentation to surgery. In some patients however an initial
presentation with spontaneously resolving biliary obstruction
was investigated which revealed potential PC, but the issue was
not taken forward due to clinical improvement. This presenta-
tion accounts for the very long IS in some patients. Although
spontaneously resolving biliary obstruction has been reported
Table 3 Multivariate analysis of potential associations with tumour size, nodal status and resection margin status among 71 patients un-
dergoing resection of ampullary cancer
Tumour Size Nodal status Resection margin status
Coefficient 95% Confidence
Interval
p Odds
Ratio
95% Confidence
Interval
p Odds
Ratio
95%
Confidence Interval
p
Interval to
surgery
(</> 49)
−0.14 −0.403 0.123 0.232 0.604 0.221 1.654 0.326 0.226 0.058 0.877 0.032*
Gender −0.51 −0.743 −0.277 0.000* 0.512 0.183 1.432 0.202 0.795 0.224 2.818 0.722
Age −0.017 −0.029 −0.005 0.005* 0.996 0.947 1.048 0.878 0.996 0.934 1.063 0.912
Bilary
obstruction
at presentation
−0.161 −0.484 0.162 0.312 2.330 0.589 9.225 0.228 0.413 0.081 2.118 0.289
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previously in ampullary cancer,22 we have noted a similar phe-
nomenon in pancreatic and bile duct cancer in this study.
Another potential weakness is the lack of discrimination of
ampullary tumours into intestinal or pancreatico-biliary
phenotype. These two tumours have different anatomical and
morphological characteristics, in addition to different prognosis.
It is possible that the phenomenon we have observed occurs
differentially in these two subsets. Distinguishing between these
two phenotypes however does not form part of the Royal College
of Pathologists’ dataset.11
Previous evidence has shown that delayed diagnosis and a
prolonged interval to surgery has an adverse outcome in other
tumour types including breast cancer,23 non-small cell lung
cancer,24 and urological cancer.25 There is little data available
however on what constitutes a safe interval to surgery after
diagnosis. The 62 day interval adopted as a target for treatment
of most solid tumours in England was selected as a pragmatic
figure without evidence of beneficial effect for each tumour
type. Although there is evidence that late diagnosis has a
negative effect on outcome in pancreatic cancer, as shown by
the low resection rate,26 the study shows that following symp-
tomatic presentation delay of up to two months prior to
resection has no further effect on outcome in pancreatic and
bile duct cancer. For ampullary cancer however a delay to
surgery within the 62-day target period has a measurable effect,
with some lesions progressing to inoperability, and improved
outcome of the selected patients whose tumours remain
resectable. This finding has significant implications for planning
surgery in patients with PC, as the final histological tumour
type is not known until surgery is completed, and early surgery
for these patients is therefore preferable. Also these findings
suggest that in some patients with inoperable PC the tumour
may originate within the ampulla, rather than the pancreas.
This may have implications for the selection of palliative
chemotherapy in this patient group.
Confirmation was obtained from the South West Health
Research Authority that under the harmonised Guidance
Approval for Research Ethics Committees (REC), REC review
was not required because patient data were collected in the
course of normal hospital care and were anonymised for research
purposes. No patient consent was required for this study.
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AIMS: To determine the relative significance of radiological signs in determining the
resectability of peri-ampullary cancer (PC) and to assess the value of multi-phase imaging in
detecting these findings.
MATERIALS AND METHODS: Blinded, double re-reporting of preoperative imaging from five
hospitals was undertaken of 411 patients undergoing surgery for PC over an 8-year period, of
whom 119 patients were found to be inoperable at the time of surgery.
RESULTS: The median tumour size was 26.7 mm and the proportion of patients reported to
have regional lymphadenopathy (RL), venous (VI) and arterial involvement (AI) was 24.7%,
11.5%, and 3.9%, respectively and was similar regardless of the number of contrast phases
undertaken. Significant associations were, however, noted between individual risk factors: VI
was closely associated with tumour size (p¼0.002) and AI (p<0.0001). In multivariate analysis
AI, VI, and RL were independently associated with resectability (relative risk of resection¼0.05,
0.31, and 0.51, respectively). Tumour size, however, was not associated with resectability when
VI was included in the multivariate model.
CONCLUSIONS: The use of multiple vascular contrast phases has no measureable impact on
the rate of determination of tumour resectability of PC. In preoperative staging, AI is the most
significant adverse finding for resectability. Large tumour diameter is not an adverse finding in
isolation from other risk factors.
 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Introduction
Determination of tumour resectability is a major aspect
of the interpretation of preoperative imaging of peri-
ampullary cancer (PC). The findings of distant metastases
and local invasion resulting in occlusion of major arteries or
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veins are contraindications to attempted surgical resection,
whereas lesser degrees of arterial involvement (AI) and
venous involvement (VI), including abutment and tapering,
are relative contraindications, as imaging can sometimes
be inaccurate in determining these findings,1e4 and vein
resection can be undertaken where incomplete venous
occlusion is noted.5e7 Tumour size8 and regional lymph-
adenopathy (RL)9,10 have also been shown to be associated
with unresectability, although RL is a relative contraindi-
cation as these nodes are removed as part of a Whipple
procedure.11 This finding may, however, be a surrogate
marker of an aggressive malignancy, which will progress
rapidly to become inoperable.
Despite preoperative imaging to exclude patients with
contraindications to surgery a proportion of patients with
PC proceeding to operation are found to be inoperable,
either due to unresectable invasion of vascular structures or
the presence of metastatic disease. This may result from
either understaging by computed tomography (CT) or rapid
tumour progression in the interval between imaging and
surgery.
Preoperative staging of PC is commonly undertaken by
contrast-enhanced CT. Some authorities recommend tri-
phasic imaging,12 including a pre-contrast phase, arterial
phase, and portal phase, although the benefits of this over
monophasic scans (portal venous phase only) and biphasic
scans (arterial and portal phases) have not been demon-
strated. This has implications in terms of radiation expo-
sure and resource utilisation. There have also been major
improvements in CT technology in recent years with the
development of multidetector (MD) imaging,13 which
would be expected to lead to a reduction in the proportion
of false-negative findings, and may have reduced the need
for multi-phase imaging.
The principal study aim is to determine a hierarchy of
radiological findings in predicting the resectability of PC in
patients undergoing surgery at a regional centre within a
Cancer Network serving five hospitals (AeE) and to inves-
tigate the cause of unresectability (local invasion or meta-
static disease) associated with these findings. Secondary
aims were to explore the effect of varied imaging protocols
in the detection of these findings to determine potential
advantages of multi-phase imaging in clinical practice.
Material and methods
Details of consecutive patients undergoing surgical
exploration for suspected PC between January 2006 and
January 2014 were collected in a prospective database. Pa-
tients were offered surgery following review of imaging at a
specialist hepatobiliary (HPB) multidisciplinary team (MDT)
meeting and all scans were performed using 64-section
MDCT. Relevant abdominal CT images were retrieved from
referring hospitals, anonymised, and uploaded to a dedi-
cated research hard-drive. Images were then re-reported
independently by two radiologists with higher training in
pancreaticobiliary imaging using standard criteria.14 The
number of vascular contrast phases was recorded for each
patient and the proportion of patients having mono-, bi-
and tri-phasic imaging in each of the referring hospitals was
determined, along with the association of the number of
scan phases with the main radiological findings. Specific
data fields were created to collect information relating to
hospital of origin, the presence of a biliary stent inserted at
endoscopic retrograde cholangiopancreatography (ERCP),
tumour size, regional nodal status (presence of lymph nodes
>1 cm in transverse diameter) and vascular involvement
status. Radiological evidence of arterial and venous
involvement were defined according to published criteria14
(Fig 1). In the assessment of a binary variable (e.g., nodal
status) a positive outcome was recorded only when both
radiologists agreed on the finding. For tumour size, the
mean of the two findings was taken.
At surgery, initially a search for metastatic disease was
undertaken before an attempt at dissection of the primary
tumour. The tumour was considered to be unresectable due
to local invasion when the operating surgeonwas unable to
resect the tumour after trial dissectionwithout undertaking
arterial resection or where there was occlusion or extensive
invasion of the portal or superior mesenteric vein. Data
retrieved from the database included the operative finding
of either unexpected distant metastases or local invasion by
tumour into vascular structures. The proportion of resect-
able tumours was recorded for consecutive quartiles (2-year
intervals) of the study period. To explore further the pre-
dictive value of radiological findings the operative outcome
among patients where the tumours were found to be
unresectable were categorised into the finding of metastatic
disease or local invasion.
Discrete variables and interdependence of radiological
findings were analysed using the chi-square test and
continuous variables using the ManneWhitney test. Esti-
mates of the relative value of radiological parameters in the
prediction of resectability of PC were determined by logistic
regression analysis.
Ethical approval for the study was obtained from the
South West Health Research Authority Research Ethics
Committees. No patient consent was required for this study
because patient data were collected in the course of normal
hospital care and were anonymised for research purposes.
The study is registered with ClinicalTrials.gov (unique
identifier NCT02296736).
Results
Operative details and relevant preoperative imaging
were available in 409 patients (Fig 2), of median age 66.9
(28e86) years, of whom 55.8% were men. The median age
(66.7 versus 67.5 years), percentage of male patients (54.5%
versus 59.8%) and median interval between imaging and
surgery (42 versus 39 days, p¼0.419) did not differ between
patients proceeding to resection and those where the lesion
was found to be unresectable.
Analysis of images revealed a similar proportion of
mono-, bi- and tri-phasic scans. There was variation in the
number of vascular contrast phases undertaken in scans
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Figure 1 (a) MDCT image demonstrating superior mesenteric artery involvement by PC (arrow). (b) MDCT image demonstrating superior
mesenteric vein involvement by PC (arrow).
Number of patients
n= 421
Scan reviewed
n= 411
Non-resectable disease
n= 117 (28.6%)
No scan available
n= 10
Locally advanced
disease
n= 72 (61.5% )
Metastatic disease
n= 45 (38.5% )
Resectable disease
n= 292 (71.4%)
Exclusions
One patient surgically 
unfit
One patient with 
pancreatitis at surgery 
with no visible mass
Figure 2 Flow chart of patients undergoing surgery for PC between January 2006 and January 2014.
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from different hospitals; however, the rate of detection of
the main radiological end-points did not differ according to
the number of contrast phases undertaken (Table 1). In
particular the proportion of patients noted to have AI did
not differ between patients where only portal venous im-
aging was performed (three of 134) and those where
additional arterial phase imaging (bi- and tri-phasic scans)
was also performed (13 of 275; p¼0.223). The primary
tumour was visible in 250 patients (61.1%), with no differ-
ence in the rate of detection in patients having different
contrast phase protocols (Table 1). Similarly the median
tumour size was 26.7 (8e70) mm and did not differ be-
tween patients having different scan phases (p¼0.39).
Where a tumour was visible RL, VI, and AI were noted in 101
(40.4%), 47 (18.8%), and 16 (6.4%) of patients, respectively.
Among the 159 patients where no primary tumour was
visible, RL was noted in 40 (25%) patients. Tumour size was
noted to be greater in patients with RL (28.5 versus 26 mm),
AI (30.7 versus 26.5 mm), and VI (33 versus 25.5 mm) than
in those without these findings (p¼0.02, 0.03, and 0.0001,
respectively). On evaluation of the interdependence of
preoperative risk factors, VI was noted to be strongly asso-
ciated with AI (p¼0.000). Of the 16 patients with AI, eight
(50%) also were noted to have VI. The finding of RL was not
significantly associated with either AI (p¼0.472) or VI
(p¼0.108).
Biliary stents had been inserted prior to CT in 73 (17.8%)
patients. The proportion of patients with radiologically
detectable RL did not differ between those who had (17/72,
23.6%) and those who had not (84/337, 25%) had a stent
inserted prior to CT scan (p¼0.814).
Surgical resection of the PC was completed in 292 pa-
tients (71.4%). Resection was completed more commonly
among the 159 patients where no lesion was visible (126,
79%) than among the 250 patients where the tumour was
visible (166, 66.4%) (p¼0.005). Among the 155 patients with
a visible tumour and no adverse risk factors (RL, AI, or VI) on
preoperative imaging, themedian tumour size did not differ
between the 121 patients where the tumour was resectable
(24.5 mm, interquartile range (IQR): 20.5e30.42) and the 34
patients where the tumour was not resectable (26.7 mm,
IQR: 20e28.5 mm; p¼0.55).
Of the 17 patients with VI on preoperative imaging
where resection was completed, partial venous resection
was necessary in three (17.6%) patients. Vein resection was
also required in five of the 348 patients (1.4%) where VI was
not noted preoperatively. The final pathological diagnosis of
resected specimens is shown in Table 2.
At univariate analysis, the presence of a visible tumour,
tumour size, RL, AI, and VI on preoperative imaging were all
associated with unresectability of the tumour (Table 3);
however, in the multivariate analysis the strongest associ-
ation with tumour resectability was with the presence of AI
(Table 3). Tumour size and VI were found to be mutually
exclusive for significance in the multivariate model.
In the 117 patients where the tumour was not resected,
this was due to the finding of hepatic metastatic disease in
45 patients (37.8%) or local invasion of vascular structures
in 72 patients (60.5%). The proportion of patients with
unresectable disease was 16/67 (23.8%), 35/93 (37.6%), 32/
119 (26.2%), and 34/130 (26.1%) (p¼0.17) in consecutive
time quartiles of the study. No difference was noted in the
reasons for unresectability (local invasion or metastatic
disease) among patients with different preoperative
radiological findings (Table 4).
Discussion
The present study enabled the determination of a hier-
archy of relative contraindications to resection of PC, based
on a systematic assessment of radiological findings. In
multivariable analysis, the likelihood of completing surgical
resectionwas reduced by a factor of 0.05, 0.31, and 0.51 by a
finding of AI, VI, and RL, respectively, compared to a patient
with none of these findings. In the absence of these find-
ings, tumour size was not associated with resectability. The
study also revealed significant interdependence of radio-
logical signs, with VI closely associated with tumour size
(p<0.0001) and with AI (p¼0.000). The present study
demonstrated that the proportion of patients with unre-
sectable disease at the time of surgery has not declined over
the 8-year period of the study, and that the radiological
findings are similar regardless of the number of scan phases
undertaken. In addition, preoperative radiological findings
Table 1
Radiological findings and surgical resection rate according to the number of computed tomography phases for 409 patients undergoing attempted surgical
resection for peri-ampullary cancer.
Monophasic (n¼134, 32.7%) Biphasic (n¼149, 36.4%) Triphasic (n¼126, 31%) p-Value
Hospital A (n¼119) 20 (16.8) 52 (43.7) 46 (38.6) 0.0001
B (n¼97) 45 (46.4) 50 (51.5) 2 (2.1)
C (n¼78) 24 (30.7) 9 (11.5) 45 (57.7)
D (n¼71) 24 (33.8) 21 (29.5) 26 (36.6)
E (n¼44) 21 (47.7) 17 (38.6) 6 (13.6)
AI (n¼16) 3 (2.4) 8 (5.4) 5 (4) 0.398
VI (n¼47) 20 (15) 11 (7.4) 16 (12.7) 0.122
RL (n¼101) 28 (21) 42 (28.2) 31 (24.6) 0.83
Tumour visible (n¼250) 72 (53.7) 99 (66.4) 79 (62.7) 0.83
Median tumour size (average) 25.25 (11.5e70) 26.25 (10.5e58) 27.75 (8e64.5) 0.39
Resection completed (n¼292) 102 (76.1) 107 (71.8) 83 (65.8) 0.187
Data are n (%).
AI, arterial involvement; VI, venous involvement; RL, regional lymphadenopathy.
B. Amr et al. / Clinical Radiology 72 (2017) 691.e11e691.e17691.e14
were not able to predict the reason the pancreatic tumour
was not resectable at the time of surgery (metastatic disease
or local progression).
Many studies have shown that AI and VI are risk factors
for non-resection of pancreatic tumours.15e17 Most have
focussed on assessing the accuracy of MDCT in identifying
these risk factors in comparison with operative findings or
histology.18e20 This study has used a structured reporting
protocol to assess the relative risk that preoperative iden-
tification of these findings entails for individual patients in
terms of tumour resectability. AI is shown to be the most
significant adverse finding, with a relative risk of resection
of 0.05 compared to a patient without this finding. This may
be due to the hepatic and superior mesenteric arteries lying
further from the duodenal ampulla than venous structures,
denoting a greater degree of invasion. The observation that
the radiological findings of AI and VI are associated with
each other may also reflect the spatial relationship of these
structures, with VI occurring first followed by AI.
The significance of radiological evidence of RL has been
less well investigated previously. It is interesting to note
that the presence of RL was not influenced by the insertion
of biliary stents, so this finding should be attributed to a
malignant, rather than inflammatory process. RL was also
not associated with other signs of local tumour progression,
and is only weakly associated with primary tumour size.
The development of lymph node metastases in PC may
therefore depend on different biological processes to pri-
mary tumour enlargement and local invasion. RL was
however independently associated with tumour unresect-
ability. This is probably due to this finding being a marker of
amore aggressivemalignancy. In a large proportion (69%) of
patients with RL however the tumour remains resectable at
surgery.
The present study confirms that although tumour size is
associated with invasion of vascular structures, size alone
does not lead to an increased risk of non-resection in the
absence of other adverse findings. This is significant as some
centres have used tumour size alone as a factor in the de-
cision to offer surgery for PC.8
The observation that 20% of patients with no detectable
tumour radiologically are found to be inoperable at the time
Table 2
Histological outcome of 292 patients undergoing surgical resection for presumed peri-ampullary cancer.
Tumour origin n (%) Median tumour
size (range) mm
Histological lymph
node involvement, n (%)
Pancreatic adenocarcinoma 132 (45.2) 30 (12e65) 122 (92.4)
Ampullary adenocarcinoma 66 (22.6) 25 (5e80) 37 (56)
Bile duct adenocarcinoma 47 (16.1) 25 (10e70) 25 (53.2)
Duodenal adenocarcinoma 7 (2.4) 40 (30e55) 4 (47)
Tubulo-villous adenoma 15 (5.1) 30 (24e55)
Inflammatory disease 12 (4.1)
Neuroendocrine tumour 6 (2) 18 (10e25) 3 (50)
Metastasis 4 (1.4) 35 (25e45)
Gastrointestinal stromal cell tumour (GIST) 1 (0.03) 0 (0)
Others (benign) 2 (0.6)
Table 3
Univariate and multivariate analysis of the association of the preoperative radiological risk factors and surgical resectability of peri-ampullary cancer in 409
patients.
Imaging characteristic Tumour resectability UVA MVA
Yes (n¼292) No (n¼117) p-Value Exponent 95% CI of exponent p-Value
Median tumour size, mm (range) 25.5 (8e70) 28 (11.5e64.5) 0.01 0.46 (0.193e1.084) 0.076
RL (n¼101), n (%) 63 (21.6) 39 (32.8) 0.017 0.51 (0.272e0.949) 0.047
AI (n¼16), n (%) 2 (0.68) 14 (11.7) 0.000 0.05 (0.007e0.445) 0.007
VI (n¼47), n (%) 17 (5.82) 30 (25.2) 0.000 0.31 (0.152e0.638) 0.001
UVA ¼ univariate analysis; MVA ¼ multivariate analysis; AI, arterial involvement; VI, venous involvement; RL, regional lymphadenopathy.
Table 4
Reasons for non-resection (local invasion or metastatic disease) among 117 patients undergoing attempted surgical resection for peri-ampullary cancer with
different preoperative radiological findings.
Radiological finding Local progression
(n¼72)
Metastatic disease
(n¼45)
Chi2 p-Value
Tumour visible (n¼84, 71.8%) 49 (58.3) 35 (41.6) 1.3 0.256
Median tumour size, mm (range) 28.25 (11.5e64.5) 27.75 (16.5e55.5) 0.838 0.36
RL (n¼38, 32.5%) 23 (60.5) 15 (39.5) 0.024 0.876
AI (n¼16, 13.7%) 9 (56.2) 5 (31.25) 0.051 0.822
VI (n¼30, 25.6%) 22 (73.3) 8 (26.6) 2.37 0.123
No adverse radiological findings (n¼54, 46.1%) 32 (59.2) 22 (40.7) 0.22 0.639
AI, arterial involvement; VI, venous involvement; RL, regional lymphadenopathy.
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of surgery is an interesting finding. This suggests that
although the interval from imaging to surgery has only a
small impact on resectability in large series,21 there may be
a more aggressive subset where progression proceeds
rapidly. Similarly, among the 271 patients where no adverse
radiological signs were identified, 54 (19.9%) were still
found to be inoperable at the time of surgery. Caution must
be exercised, therefore, in the interpretation of radiological
findings when counselling patients. In addition, although
vein resection was required in 17.6% of patients undergoing
resection where VI was noted on preoperative imaging, it
was also necessary in 1.4% of cases without VI on preoper-
ative imaging. These observations emphasise the limita-
tions of preoperative imaging in planning surgery for PC.
The weaknesses of this study mainly relate to the non-
standardised imaging protocols undertaken in different
centres, and its retrospective nature. This study, however,
represents an analysis of the value of preoperative imaging
in routine clinical practice, rather than under trial condi-
tions, and the results are therefore likely to be relevant to
other centres undertaking this type of surgery. Of particular
interest is the finding that the radiological findings and
resection rate are similar regardless of the number of
contrast phases. Although multi-phase pancreatic-protocol
CT is considered the reference standard in assessing
resectability of PC,12 the results of the present study indicate
that the resectability rate is unaltered by the CT technique
used. It is possible that with a larger study the use of arterial
phase contrast may lead to greater sensitivity in the
detection of AI. This, however, does not seem necessary in
patients with small tumours and no evidence of VI, where
the risk of AI is very low. The study is also limited by the
number of radiologists undertaking rereporting (two). The
agreement between radiologists is being addressed sepa-
rately, and it is possible that the results have been biased by
individual radiologists performance.
The analysis of surgical outcomes has revealed the most
common cause for non-resection was invasion of vascular
structures (60.5%), with metastatic disease a less common
finding (37.8%). Patients noted to have AI or VI on preop-
erative imaging had a similar likelihood of being inoper-
able due to metastatic disease or local invasion at the time
of surgery, suggesting that these findings are markers of
aggressive malignancy. CT has a high resolution for hepatic
metastases, which has increased in recent years.22 Despite
this the proportion of patients with unresectable disease
has remained largely unchanged over the period of study.
This finding suggests that disease progression between
imaging and the time of surgery may be a more significant
cause of inoperability than understaging by CT. There may
therefore be an irreducible number of patients with rapidly
progressive disease who will be unresectable at the time of
surgery, regardless of the quality of the imaging and
reporting undertaken.
The strength of this study lies in its large size and in the
assessment of imaging of heterogeneous technique from
different hospitals. Other studies have shown similar risk
factors for non-resection,23,24 and a similar rate of non-
resection23,24 at the time of surgery, and there is little
available evidence that this rate has declined with improved
imaging. This may be due to alterations in the threshold for
undertaking surgery in borderline cases and improvements
in surgical technique. The study however reveals significant
limitations in the ability of MDCT to predict the presence of
surgically significant operative findings.
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